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Development	of	 coronary	 artery	 stents	have	 revolutionised	 the	 treatment	of	 coronary	 artery	disease.	
However,	the	currently	available	stents	have	several	limitations	and	side	effects,	which	still	need	to	be	
addressed.	 Within	 this	 group	 of	 biomaterials	 Polyhydroxyalkanoates	 (PHAs),	 which	 are	 biopolyesters	
produced	by	bacteria,	have	a	great	potential	 in	 coronary	 stent	development.	They	are	biodegradable,	
non-toxic	and	biocompatible.	PHAs	have	a	broad	range	of	properties,	which	can	be	tailored	based	on	the	











material,	but	also	 improved	 surface	 topography	and	 increased	 the	biocompatibility	of	 the	 scaffolds	 in	
comparison	to	neat	P(3HB).		
The	 P(3HB)/oligo-PHA	 90/10	 blend	 was	 selected	 for	 the	 fabrication	 of	 radiopaque	 composites	 using	
addition	of	1%,	3%	and	5%	wt	barium	sulphate.	BaSO4	is	well-known	contrast	agent,	commonly	used	in	
biomedical	 applications.	 The	 composites	were	 fully	 characterised	with	 respect	 to	material	 properties,	
surface	 topography	 and	 biocompatibility.	 Preliminary	 studies,	 performed	 by	 MicroCT	 confirmed	 the	
radiopacity	of	the	composite	material.	The	composites	exhibited	an	increased	surface	roughness,	lower	
contact	 angle	 values	 and	 higher	 protein	 adsorption	 in	 comparison	 to	 the	 neat	 blend	without	 barium	
sulphate.	 The	 observed	 cell	 viability	was	 significantly	better	 in	 comparison	 to	 standard	 Tissue	 Culture	
Plastic	(TCP).		
The	P(3HB)/oligo-PHA	90:10	blend	was	selected	as	a	base	material	 for	 tube	manufacturing	by	 the	dip	
moulding	 technique.	Mechanical	properties	of	 the	blend	 tubes	were	similar	 to	 those	obtained	 for	 flat	
films,	except	 for	 tensile	strength,	which	was	slightly	higher	 in	 tubes.	An	 incubation	of	 tubes	 in	DMEM	
media	at	37°C	for	7	weeks	resulted	in	the	decrease	values	of	tensile	strength,	Young’s	Modulus	values	and	
elongation	 at	 break	 in	 comparison	 to	 the	 tubes	 stored	 at	 room	 temperature	 without	 any	 media.	
Additionally,	In	vitro	degradation	study	was	carried	out	on	the	tubes.	After	6	months	of	incubation	in	PBS,	
The	 P(3HB)/oligo-PHA	 90/10	 tubes	 underwent	 a	 30%	 weight	 loss.	 pH	 of	 the	 media	 has	 dropped	
insignificantly,	due	to	release	of	slightly	acidic	degradation	products.	Scanning	Electron	Microscope	(SEM)	
images	confirmed	an	enlarged	porosity	in	the	tube	wall	with	an	increased	time	of	incubation.		
Furthermore,	 an	 investigation	 of	 the	 P(3HB)/oligo-PHA	 90/10	 tubes	 coated	 with	 PCL-PEG550	 with	








erythrocytes	 and	 low	 risk	 of	 thrombogenicity.	 Although	 all	 tested	 materials	 demonstrated	 slightly	
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Currently	 CAD	 treatments	 require	 percutaneous	 coronary	 intervention	 (PCI),	 which	
involves	balloon	angioplasty	and	stent	implantation	(Iqbal	et	al.,	2013).	Only	in	United	
Kingdom,	97,376	PCIs	were	performed	in	2015,	which	is	60%	an	increase	in	comparison	









form	 and	 inflated	 inside	 narrowed	 blood	 vessel.	 This	 results	 in	 compressing	 plaque	
against	the	artery	wall	and	restore	the	normal	blood	flow	(Grabow	et	al.,	2010).	It	is	very	
important	 to	 understand	 that	 coronary	 stent	 does	 not	 act	 as	 a	 tissue	 engineering	
scaffold	(TES).	The	main	function	of	stent	is	to	widen	and	support	the	narrowed	artery,	
whereas,	the	main	role	of	tissue	engineering	scaffold	is	to	repair,	replace	or	regenerate	




Chan	 and	 Leong,	 2008).	 Coronary	 stents	 require	 only	 suitable	 material,	 which	 will	
mechanically	support	blood	vessel	during	natural	healing	of	the	artery	 injured	during	
angioplasty	and	stent	deployment	 (Waksman,	2006).	However,	high	biocompatibility,	












are	 known	 to	 reduce	 some	 major	 side	 effects	 of	 balloon	 angioplasty,	 such	 as	 re-
narrowing	 of	 the	 artery	 caused	 either	 by	 reforming	 of	 the	 blockage	 or	 new	 tissue	
formation	(Takayama	et	al.,	2011).	Currently	available	stents	can	be	divided	into	three	













Stents	are	delivered	 to	 the	vessel	on	a	 catheter	 through	a	guide	wire	and	expanded	
restoring	normal	blood	flow	to	the	heart	(Figure	1).	Considering	the	type	of	deployment	
stents	can	be	divided	 into:	balloon-expandable	or	self-expandable.	Depending	on	the	
type	 of	 expansion,	 stents	 require	 different	 material	 properties.	 For	 example,	 self-
expanding	 stents	need	 to	have	 low	elastic	modulus	and	high	yield	 stress,	due	 to	 the	
specific	 manufacturing	 diameters,	 which	 should	 be	 larger	 than	 the	 diameter	 of	 the	
target	structure.	Balloon	expandable	stents	must	be	able	to	maintain	expanded	shape	
and	used	materials	require	low	yield	stress.	Therefore,	for	a	balloon	expandable	stent,	
316L	 stainless	 steel	 is	 the	 most	 common	 choice	 due	 to	 its	 excellent	 mechanical	
properties.	However,	due	to	its	limited	biocompatibility	and	ferromagnetic	properties,	
other	 non-corrosive	materials	 have	 been	 considered,	 such	 as	 platinum-iridium	 alloy,	
tantalum,	cobalt-chromium	alloy,	and	titanium	(Zahora	et	al.,	2007).	For	self-expanding	
stents	Nitinol,	a	nickel-titanium	alloy	has	been	widely	used	because	of	material	shape	









The	 coronary	 artery	 stent	 is	 considered	 as	 a	 foreign	 body;	 hence	 there	 is	 an	
inflammatory	 response	 triggered	 by	 the	 immune	 system	 (Jamshidi	et	 al.,	 2008).	 The	









injury,	 followed	 by	 neutrophils	 and	 monocytes	 activation.	 Acute	 inflammation	 is	
dominated	 by	 presence	 of	 neutrophils,	 which	 normally	 destroy	microorganisms	 and	
degrades	foreign	body.	However,	due	to	the	difference	in	size	between	an	implant	and	
neutrophils	 cell,	 “frustrated	 phagocytosis”	 event	 may	 occur.	 This	 process	 involves	
production	 of	 free	 oxygen	 radicals	 and	 lysozyme	 proteases	 by	 leukocytes	 with	 an	
intention	to	degrade	the	biomaterial.	Neutrophils	have	very	short	life	spun,	therefore	




determinants	 of	 chronic	 inflammation,	 followed	 by	 foreign	 body	 reaction	 (FBR)	
(Anderson	et	al.,	2008).	FBR	consists	an	accumulation	of	macrophages	and	foreign	body	
giant	cells,	which	may	remain	for	the	lifetime	of	the	implant.	The	last	phase	of	the	body	

















and	 reducing	 the	 toxic	 effects	 of	 the	 systemic	 delivery	 of	 the	 same	 drug	 at	 higher	
concentration	 (Acharya	 and	 Park,	 2006).	 The	 use	 of	 DES	 has	 been	 widened	 from	
coronary	 interventions	 to	 bifurcation	 lesions,	 complex	 lesions,	 inlet	 main	 trunk	 and	
multivessel	 disease.	However,	 late	 stent	 thrombosis	has	become	an	 issue	associated	
with	this	type	of	devices	(McFadden	et	al.,	2004).		
DES	 reduced	 the	 restenosis	 rate	 to	 up	 to	 10%	 by	 the	 inhibiting	 effect	 of	 drugs	 on	
proliferation	of	vascular	smooth	muscle	cells.	Although	the	restenosis	rate	was	reduced,	
presence	of	drugs	usually	impeded	the	normal	healing	process	by	inhibiting	proliferation	
of	endothelial	 cells.	 This	may	 lead	 to	a	high	 risk	of	 late	 thrombosis	and	 require	dual	
antiplatelet	therapy	(Morice	et	al.,	2002).	Moreover,	the	polymer	in	the	coating	layer	

















not	 needed.	 Therefore,	 the	 concept	 of	 biodegradable	 stents	 was	 introduced	 that	
perform	 their	 function	 and	 then	 slowly	 disappear	 within	 18	 months.	 The	 main	
advantages	 of	 biodegradable	 stents	 are:	 shorter	 dual-antiplatelet	 therapy,	 which	
reduces	the	risk	of	bleeding,	no	need	for	surgical	removal,	absence	of	a	foreign	body	in	
the	 long	run	reducing	the	potential	 inflammatory	response	and	enhances	the	natural	
healing	 process	 of	 the	 artery	 wall	 (Waksman,	 2006).	 Arterial	 wall	 is	 very	 sensitive	
towards	 mechanical	 injury.	 Only	 touching	 with	 catheter	 is	 sufficient	 to	 damage	 the	
endothelial	layer,	which	results	in	cell	detachment	and	death	of	endothelial	cells.	This	
causes	 immediate	healing	response	by	platelets	adhesion	and	thrombus	formation	 in	
order	 to	 cover	 and	 protect	 injured	 place.	 	 Healing	 process	 is	 supported	 by	 smooth	
muscle	cells	proliferation	leading	to	the	reconstruction	of	the	arterial	wall	(Van	Erven	et	
al.,	1991).	Although	biodegradable	stents	were	introduced	around	20	years	ago,	most	
of	 them	 have	 failed	 during	 preclinical	 evaluation	 (Sun	 et	 al.,	 2014).	 The	 polymeric	
biodegradable	stents,	which	disappear	slowly	after	implantation,	are	hence	promising	














investigated,	 such	 as	 poly(L-lactic	 acid)	 (PLLA),	 poly(D,L-lactic	 acid)	 (PDLLA)	 and	
poly(lactic-co-glycolic	acid)	(PLGA).	However,	there	have	been	some	concerns	related	to	
their	immunogenic	response	and	unsuitable	mechanical	properties	(Van	der	Giessen	et	
al.,	 1996).	 Polymers	 are	 pliable	 to	 deformation.	 They	 might	 require	 special	 storage	
conditions,	 like	 for	 example	 very	 low	 temperatures	 in	 order	 to	 avoid	 aging	 of	 the	
material	 (Waksman	and	Pakala,	2010).	Polymers	are	not	radiopaque	in	nature,	which	
requires	 an	 addition	 of	 contrast	 agents	 or	 radiopaque	markers.	 All	 these	 properties	
make	 the	 use	 of	 polymers	 as	 a	 base	material	 for	 coronary	 stent	 a	 very	 challenging	
application	 (Agrawal	 et	 al.,	 1992).	 Many	 studies	 have	 been	 performed	 towards	
overcoming	these	limitations.  




The	good	biocompatibility	of	magnesium	makes	 it	a	potential	 target	material	 for	this	






demonstrated	 clinical	 safety	 of	 magnesium	 stents.	 Struts	 were	 not	 present	 after	 4	
months.	However,	radial	strength	was	lost	much	earlier	and	was	insufficient	to	prevent	












stent	 after	 4	months.	 Further	 improvement	 was	 obtained	 by	 addition	 of	 rare	 earth	
elements	or	other	metals,	such	as	calcium,	zirconium	and	lithium.	Bioabsorbable	stents,	
containing	magnesium	 and	 zinc	 (Zn),	 calcium	 (Ca),	 yttrium	 (Y)	 and	manganese	 (Mn)	
demonstrated	 improved	 corrosion	 resistance	 in	 simulated	 body	 fluid,	 promising	
degradation	profile	and	high	biological	response			in	animal	models	(Hänzi	et	al.,	2010).		
Iron	 is	 another	 possible	 metal	 considered	 for	 stent	 application,	 due	 to	 its	 good	
mechanical	 properties	 and	 high	 biocompatibility.	 The	 first	 iron-based	 stent	
demonstrated	promising	results	(Peuster	et	al.,	2001).		The	stents	were	able	to	provide	
mechanical	support	during	the	remodelling	process	and	beyond.	High	biocompatibility	









but	 still	 insufficient	 to	meet	 the	 requirement	 for	 an	 ideal	material,	 i.e.	 material	 for	
coronary	stent	should	be	stable	for	the	first	6	months	and	completely	degrade	within	
18-24	months.	There	 is	a	 lack	of	 results	 from	 in	vivo	 study	on	this	alloy,	which	could	
confirm	long-term	safety	and	performance	under	physiological	conditions	(Hermawan	















The	 clinical	 trial	 data	demonstrated	normal	 functionality	 of	 the	 treated	 vessels	 after	
compete	 stent	 disappearance.	 It	 contains	 100µg/cm2	 of	 everolimus	 to	 prevent	




After	 preliminary	 data,	 the	 design	 of	 the	 stent	 was	 changed	 to	 zigzag	 segments	
connected	 with	 bridges,	 to	 achieve	 uniform	 strut	 distribution	 and	 enhanced	 radial	





time	 frame,	 the	 antiproliferative	 drug	 is	 completely	 released	 and	 radial	 strength	 is	
maintained.	Revascularisation	is	followed	by	the	restoration	phase,	when	hydrolysis	of	
PLLA	occurs	 and	 entire	 stent	 structure	 becomes	unstable.	 Radial	 strength	decreased	
steadily	 and	within	 6	months	 neointima	 covered	 almost	 100%	 of	 the	 struts.	 After	 6	
months	 a	 resorption	 phase	 occurred,	 where	 the	 remaining	 part	 of	 the	 scaffold	 was	
absorbed	 slowly	 (Oberhauser	 et	 al.,	 2009).	 The	 most	 significant	 weight	 loss	 was	



















radial	 support	 to	 the	 vessel	walls.	 Although	 second	 generation	 of	 the	 bioresorbable	





can	 trigger	 inflammatory	 response	 and	 has	 poor	 surface	 characteristics	 preventing	
complete	endothelialisation.	Surgeons	require	special	training	before	they	are	able	to	
carry	 out	 the	 stent	 deployment	 procedure.	 Additionally,	 Absorb	 stent	 is	much	more	
expensive	in	comparison	to	commonly	used	bare	metallic	stents	(Gogas	et	al.,	2014).	
1.3. Drugs	used	in	drug	eluting	stents	
Drug	 eluting	 stents	 were	 designed	 to	 prevent	 restenosis,	 the	 most	 common	
complication	after	balloon	angioplasty.	Considering	the	mechanism	of	the	development	










demonstrates	 immunosuppressive	properties	 (Figure	2).	 It	was	 isolated	 in	1975	 from	
Streptomyces	hygroscopicus.	Rapamycin	obtained	FDA	approval	in	1999	for	application	
to	 prevent	 renal	 transplant	 rejection.	 Few	 other	 analogues	 of	 rapamycin	 have	 been	









protein-12	 (FKBP12).	 This	 is	 12kDa	 in	 size,	 which	 catalyses	 peptidyl-prolyl	 cis-trans	
isomerization.	 FKBP12	 protein	 is	 upregulated	 in	 neointimal	 smooth	 muscle	 cells	
(Sabatini	et	al.,	1994).	A	complex	of	FKBP12	and	rapamycin	attaches	to	the	mechanistic	
target	 of	 rapamycin	 (mTOR)	 and	 inhibits	 its	 activation.	 mTOR	 is	 a	 serine-threonine	












stopped	 restenosis	 in	 coronary	 arteries	 after	 angioplasty.	 Hence,	 application	 of	
Rapamycin	resulted	in	a	meaningful	reduction	in	coronary	stenosis	(Gallo	et	al.,	1999).	






al.,	 2006).	 	 It	was	 reported	 that	 long-term	 systemic	 treatment	with	 rapamycin	 after	
kidney	transplantation	may	give	serious	adverse	effects,	such	as	hypercholesterolemia	




Zotarolimus	 and	 everolimus	 are	 analogues	 of	 rapamycin.	 They	 demonstrated	 similar	
therapeutic	activity	 like	rapamycin.	Rapamycin	analogues	were	developed	in	order	to	
improve	the	hydrophilic	properties	of	the	drug,	which	allows	oral	and	intravenous	drug	
administration.	 They	 bind	 to	 cytosolic	 FK-506	 binding	 protein-12	 and	 inhibit	 the	
proliferation	 of	 smooth	 muscle	 cells	 and	 T-cells	 (Kar	 et	 al.,	 2003).	 Three	 different	
zotarolimus	eluting	 stents	were	 studied	during	clinical	 trials:	Prefer	 stent,	Endeavour	
stent	 and	 zotarolimus-eluting	 stent,	 named	 ZoMaxxTM.	 They	 were	 compared	 with	

















has	 resulted	 in	 the	 development	 of	 the	 paclitaxel	 analogue,	 named	 docetaxel.	 The	
modifications	include	presence	of	the	hydroxyl	group	on	carbon	number	10	and	tert-




















the	 tumour	 (Farb,	 2001).	 Animal	 models	 have	 demonstrated	 that	 paclitaxel	 at	 a	
concentration	200µg	per	stent	reduced	neointimal	and	endothelial	cell	proliferation	up	
to	180	days.	However,	the	arteries	showed	incomplete	healing	(Drachman	et	al.,	2000).	
Another	 clinical	 trial,	 investigated	 polymer-free	 stainless	 steel	 stents,	 containing	 2-3	




Tacrolimus	 (FK506)	 (Figure	4)	belongs	to	 the	group	of	macrolide	 lactones,	which	was	
isolated	 from	 the	 bacterial	 strain	 Streptomyces	 tsukubaesis	 (Tanaka	 and	Marusawa,	
1987).	It	was	applied	as	an	immunosuppressive	agent	after	solid	organ	transplantation,	
for	example	heart,	pancreas,	lung,	liver,	kidney	(Plosker	and	Foster,	2000).	Tacrolimus	
belongs	 to	 the	 group	 of	 calcineurin	 inhibitors	 and	 can	 be	 used	 in	 the	 treatment	 of	
autoimmune	 diseases,	 such	 as	 autoimmune	 chronic	 active	 hepatitis,	 inflammatory	







The	 half-life	 of	 tacrolimus	 inside	 the	 human	 body	 is	 from	 8.7	 to	 11.3	 hours	
(Venkataramanan	et	al.,	1995).	Tacrolimus	can	cause	several	adverse	effects,	including:	
neurotoxicity,	 nephrotoxicity,	 gastrointestinal	 toxicity,	 hyperkalaemia,	 hypertension,	
and	myocardial	hypertrophy	(Morales	et	al.,	2001;	Nakata	et	al.,	2000).	The	mechanism	
of	action	of	tacrolimus	is	similar	to	zotarolimus	and	everolimus,	which	include	inhibition	
of	 calcineurin,	 calcium	and	calmodulin-dependent	phosphatase	activity	by	binding	 to	
calcium,	 calmodulin,	 and	 calcineurin	 through	 the	 immunophilin	 FK506	 protein	 12.	





(Lampen	 et	 al.,	 1995).	 The	 solubility	 of	 tacrolimus	 is	 within	 the	 range	 4-12	 μg/mL.	




















Several	 studies	have	been	performed	to	 investigate	possible	application	of	 this	drug.	
Han	and	 co-workers	 studied	BiodivYsio	Matrix	 LO	 stent	with	a	high	 concentration	of	
dexamethasone.	The	results	were	very	encouraging.	These	stents	reduced	the	amount	
of	major	 cardiac	events	and	 in-stent	 restenosis	 after	6	months	 in	 comparison	 to	 the	










of	 antibodies	 is	 this	 device	 was	 to	 stimulate	 cell	 growth	 in	 the	 vessel	 wall.	 Faster	
endothelialisation	will	result	in	the	faster	integration	of	stents	in	the	arterial	wall,	which	











neighbourhood.	 However,	 the	 effects	 were	 temporary	 and	were	 determined	 by	 the	
presence	 of	 antibodies.	 After	 complete	 release	 of	 all	 antibodies,	 the	 stent	 lost	 its	
antithrombogenic	 effect.	 Therefore,	 other	 solutions	 need	 to	 be	 considered,	 such	 as	
incorporation	of	 antithrombogenic	 agents,	 such	as	heparin,	 hirudin	 and	glycoprotein	
IIb/IIIB	(Aggarwal	et	al.,	1996).		
1.4. Biopolymers	used	as	a	drug	carriers	in	the	prevention	of	restenosis	




to	 the	 appropriate	 location	 in	 sufficient	 concentration	 over	 designed	 period	 of	 time	
(Raval	et	al.,	2010).		Controlled	drug	release	is	expected	from	drug	eluting	stents	in	order	
to	prevent	restenosis	without	any	toxic	effect	(Wise,	2000).	Controlled	drug	release	can	
be	 achieved	 by	 few	mechanisms,	 such	 as:	 diffusion,	 degradation	 by	 surface	 or	 bulk-
erosion	 or	 an	 active	 efflux.	 The	 main	 drug	 release	 mechanism	 in	 DES	 is	 based	 on	
diffusion,	either	directly	from	polymeric	matrix	or	from	reservoir	systems,	where	drug	is	










materials,	 in	 order	 to	 allow	 controlled	 release	 of	 rapamycin.	 PLLA	 was	 used	 as	 the	
platform	material,	 as	 the	 core	 of	 the	 stent.	Whereas	 PLGA	was	 the	matrix	 for	 drug	









with	 two	 layers	 containing	 three	 polymeric	 biomaterials,	 such	 as:	 PLLA,	 PLGA	 and	






such	 as	dip	 coating	 and	 spray	 coating	 are	more	 suitable	 for	 hydrophobic	drugs	 than	
water-soluble	 drugs	 or	 deoxyribonucleic	 acid.	 It	 was	 found,	 that	 stents	 coated	 with	
oligonucleotides	 in	 water	 soluble	 polymer	 demonstrated	 limited	 delivery	 efficiency,	
which	 had	 negative	 impact	 on	 the	 therapeutic	 effect	 of	 the	 device.	 Therefore,	
nanoparticle-eluting	 stents	 were	 produced	 by	 cationic	 electrodeposition	 coating	
technology	to	overcome	this	limitation	(Nakano	et	al.,	2009).		PLGA	in	general	has	been	
a	 preferred	 material	 used	 in	 drug	 delivery	 related	 to	 prevention	 of	 restenosis.	
Additionally,	targeting	molecules	can	be	attached	to	the	surface	of	the	polymer,	which	
can	be	recognised	by	vectors	allowing	travel	to	the	target	tissue.	Chorny	and	co-workers	
developed	magnetic	 nanoparticles	made	 from	 PLA	with	 incorporated	 paclitaxel.	 The	
results	were	up	to	10	times	more	successful	than	the	non-magnetic	system	in	smooth	
muscle	cells	 (Chorny	et	al.,	2010).	Another	researcher,	Luderer	and	co-workers,	2011	















stents	 results	 still	 with	 high	 rate	 of	 restenosis.	 Moreover,	 BMS	 remain	 in	 the	 body	
permanently	 and	 can	 lead	 to	 complications,	 mainly,	 inflammation	 and	 in-stent	
restenosis	(Serruys	et	al.,	199).	Hypersensitivity	reaction	to	nickel	and	molybdenum	was	
reported	in	10%	of	patients	after	BMS	implantation	(Koster	et	al.,	2000).	Drug	eluting	
stents	 were	 developed	 to	 resolve	 some	 issues	 related	 to	 BMS,	 like	 for	 example	
restenosis.	However,	deployment	of	DES	resulted	in	appearance	of	another	side	effect,	
named	 as	 late	 thrombosis,	 which	 will	 be	 described	 in	 section	 1.5.2.	 Moreover,	
deployment	 of	 DES	 lead	 to	 delayed	 endothelialisation,	 caused	 by	 release	 of	 anti-
proliferative	agents.	Endothelial	cells	are	able	to	covered	bare	metallic	stents	within	6-
7	months,	whereas	DES	achieve	50%	endothelialisation	after	3	years	(Joner	et	al.,	2006).	
Drug	 eluting	 stents	 are	 usually	 made	 from	 metals,	 hence	 remain	 in	 the	 body	
permanently	 and	 can	 lead	 to	 similar	 side	 effects	 as	 BMS	 (Sun	 et	 al.,	 2013).	 Also	
hypersensitivity	 reaction	 towards	 polymeric	 coatings	 have	 been	 reported	 in	 patients	
after	DES	deployment	(Jeewandara	et	al.,	2014).	Biodegradable	stents	were	developed	
in	order	to	overcome	the	limitations	of	previously	described	stents.	However,	the	results	
are	 still	 not	 satisfactory.	 Although,	 magnesium	 and	 iron	 have	 been	 considered	 as	
biodegradable	 metals	 for	 stents,	 due	 to	 their	 high	 biocompatibility,	 they	 represent	
degradation	profile,	unsuitable	for	this	application.	Magnesium	degrades	too	fast,	hence	
cannot	 support	 the	 vessel	 wall	 for	 required	 period	 of	 time	 (Erbel	 et	 al.,	 2007).	
Degradation	rate	of	an	iron	stent	is	very	slow;	hence	it	acts	similarly	to	the	commonly	
use	bare	metallic	 stents	 (Peuster	et	al.,	 2006).	Biodegradable	polymers	on	 the	other	
hand,	 have	weaker	mechanical	 properties	 in	 comparison	 to	metals.	 Therefore,	 stent	
thickness	has	to	be	much	greater	than	metallic	stents	and	cannot	be	used	in	small	blood	
vessels.	 Moreover,	 recoil	 after	 expansion	 have	 been	 observed.	 Polymers	 cannot	 be	
visible	under	X-Ray,	which	 is	additional	 limitation	of	 this	materials	 (Ramadugu	et	al.,	






coronary	 artery.	 The	 reaction	 between	 the	 stent	 and	 the	 vessel	 wall	 has	 been	





Stent	 implantation	 is	usually	accompanied	by	side	effects	such	as	thrombosis	and	 in-
stent	restenosis.	The	risk	of	stent	thrombosis	is	the	highest	in	the	first	month	after	stent	
implantation	and	in	70%	cases	leads	to	myocardial	infarction	or	sudden	death.	Unlike	
thrombosis,	 in-stent	 restenosis	 usually	 occurs	 between	 6-12	 months	 of	 stent	
implantation	(Wilson	and	Cruden,	2013).	In-stent	restenosis	is	defined	as	the	narrowing	
or	lumen	loss	of	over	50%	following	stent	deployment.	In-stent	restenosis	is	primarily	
induced	by	neointimal	proliferation;	however,	 there	are	a	number	of	 known	 factors,	
which	may	affect	the	appearance	of	in-stent	restenosis,	such	as	diabetes	mellitus,	lesion	









wall,	which	connects	 the	vessel	 to	 the	surrounding	 tissues.	This	 layer	contains	highly	














might	 lead	 to	 in-stent	 restenosis.	 Restenosis	 is	 developed	 as	 an	 effect	 of	 a	 healing	
process	of	the	arterial	wall	caused	by	mechanical	injury	during	balloon	angioplasty	and	
stent	 implantation.	 It	 involves	two	main	processes,	neointimal	hyperplasia	and	vessel	




the	 denudation	 of	 the	 most	 internal	 layer,	 named	 endothelium.	 In	 addition,	 the	
compression	of	 the	plaque	can	cause	delamination	within	 inner	 layers	of	 the	arterial	
wall,	such	as	tunica	media	or	even	externa.	The	whole	artery	is	stretched.	Fibrins	along	
with	platelets	are	embedded	directly	at	the	wounded	site.		The	platelets	get	activated	
and	 express	 P-selectin,	 an	 adhesive	 molecule,	 which	 recruits	 the	 leucocytes.	 The	
leukocytes	 bind	 closely	 across	 adhesive	 molecules	 by	 direct	 attachment	 to	 platelet	
receptors	 or	 through	 cross-linking	with	 fibrinogen.	 In	 the	 next	 stage,	 the	 leucocytes	
migrate	through	the	layer	of	platelets	and	fibrin	as	well	as	tissues.	This	is	mediated	by	










development.	 After	 several	 weeks,	 the	 last	 phase	 of	 remodelling	 occurs.	 The	 main	
change	 observed	 during	 this	 period	 is	 a	 higher	 production	 of	 extracellular	 matrix,	
composed	of	various	types	of	collagens	and	proteoglycans,	which	are	the	key	elements	
of	the	fully	formed	restenosis	plaque	(Welt	and	Rogers,	2002).		









Brachytherapy	 has	 been	 approved	 by	US	 FDA	 as	 a	 technique	 safe	 to	 be	 use	 for	 the	








before	 intervention,	 B	 –	 changes	 in	 the	 artery	 environment	 immediately	 after	 stent	








detachment	 from	 residual	 lesion,	 internal	 fractures.	 The	 second	 type,	 called	 late	
thrombosis	appears	between	1	to	12	months	after	stent	deployment.	This	type	is	related	











Figure	 8:	Mechanism	of	 the	development	 of	 the	 late	 thrombosis	 in	 the	drug	 eluting	
stents	in	correlation	to	time	after	stent	deployment	(Nakazawa,	2011).	




and	 fibrin	 deposition	 in	 the	 drug	 eluting	 stent,	 delayed	 arterial	 healing	 caused	 by	
incomplete	reendothelialization	and	persistence	of	fibrin	was	observed	in	the	patients	
who	died	due	to	late	thrombosis,	(Morice	et	al.,	2002).		Some	procedure	related	factors,	
such	 as:	 smaller	 final	 lumen	 dimensions,	 caused	 by	 stent	 underexpansion	 or	
malapposition,	stent	length,	persistent	slow	coronary	blood	flow,	placement	of	multiple	
stents,	 positive	 remodelling	 play	 a	 significant	 role	 in	 late-thrombosis	 development	




(Nakazawa	 et	 al.,	 2011).	 Moreover,	 drugs	 used	 in	 DES,	 which	 slow	 down	


























h) excellent	 haemo-	 and	 biocompatibility,	 the	 material	 must	 not	 cause	 side	
effects	in	the	body	












and	 biodegradability.	 Poly(L-lactic)	 acid,	 poly(D-lactic)	 acid,	 polycaprolactone	 and	




used	 for	 several	 medical	 applications,	 especially	 for	 devices,	 which	 require	 great	
strength	 and	 toughness	 from	 the	 material,	 such	 as	 orthopaedic	 and	 cardiovascular	
devices	or	 sutures.	Moreover,	PLLA	can	be	processed	by	various	 techniques,	 such	as	
electrospinning,	moulding,	extrusion	as	well	as	solvent	casting	(Zilberman	and	Eberhart,	
2006).	PCL	is	a	semicrystalline	polymer	with	lower	tensile	strength	and	Young’s	modulus	








required	 high	 temperature	 (70°C).	 Further	 expansion	 required	 the	 application	 of	 a	
pressure	gradient.	The	most	important	innovation	proposed	by	Tamai	was	the	unique	
“zigzag”	 stent	 design	 (Tamai	 et	 al.,	 1999;	 2000).	 Initial	 results	 on	 Igaki/Tamai	 stents	






















diameter,	 within	 the	 cytoplasm	 (Figure	 9).	 They	 are	 produced	 under	 conditions	 of	
nutrient	 limitation	 with	 one	 of	 the	 growth	 components,	 such	 as	 nitrogen,	 sulphur,	
oxygen,	 magnesium	 or	 phosphorus	 in	 limiting	 concentration,	 with	 excess	 of	 carbon	
(Anderson	and	Dawes,	1990;	Khanna	and	Srivastava,	2005;	Chen	et	al.,	2001;	Thakor	et	




Figure	 9:	 Polyhydroxyalkanoates	 granules	 inside	 bacterial	 cells.	 (Source:	 Chen	 et	 al.,	
2001).	

















properties	 of	 PHAs	 are	 dependent	 primarily	 on	 the	 number	 of	 carbon	 atoms	 in	 the	
monomer	unit.	Homopolymers,	random	copolymers	and	block	copolymers	of	PHAs	can	
be	 produced	 depending	 on	 the	 bacterial	 species	 and	 growth	 conditions.	 Over	 150	
different	PHA	monomers	have	been	reported	so	far	(Loo	and	Sudesh,	2007;	Gao	et	al.,	
2011).	Monomers	 can	 include	aromatic	 or	 aliphatic	 side	 chains	or	 can	be	 chemically	
modified	in	order	to	improve	the	functionality	and	applicability	of	the	polymer	(Lu	et	al.,	
2009).	 PHAs	 are	 divided	 into	 two	 main	 groups:	 short-chain	 length	 (scl),	 where	 the	












addition	 of	 specific	 precursors,	 such	 as	 1,4-butanediol	 or	 γ-butyrolactone	 into	 the	
feedstock.	Mcl-PHAs	are	biopolymers,	which	are	elastomeric	in	nature	with	low	melting	
point,	low	glass	transition	temperature.	Usually	they	do	not	undergo	cold-crystallisation.	
Mcl-PHAs	 represent	a	group	of	 soft	materials	with	 low	tensile	 strength	and	very	 low	
values	 of	 Young’s	 Modulus	 in	 comparison	 to	 scl-PHAs.	 Their	 elastomeric	 nature	
increases	with	the	length	of	the	side	chain	(Khanna	and	Srivastava,	2005;	Williams	et	al.,	

















renewable	materials,	 high	 biocompatibility	 and	 non-toxicity.	 The	 summary	 of	 typical	
material	properties	of	scl-PHA	and	mcl-PHA	is	presented	in	Table	1.		
P(3HB),	which	belongs	to	scl-PHA	group	represents	completely	different	properties	than	











































































available	 in	 large	 amounts.	 Another	 drawback	 is	 related	 to	 processability.	Mcl-PHAs	
have	low	temperature	of	melting,	therefore	cannot	be	used	for	techniques	required	high	







This	 project	 will	 try	 to	 address	 some	 of	 the	 limitations	 mentioned	 above,	 such	 as	









(3HB),	 as	 a	 compound	 associated	 with	 ketone	 body	 formation	 (Pawan	 and	 Semple,	
1983).		P(3HB)	is	found	in	transmembrane	channels	in	eukaryotic	and	prokaryotic	cell	
membranes	 (Reusch,	 2000).	 Therefore,	 it	 is	 expected	 that	 implants	 or	 sutures	made	
from	 PHAs	 containing	 P(3HB)	 should	 not	 trigger	 an	 immune	 response	 in	 the	 body	
(Brigham	 and	 Sinskey,	 2012).	 Moreover,	 in	 vitro	 cell	 study	 has	 confirmed	 high	
biocompatibility	of	P(3HB)	 towards	a	 range	of	different	 cell	 lines	 (Misra	et	al.,	 2006;	
Shishatskaya	 et	 al.,	 2004).	 Sevastianov	 and	 co-workers	 measured	 the	
haemocompatibility	of	PHAs	and	demonstrated	 that	both	P(3HB)	and	P(3HB-co-3HV)	
were	compatible	with	blood	and	do	not	trigger	any	immune	response	(Sevastianov	et	
al.,	 2003).	 P(3HB)	 have	been	 studied	 intensively	 for	 hard	 tissue	 engineering	 and	has	
demonstrated	 good	 biocompatibility	 with	 several	 cell	 lines,	 such	 as	 fibroblasts,	
chondroblasts	or	osteoblasts	(Köse	et	al.,	2003).	Biocompatibility	of	P(3HB)	films	has	also	
been	confirmed	in	vivo.	The	tissue	reaction	to	the	implanted	material	did	not	differ	from	
















with	 fibronectin	and	additional	 surface	 functionalization	by	plasma	 treatment.	These	
modifications	 led	 to	 increased	attachment	and	proliferation	of	human	umbilical	 vein	
endothelial	cells	(HUVECs)	as	well	as	smooth	muscle	cells	isolated	from	the	rabbit	aorta	
(RaSMCs)	(Qu	et	al.,	2005).	The	P(3HB-co-3HHx)	copolymer	promoted	differentiation	of	









devices	 used	 for	 vascular	 repair,	 grafts,	 stents	 and	 heart	 valves,	where	 contact	with	
blood	 is	constant.	 Interactions	between	blood	and	the	material	are	very	complicated	
and	 contain	 many	 stages	 connected	 with	 each	 other	 (Tsai	 et	 al.,	 1999).	 Healthy	
endothelium	 has	 anticoagulant	 properties.	 However,	most	 of	 the	materials,	 such	 as	
polymers	or	metals,	their	oxides	and	alloys,	used	for	medical	devices,	can	activate	the	
body	 inflammatory	 response	 (Ratner,	 2007).	 Immediately	 after	 implantation,	 protein	






minutes	 after	 contact	 with	 a	 foreign	 material	 lead	 to	 thrombus	 formation	 and	
fibrinolysis.	Longer	contact	may	result	in	complete	closure	of	the	vessel,	or	calcification	







prevent	 fibrinogen	 adsorption	 (Zhang	 et	 al.,	 2006).	 Blood-material	 interaction	 can	
trigger	inflammatory	response,	which	may	lead	to	the	implant	rejection.	Initial	contact	









the	 contact	 angle,	 required	 for	 cell	 attachment	 is	 still	 controversial.	 It	 is	 commonly	
known	 that	 cells	 prefer	 to	 attach	 to	 the	 weakly	 hydrophilic	 surfaces	 (contact	 angle	
around	 60o),	whereas	 highly	 hydrophilic	 or	 hydrophobic	 surfaces	 have	 been	 used	 to	
inhibit	cell	adhesion.	Highly	hydrophilic	surfaces	prevent	adsorption	of	proteins.	On	the	
other	 hand,	 proteins	 adsorbed	 to	 the	 strongly	 hydrophobic	materials	 are	 in	 inactive	
form,	which	inhibit	cell	adhesion	(Bacakova	et	al.,	2011).	it	is	also	well	known	fact,	that	










important	 role.	 The	 internal	 wall	 of	 the	 artery	 is	 negatively	 charged,	 as	 well	 as	 the	
platelets,	hence	they	repel	from	the	wall.	Cells	tend	to	attach	to	the	positively	charged	
surfaces	 better	 than	 to	 negatively	 charged	 surfaces.	 This	 can	 additionally	 lead	 to	 an	
activation	of	the	complement	system	and	increase	the	inflammatory	response	(Franke	
and	Jung,	2012).	Therefore,	many	research	groups	have	focused	on	the	modifications	of	
the	 surfaces	 of	 the	materials.	 There	 are	 three	 different	 approaches,	 such	 as	 surface	
passivation,	which	is	a	coating	with	a	thin	layer	of	protective	material,	incorporation	of	


























P(3HB-co-3HHx)	 degraded	 completely	 within	 3	 months,	 when	 implanted	
subcutaneously	(Philip	et	al.,	2007).	Degradation	rate	of	PHAs	can	be	accelerated	by	an	
addition	of	other	materials,	which	degrades	faster,	like	for	example	PLA	or	gelatine.	Li	
et	 al.,	 investigated	 the	 influence	 of	 the	 addition	 of	maleic	 anhydrate	 into	 P(3HB-co-
3HHx)	copolymer	grafts.	After	21	weeks,	the	graft	material	underwent	over	21%	weight	
loss	 in	 comparison	 to	 the	 neat	 copolymer	 (7.3%)	 (Li	et	 al.,	 2008).	UV	 treatment	 has	
beneficial	impact	on	the	degradation	of	PHAs.	For	example,	P(3HB-co-3HHx)	films	made	
from	 UV	 treated	 polymer	 powders	 demonstrated	 accelerated	 degradation	 after	 15	
weeks.	Moreover,	UV	radiated	material	enhanced	the	cell	attachment	and	proliferation	
of	L929	fibroblast	cell	 line	 (Shangguan	et	al.,	2006).	Miller	and	Williams,	 investigated	





only	 small	 residues	of	patch	were	present	 in	one	animal.	The	defect	was	completely	
healed.	The	results	demonstrated	complete	degradability	of	the	PHA	biomaterial	in	the	





















well	 as	 genetically	 modified	 strains	 (Figure	 11).	 They	 are	 synthesised	 by	 several	
enzymatic	 reactions	 from	 acetyl-CoA,	 in	 the	 presence	 of	 substrate	 specific	 PHA	
synthases	located	in	the	cytosol	of	PHA	accumulating	bacteria	(Du	and	Yu,	2002).	Most	
of	the	bacteria	are	able	to	synthesize	scl-PHAs,	such	as	P(3HB)	or	mcl-PHAs,	containing	
medium	 chain	 length	 3-hydroxy	 fatty	 acids	 (Koller	 et	 al.,	 2010).	 The	 PHA	metabolic	
pathways	 include	 several	 biochemical	 reactions,	 such	 as	 the	 Krebs	 cycle,	 glycolysis,	
Calvin	Cycle,	serine	pathway,	β-oxidation,	de	novo	fatty	acid	synthesis	and	amino	acid	
catabolism	(Shilalipi	and	Nirupama,	2012;	Steinbüchel	et	al.,	1992).	The	type	of	reaction	
selected	 for	 the	biosynthesis	of	PHAs	depends	mainly	on	 the	 type	of	 carbon	 source,	
availability	 of	 nutrients	 and	 the	 bacterial	 strain	 used.	Metabolism	 of	 some	 bacterial	
strains,	 such	 as	 Cupriavidus	 necator	 or	 Pseudomonas	 sp.	 is	 very	 sensitive	 towards	
nutrient	balance	in	the	surrounding	environment.	For	example,	nutrient-rich	conditions	







([R]-3-HA-CoA)	 is	 the	 most	 common	 precursor	 for	 PHA	 production.	 However,	 the	
metabolism	of	 cyclohexanol	 to	6-hydroxyhexanoyl-CoA	and	4,5-alkanolactone	 to	4,5-
hydroxyacyl-CoA	(4,5-HA-CoA)	shown	in	metabolic	routes	L	and	M,	have	been	recently	
proposed	as	the	alternative	precursors,	which	can	lead	to	PHA	biosynthesis	(Chen,	2010;	
Lu	 et	 al.,	 2009).	 Nevertheless,	 the	 possible	 pathways,	 L	 and	 M	 require	 further	
investigation.	Discovery	of	larger	number	of	metabolic	pathways	will	help	bioprocessing	











reduction	 of	 acetoacetyl-CoA	 to	 (R)-3-hydroxybutyryl-CoA	 by	 an	 NADPH-dependent	
acetoacetyl-CoA	dehydrogenase	(encoded	by	phbB)	occurs.	Finally,	P(3HB)	precursors,	(R)-
3-hydroxybutyryl-CoA	 monomers	 are	 polymerised	 to	 poly(3-hydroxybutyrate)	 by	 P(3HB)	
polymerase	 (encoded	 by	 phbC).	 This	 metabolic	 pathway	 is	 typically	 found	 in	 Ralstonia	











1969).	 This	 pathway	was	described	30	 years	 ago.	However,	Madison	 and	Huisman	drew	


























































































chain	 length	 as	 the	 carbon	 source,	 or	 were	 shorter	 by	 2,	 4	 or	 6	 carbon	 atoms	 in	
















Pseudomonas	 species	 are	 able	 to	 produce	 mcl-PHAs	 from	 carbohydrates.	 When	
Pseudomonas	 fluorescens	 was	 grown	 on	 sugars,	 the	 mcl-PHA	 obtained,	 contained	
mainly	C8	and	C10	long	chains	(Huijberts	et	al.,	1992).	PHA	production	from	glucose	is	
connected	with	the	fatty	acid	biosynthesis	pathway	and	utilises	(R)-3-hydroxyacyl-ACP.	
When	 using	 sugars,	 additionally	 this	 internal	 product	 has	 to	 be	 converted	 to	 (R)-3-
hydroxyacyl-CoA.	It	was	found,	that	phaG	was	responsible	for	this	transformation	(Rehm	




unrelated	 carbon	 sources,	 such	 as	 carbohydrates	 or	 1,3-butanediol	 (Steinbüchel	 and	












Gram-positive	 bacteria	 have	 been	 found	 to	 be	 able	 to	 produce	 PHAs.	 P(3HB)	 was	
discovered	 for	 the	 first	 time	 in	Bacillus	megaterium	by	 Lemoigne	 (Lemoigne,	 1926).	
Within	 this	 group	 of	 bacteria,	 several	 genera,	 such	 as:	 Bacillus,	 Caryophanon,	




mcl	 and	 scl-mcl-PHA	 copolymers	 under	 specific	 conditions.	 For	 example,	 Bacillus	




positive	 bacteria	 have	 lower	 polymer	 accumulation	 in	 comparison	 to	 Gram-negative	
bacteria.	Nevertheless,	the	main	advantage	of	using	Gram-positive	bacteria	is	the	lack	
of	 lipopolysaccharides	 (LPS)	within	 the	 cell	wall,	which	 can	 trigger	 an	 immunological	
response	 (Ray	 et	 al.,	 2013).	 It	 is	 worth	mentioning,	 that	 some	 of	 the	 Gram-positive	






Since	 then	many	 research	groups	 investigated	biocompatibility	of	PHAs	produced	by	






production	 of	 scl-PHAs,	mainly	 Cupriavidus,	Azohydromonas	 (previously	 classified	 as	






sources,	 such	 as	CO2,	 sugars,	n-alkanoic	 acids	 and	 vegetable	oils	 (Chakraborty	et	 al.,	
2009;	 Gomez	 et	 al.,	 1996).	 Methylotrophs,	 are	 another	 group	 of	 bacteria,	 able	 to	
produce	 scl-PHAs	 from	 alcohols.	 For	 example,	Methylobacterium	 extorquens	 utilises	
methanol	to	produce	P(3HB)	(46%	dcw),	whereas	Paracoccus	denitrificans	produced	up	
to	24%	dcw	of	P(3HV)	from	n-pentanol	(Mokhtari-Hosseini	et	al.,	2009;	Yamane	et	al.,	
1996).	 Methanol	 is	 a	 cheaper	 carbon	 source	 than	 sugar,	 therefore	 selection	 of	
methylotrophs	 can	 be	 an	 option	 towards	 reduction	 of	 the	 PHA	 production	 cost.	
However,	 optimisation	 studies	 are	 required	 to	 improve	 productivity	 and	 PHA	
accumulation	rate	within	the	biomass	(Khanna	and	Srivastava,	2005).		
Gram-negative	 bacteria	 are	 among	 the	 main	 producers	 of	 mcl-PHAs.	 Various	
Pseudomonas	 sp.	 are	 able	 to	 produce	 a	 range	of	mcl-PHA	homopolymers	 as	well	 as	
copolymers.	The	average	level	of	polymer	yield	is	around	30%	dcw.	However,	some	of	
the	strains,	such	as	P.	putida	mt-2,	could	produce	up	to	77	%	dcw	mcl-PHA	from	octanoic	
acid	 (Shahid	 et	 al.,	 2013).	 Some	 Pseudomonas	 species,	 such	 as	 P.	 marginalis,	 P.	
mendocina,	P.	putida	GPo1and	P.	oleovorans	synthesized	scl-mcl-PHA	copolymers,	using	
a	 range	of	n-alkanoates	and	1,3-butanediol	as	 carbon	sources	 (Lee	et	al.,	 1995).	The	















concern	 is	due	to	presence	of	LPS	 in	 the	outer	cell	membrane,	which	may	trigger	an	
immunological	 response	 and	 exclude	 them	 from	 biomedical	 applications	 (Ray	 et	 al.,	
2013).	 Endotoxins	 can	 be	 eliminated	 by	 repeated	 solvent	 extractions	 with	 oxidizing	






accumulate	 PHAs.	 Those	 are	 halophilic	 species,	 which	 require	 extremely	 high	
concentrations	of	sodium	chloride,	optimally	5%	to	grow	(Danson	and	Hough,	1997).	
The	main	 PHA	 producers	 from	 the	Archeabacteria	 belong	 to	 the	 genera:	Haloferax,	
Halalkalicoccus,	 Haloarcula,	 Halobacterium,	 Halobiforma,	 Halococcus,	 Halopiger,	
Haloquadratum,	Halorhabdus,	Halorubrum,	Halostagnicola,	Haloterrigena,	Natrialba,	
Natrinema,	 Natronobacterium,	 Natronococcus,	 Natronomonas,	 and	 Natronorubrum	
(Han	et	al.,	2010).	They	can	convert	many	carbon	sources,	such	as:	glucose,	fatty	acids	














related	 to	 sterilisation	can	be	excluded.	Another	very	 interesting	aspect	 is	 related	 to	
polymer	recovery.	The	huge	advantage	of	usage	of	haloarcheal	strain	is	the	ability	of	the	







or	 undefined	 co-cultures,	 which	 contains	 two	 or	 more	 microorganisms.	 “Defined”	
means	 selected	 deliberately,	 according	 to	 the	 targeted	 outcomes.	 Presence	 of	 an	
additional	 strain	 may	 lead	 to	 the	 utilisation	 of	 more	 complicated	 carbon	 sources,	
including	 a	mixture	 of	 different	 chemical	 compounds,	 which	 can	 be	 toxic	 or	 has	 an	
inhibiting	 effect	 on	 a	 single	 microbial	 culture.	 	 Co-cultures	 have	 been	 successfully	
applied	 for	 PHA	 production.	 For	 example,	 Nikodinovic	 and	 co-workers	 reported	
















aerobic	PHA	production.	Preliminary	 results	 looked	promising,	however,	 this	concept	
still	needs	further	validation	(Ha	et	al.,	2012).	There	are	a	lot	of	challenges	associated	
with	mixed	cultures.	One	of	the	challenges	is	connected	to	ensure	right	fermentation	
parameters,	which	will	 result	 in	efficient	 conversion	of	 the	carbon	source	 into	PHAs.	
Sometimes	two	different	types	of	bacteria	require	opposite	conditions	of	oxygen	supply.	
Therefore,	selection	of	the	right	bioreactor	design	is	crucial.	Another	challenge	applies	
to	 harvesting	 and	 separation	 of	 PHA-producers	 from	 non-PHA-containing	 biomass.	
Extraction	 of	 the	 polymer	 from	 both	 fractions	 would	 increase	 the	 cost	 of	 polymer	




sp.	 Due	 to	 the	 poor	 yield	 of	 polymers	 using	 wild	 type	 bacteria,	 some	 recombinant	






a	 few	 steps,	 which	 are:	 polymer	 extraction,	 purification,	 concentration	 and	
precipitation.	Depending	on	the	method	used,	the	order	might	change.		
The	extraction	methods,	commonly	used	can	be	divided	into	four	main	groups,	such	as:	
solvent	 extraction,	 chemical	 digestion,	 enzymatic-based	 digestion	 or	 combination	
methods.	Among	all	of	them,	solvent	extraction	is	the	most	commonly	used	to	obtain	
polymer	 with	 high	 purity.	 Few	 solvents,	 such	 as:	 chloroform,	 1,2-dichloroethane,	
propylene	carbonate	and	methylene	chloride	were	studied	(Muhammadi	et	al.,	2015).	
It	is	worth	to	mention,	that	in	contrast	to	mcl-PHAs,	scl-PHAs	are	not	soluble	in	acetone.	
This	 solvent	 can	 be	 used	 to	 separate	 the	 two	 types	 of	 polymers	 (Yao	 et	 al.,	 1999).		













reduction	 of	 molecular	 weight	 (Ramsay	 et	 al.,	 1994).	 	 A	 novel	 method	 for	 scl-PHA	




be	 called	 “scl-PHA	 anti-solvents”	 and	 used	 at	 temperature	 above	 boiling	 point	 and	
pressure	of	7bar.	Acetone	as	a	solvent,	presented	many	advantages	such	as	recyclability,	
































































were	 used	 as	 the	 carbon	 source	 (Liu	 et	 al.,	 1998;	 Chen	 et	 al.,	 1997).	 However,	 the	
problem	associated	with	general	applicability	of	molasses	is	related	to	the	downstream	
decolourisation	process.	This	creates	extra	cost	which	diminishes	the	positive	impact	on	
the	PHA	cost	 reduction	 (Chanprateep,	2010).	The	second	group	 include	whey	and	 its	





(Haas	 et	 al.,	 2008).	 In	 another	 study,	 Kim	 and	 Chang	 studied	 various	 modes	 of	
fermentation	 using	Azotobacter	 chroococcum	 and	 starch.	 They	 obtained	 the	 highest	
yield	 74%	 dcw	 P(3HB)	 yield	 from	 the	 shaken	 flask	 culture.	 Oxygen	 limitation	 was	
required	to	obtain	high	polymer	accumulation	(Kim	and	Chang,	1998).	Another	group	of	
raw	materials	 to	 be	 considered	 are	 lignocellulosic	 raw	materials,	 like:	wood,	 xylose,	
hemicellulosic	hydrolysates,	wheat	bran	(Tamer	et	al.,	1997).	Another	group	of	sources	










from	 the	 production	 of	 biodiesel	 is	 another	 potential	 cheap	 carbon	 source	 for	 PHA	
production	(Baei	et	al.,	2009).	Cavalheiro	and	co-workers	reported	P(3HB)	production	
from	waste	glycerol	using	C.	necator.	The	polymer	productivity	achieved	was	1.1g/L	and	




reports	 demonstrated	 successful	 utilisation	 of	 wastewater	 for	 PHA	 production.	 For	
example,	Martinez	et	al.,	worked	on	the	production	of	PHAs	from	C.	necator	and	treated	
olive	 mill	 wastewater	 and	 obtained	 a	 yield	 of	 55%	 dcw	 with	 11%	 of	 HV	 monomer	
(Martinez	et	al.,	2015).	Khardenavis	et	al.,	obtained	67%	dcw	PHA	accumulation	from	a	
mixed	culture	fed	with	wastewater	derived	from	rice	grain	distillery	(Khardenavis	et	al.,	
2007).	 Another	 group	 of	 potential	 carbon	 sources	 are	 agricultural	 waste,	 such	 as:	
harvestable	parts	of	plants,	plant	extracts,	flower	and	fruit	extracts	(Aditi	et	al.,	2015).	
Koller	and	co-workers	included	vinegar	waste,	food	waste,	plastic	waste	and	landfill	gas	






discovered.	 Most	 of	 the	 cheap	 carbon	 sources	 require	 additional	 processing,	 which	
involves	expensive	enzymes	and	raises	 the	price	of	 the	substrate.	 In	addition	to	 this,	
further	purification	of	the	polymer	might	be	required	to	avoid	presence	of	any	potential	





















improve	 the	 production	 of	 PHAs	 thanks	 to	 increasing	 the	 volumetric	 capacity	 of	 the	
bacterial	cell	(Kadoya	et	al.,	2015).	Zhang	et	al.,	reported	construction	of	an	E.	coli	strain,	

























described	 previously	 in	 the	 section	 1.9.5.	 Zhang	 and	 co-workers	 reported	 combined	
engineering	 of	 serine-deamination	 pathway	 and	 the	 Entner-Doudoroff	 (ED)	 pathway	






















compounds	by	 six	 secretory	pathways	 (Desvaux,	et	al.,	 2009).	However	 recombinant	
proteins	can	be	targeted	to	type	I	or	II	secretory	pathways.	Type	I	secretory	pathway	can	
translocate	proteins	up	 to	900kDa	 from	cytoplasm	 to	extracellular	medium	 in	Gram-
negative	 bacteria	 without	 protein-periplasm	 interplay	 (Mergulhão	 et	 al.,	 2005).	







pathway.	Development	 of	 a	 secretion	mechanism	will	 simplify	 the	 polymer	 recovery	









workers,	 optimised	 fermentation	 by	 mixing	 cultures,	 feeding	 strategies	 and	 applied	
constant	pH	control	over	the	time	of	fermentation	(Chen	et	al.,	2015).	Lack	of	oxygen	in	
the	environment	resulted	in	improved	PHA	production	(Davis	et	al.,	2015).	Fermentation	
strategy	plays	a	very	 important	 role	 in	 the	PHA	production.	For	example,	continuous	
fermentation	 offers	 better	 results	 in	 terms	 of	 the	 obtained	 biomass	 and	 polymer	
productivity	as	compared	to	batch	cultivation	(Amulya	et	al.,	2015;	Marang	et	al.,	2014).	
Koller	and	Braunegg,	2015	studied	a	multistage	system,	containing	series	of	connected	
continuous	 bioreactors	 in	 order	 to	 obtain	 novel	 materials	 with	 higher	 polymer	
productivity.	This	system	will	allow	production	of	novel	copolymers,	containing	blocks	




Physical	 blending	with	particles	or	other	polymers	 in	 the	most	 common	approach	 in	
order	 to	 overcome	 or	 improve	 some	 of	 the	 properties	 of	 the	 materials,	 such	 as	
brittleness	in	case	of	scl-PHAs.	For	example,	inorganic	particles	have	a	positive	impact	











al.,	 2003).	 Addition	 of	 reinforcing	 agents	 have	 a	 positive	 impact	 on	 mechanical	
properties.	 For	 example,	 P(3HB-co-3HV)	 and	 graphene	 nanocomposites	 presented	
significantly	higher	storage	modulus	as	compared	to	neat	P(3HB-co-3HV)	(Sridhar	et	al.,	
2013).	 Another	 example	 described	 addition	 of	 hydroxyapatite	 and	 silane-modified	
hydroxyapatite	 to	 PHBV	 and	 sample	 preparation	 by	melt	 extrusion.	 As	 a	 result,	 the	
toughness	 as	well	 as	 strength	 and	 stiffness	of	 the	material	was	 improved	 (Oner	 and	
Idotlhan,	 2016).	 Cellulose	 nanowhiskers	 were	 found	 to	 be	 very	 efficient	 reinforcing	
agents	 for	PHBV.	They	promoted	chain	orientation	and	significantly	 improved	tensile	
strength,	Young’s	modulus	value	and	storage	modulus	(Patricio	et	al.,	2013).		




(Yu	 et	 al.,	 2006).	 Good	miscibility	may	 result	 in	 uniform	 polymer	 blends	 with	 novel	





blends.	 For	 example,	 Furukawa	 and	 co-workers	 studied	 P(3HB)/PLLA	 and	 P(3HB-co-
3HHx)/PLLA	 blends.	 They	 found	 that	 both	 blends	were	 immiscible.	 However,	 blends	
containing	P(3HB-co-3HHx)	copolymer	with	PLLA	were	more	compatible.	Analysis	of	the	
cold	 crystallisation	 temperature	 proposed	 mixed	 semicrystalline	 structure	 of	 both	
developed	PHAs/PLLA	blend	materials	described	above.	PHA	copolymers	when	present	
within	the	PLLA	matrix	in	low	concentration	did	not	crystallise	(Furukawa	et	al.,	2007).	
Interestingly,	 blends	 of	 P(3HB)	 with	 PDLLA	 prepared	 at	 room	 temperature	 were	







in	 comparison	 to	 neat	 P(3HB)	 (Zhang	et	 al.,	 1996).	 Park	 and	 co-workers	 studied	 the	
influence	of	the	molecular	weight	of	P(3HB)	and	monoaxial	drawing	at	glass	transition	
temperatures	of	the	dominant	compound	in	the	blend	with	PLLA	on	the	properties	of	
the	 materials.	 Commercially	 available	 bacterial	 origin	 P(3HB)	 as	 well	 as	 ultra-high	
molecular	weight	P(3HB)	obtained	from	recombinant	E.	coli	were	used	with	PLLA.	Both	










2000).	 In	 another	 example,	 P(3HB)	 was	 mixed	 with	 P(3HB-co-3HV)	 copolymer,	
containing	various	amounts	of	the	3HV	unit.	It	was	found	that	increased	amount	of	the	
3HV	unit	resulted	in	a	higher	degree	of	phase	separation	and	weaker	miscibility	between	
both	 components.	 To	 obtain	 co-crystallisation	 between	 two	 or	 more	 compounds,	
certain	criteria	need	to	be	met	including,	miscibility	at	the	melt	stage,	similar	crystalline	
structure	and	crystallisation	rates.	In	all	blends,	there	is	a	competition	between	phase	





maintain	 the	 mechanical	 property	 was	 found	 to	 be	 30	 wt%.	 Results	 demonstrated	





The	main	 problem	 associated	with	 blending	 is	miscibility	 between	 the	 components.	
Therefore,	 a	 lot	 of	 different	 types	 of	 compatibilizers,	 like	 oxidized	 polyethylene	wax	
(OPW)	have	been	used	to	overcome	this	limitation	(Rosa	et	al.,	2007).	Another	type	of	
material,	such	as	wood	flour,	tannic	acids	and	plant	polyphenols	were	used	to	improve	


































been	 already	 specified	 by	 Knight	 and	 Evans,	 2004.	 They	 have	 to	 meet	 certain	
requirements,	 such	 as	 non-toxicity	 and	 high	 biocompatibility	 and	 should	 be	 non-






PHAs	 can	be	 tailored	by	 adding	different	 types	 of	 blocks,	 various	 treatments	 can	be	
performed	on	the	surface	to	allow	the	attachment	of	bioactive	agents.	Apart	from	that,	
scaffolds	can	be	fabricated	by	a	broad	range	of	techniques,	which	allows	the	production	
of	 the	appropriate	design	 suitable	 for	 the	 specific	application	 (Williams	et	al.,	 1999).	
PHAs,	its	blends	and	composites	have	been	used	for	the	production	of	sutures,	tacks,	
staples,	screws,	bone	plates,	surgical	meshes,	repair	patches	and	orthopaedic	pins	(Dai	
et	 al.,	 2009).	 Also,	 several	medical	 devices,	 such	 as:	 stents,	 nerve	 conduits,	 artificial	
cartilage,	wound	dressing,	artificial	skin	and	drug	delivery	carriers	have	been	developed	
using	PHAs	(Bian	et	al.,	2009;	Wang	et	al.,	2008).	Rai	et	al.,	2011,	reported	development	
of	 scaffolds	 based	 on	 P(3HO)	 homopolymer	 for	 soft	 tissue	 engineering.	 Material	
supported	 attachment	 and	 proliferation	 of	 human	 adult	 low	 calcium	 temperature	
keratinocytes	 (HaCaT).	 This	 study	 demonstrated	 suitability	 of	 mcl-PHA	 scaffolds	 for	
wound	healing	applications	(Rai	et	al.,	2011).	PHA	based	blends	were	also	considered	
for	 various	 biomedical	 applications.	 For	 example,	 Basnett	 et	 al.,	 2013	 reported	
development	of	P(3HO)/P(3HB)	blends	for	biomedical	applications.	Addition	of	P(3HB)	
resulted	 in	 the	 significant	 improvement	 of	 mechanical	 properties,	 such	 as	 tensile	
strength	and	Young’s	Modulus	and	the	protein	adsorption	to	the	surface	in	comparison	
to	 neat	 P(3HO).	 Material	 was	 considered	 as	 highly	 biocompatible	 and	 suitable	 for	
various	types	of	medical	applications	(Basnett	et	al.,	2013).	In	another	study,	Lizarraga-





higher	 compatibility	 to	NG108-15	neuronal	 cells,	 especially	 in	 the	 context	 of	 neurite	
extension.	 	Therefore,	this	composition	was	recommended	as	potential	candidate	for	
nerve	 conduit	 in	 peripheral	 nerve	 repair	 (Lizarraga-Valderrama	 et	 al.,	 2015).	 Many	
different	 types	 of	 PHA	 based	 composites	 have	 been	 developed	 for	 bone	 tissue	
engineering.	 Changing	mechanical	 and	 topographical	 properties	 by	 addition	of	 other	
materials	have	allowed	them	to	be	used	in	a	variety	of	applications.	Misra	et	al.,	2010,	
demonstrated	suitability	of	P(3HB)/BioglassTM	composites	containing	carbon	nanotubes	
as	a	 functional	 scaffold	material	 for	bone	 tissue	engineering	 (Misra	et	al.,	 2010a).	 In	
another	 study	 Misra	 et	 al.,	 reported	 the	 development	 of	 3D	 highly	 porous	
P(3HB)/bioglass	 composite	 foams	 for	 bone	 tissue	 engineering.	 This	 novel	 material	
demonstrated	 antimicrobial	 properties	 against	 Staphylococcus	 aureus	 due	 to	 the	
presence	 of	 bioglass.	 Addition	 of	 carbon	 nanotubes	 induced	 electrical	 conductivity.	
Obtained	3D	scaffold	allowed	vascularisation	in	the	animal	model	(Misra	et	al.,	2010b).	
Recently,	 Akaraonye	 et	 al.,	 2016	 reported	 results	 on	 two	 types	 of	 P(3HB)	magnetic	




plastic.	Hence	 confirm	 suitability	 for	 bone	 tissue	 repair	 (Akaraonye	et	 al.,	 2016a).	 In	
another	study,	Akaraonye	et	al.,	used	P(3HB)	with	microfibrillated	bacterial	cellulose	for	
articular	 cartilage	 regeneration,	 especially	 in	 load	 bearing	 joints.	 The	 developed	 3D	
scaffolds	 had	 high	 porosity	 and	 surface	 area.	 The	 scaffolds	 demonstrated	 similar	
topography	 to	 the	 extracellular	 matrix	 and	 exhibited	 high	 biocompatibility	 towards	
chondrogenic	ATDC5	cells	 (Akaraonye	et	al.,	2016b).	Cheng	et	al.,	demonstrated	that	
P(3HB)	promoted	proliferation	of	L929	cells	by	preventing	apoptotic	and	necrotic	cell	
death.	 This	 can	 be	 useful	 in	 the	 applications,	 that	 require	 regeneration	 of	 the	 large	














2016).	 PHAs	 have	 also	 been	 considered	 for	 these	 applications.	 For	 example,	 Poly(3-
hydroxybutyrate)	has	been	studied	for	cardiovascular	applications.	Although	it	belongs	
to	scl-PHA,	containing	strong	and	stiff	materials,	it	demonstrated	promising	results	for	





Although	 many	 macrophages	 were	 present,	 P(3HB)	 did	 not	 accelerate	 platelet	
aggregation.	Moreover,	 the	 regenerated	vessel	demonstrated	 similar	 functionality	 to	
the	native	pulmonary	 artery	 (Malm	et	 al.,	 1994).	 The	P(3HB-co-3HV)	 copolymer	was	









2000a).	 Another	 polymer,	 Poly(4-hydroxybutyrate),	 which	 exhibits	 exceptional	
elastomeric	properties	in	comparison	to	other	members	of	the	scl-PHA	group	was	also	
used	 in	 cardiovascular	 tissue	 engineering.	 However,	 it	 has	 demonstrated	 rapid	
degradation	 in	 vivo,	which	 limited	 its	 applicability	 in	 this	 area	 (Chen	and	Wu,	 2005).	
However,	P(4HB)	was	also	used	as	a	replacement	of	the	pulmonary	valve	in	an	animal	










vessels.	The	amount	of	elastin	 found	 in	 the	animal	model	was	160%	higher	 than	 the	
P(3HB-co-3HHx)	studied	previously	 for	 this	application	 (Cheng	et	al.,	2008).	Coronary	
stents	are	demanding	medical	devices,	which	require	specific	material	properties.	One	
of	the	very	important	factors	to	consider	is	the	excessive	vascular	smooth	muscle	cell	




demonstrate	 high	 biocompatibility	 towards	 endothelial	 cells	 to	 reduce	 immunogenic	
response	and	the	development	of	restenosis.	Most	of	the	tested	biomaterials	tested	for	
coronary	stent	development	demonstrated	tissue	incompatibility	(Regar	et	al.,	2001).	
PHAs	 can	 be	 considered	 for	 this	 application.	 Various	 types	 of	 PHAs	 have	 been	
investigated	 for	 this	 application.	 For	 example,	 Basnett	 et	 al.,	 2013	 reported	









Polyhydroxyalkanoates	 are	 considered	 as	 very	 attractive	 group	 of	materials	 for	 drug	
delivery.	This	 is	due	to	their	proven	biocompatibility	and	material	properties,	such	as	
degradation	 kinetics	 and	 non-toxicity.	 Moreover,	 PHAs	 as	 natural	 biopolymers	 are	





synthesis.	 Apart	 from	 that,	 PHAs	 demonstrate	 higher	 stereochemical	 purity	 as	
compared	 to	 synthetic	 materials,	 which	 can	 be	 produced	 as	 a	 mixture	 of	 both	




has	 progressed	 substantially.	 P(3HB)	 and	 PLA	microspheres	 have	 been	 compared	 in	
order	to	release	the	anticancer	agent,	lomustine	by	Bissery	et	al.,	1985.	It	was	found,	








sulperazone	demonstrated	presence	of	drugs	 in	 the	body	within	2	weeks.	 P(3HB-co-




the	 amount	 of	 released	drugs	were	higher	 than	 in	 neat	 P(3HB).	Moreover,	 the	 drug	
delivery	systems	were	haemocompatible	and	did	not	induce	any	negative	effect	on	the	
blood	 cells	 (Rossi	 et	 al.,	 2004).	 Francis	 et	 al.,	 reported	 production	 of	 P(3HB)	 based	














P(3HB)	 microspheres,	 containing	 the	 anti-cancer	 drug,	 rubomycin,	 inhibited	 the	




were	 hepatocellular	 carcinoma	 cells.	 The	 ligand-PhaP-PHA	 drug	 delivery	 system	
demonstrated	effectiveness	in	vitro	as	well	as	in	vivo	in	the	animal	models	(Yao	et	al.,	
2008).		
Hence,	 Polyhydroxyalkanoates	 are	 a	 group	 of	 biomaterials	 with	 very	 high	 potential	
towards	biomedical	applications.	Their	unique	properties,	such	as	high	biocompatibility,	
biodegradability,	 non-toxicity	 and	 tuneable	mechanical	 and	 thermal	properties	make	
them	especially	attractive	for	medical	devices,	such	as	coronary	stents.	Moreover,	some	

































2. Development	 of	 novel,	 biocompatible	 and	 biodegradable	 P(3HB)/oligo-PHA	
blends.		
Three	 different	 compositions	 of	 the	 blends	 of	 P(3HB)/oligo-PHA	 were	 studied	 with	
respect	to	their	mechanical	properties	using	tensile	testing	and	thermal	properties	using	
DSC.	 In	 addition,	 the	 microstructural	 properties	 were	 investigated	 using	 Scanning	
Electron	Microscopy	(SEM),	surface	roughness	analysis,	protein	adsorption	and	contact	
angle	measurement.	 Thermal	 and	mechanical	 properties	were	 also	 studied	 during	 7	
weeks	of	storage	at	the	room	temperature	in	order	to	investigate	the	effect	of	ageing	
on	the	properties	if	the	blends.		Biocompatibility	of	these	P(3HB/oligo-PHA)	blends	were	
tested	 using	 human	 dermal	 microvascular	 endothelial	 cells	 (HMEC-1).	








biodegradable	 P(3HB)/oligo-PHA	 composites	 with	 barium	 sulphate	 as	 a	
radiopaque	agent.		
A	 selected	blend	 film	 composition	P(3HB/oligo-PHA)	90/10	was	mixed	with	different	
amounts	of	barium	sulphate	in	order	to	obtain	radiopaque	composites.	Materials	were	
characterised	with	 respect	 to	 their	mechanical	 properties	 using	 tensile	 test,	 thermal	
properties	 using	 DSC	 and	 microstructural	 properties	 using	 SEM,	 MicroCT,	 protein	
adsorption	 and	 contact	 angle	measurements.	 They	were	 also	 characterised	 for	 their	
bioactivity	 using	 HMEC-1	 cells	 to	 assess	 their	 suitability	 in	 the	 development	 of	




P(3HB)/oligo-PHA	 90/10	 blend	 were	 selected	 for	 tube	 manufacturing	 by	 the	 dip	
moulding	technique	as	a	potential	candidate	for	coronary	stent	application.	Tubes	were	
characterised	with	respect	to	the	mechanical	and	thermal	properties	within	7	weeks	of	
storage	 at	 room	 temperature	 in	 order	 to	 investigate	 the	 effect	 of	 ageing	 on	 the	
properties	of	the	material.	Tubes	were	also	incubated	in	DMEM	media	at	37°C	in	order	
to	mimic	 in	 vivo	 conditions	 and	 observe	 influence	 of	 the	 body	 environment	 on	 the	
material	 properties.	 In	 addition,	microstructural	 studies	were	 performed	 using	 SEM,	
microCT	and	protein	adsorption	studies.	HMEC-1	were	grown	on	the	 tubes	 to	assess	





5. Incorporation	 of	 the	 drugs,	 such	 as	 rapamycin	 or	 tacrolimus	 in	 the	
P(3HB)/oligo-PHA	 tubes	 coated	with	 PCL-PEG550	 as	 a	 platform	material	 for	
development	of	drug	eluting	biodegradable	stent.	
P(3HB)/oligo-PHA	90/10	blend	tubes	were	coated	with	PCL-PEG550	with	incorporated	
rapamycin	or	 tacrolimus	 (1-1.5µg/mm2)	 and	were	 characterised	 for	 their	mechanical	







investigate	 the	 reaction	 of	 the	 blood	 cells	 after	 direct	 contact	 with	 the	 material.	
Degradation	studies	were	also	carried	out	to	confirm	suitability	of	the	selected	materials	
for	 coronary	 stent	 application.	 Drug	 release	 studies	 were	 carried	 out	 using	 High	



































Various	 types	 of	 PHAs	 were	 produced	 by	 Cupriavidus	 necator	 (NCIMB	 10442),	
Pseudomonas	mendocina	CH50	(NCIMB	10541),	obtained	from	the	National	Collection	
of	the	Industrial	and	Marine	Bacteria	(NCIMB),	Bacillus	cereus	SPV,	obtained	from	the	














from	 Thermo	 Fisher	 Scientific	 (Dartford,	 UK)	 and	 PromoCell	 (Heidelberg,	 Germany).	
Protein	 estimation	 was	 done	 using	 the	 BCA	 estimation	 kit	 purchased	 from	 Sigma-
Aldrich.	Biodiesel	waste	was	obtained	from	Dr.	Godfrey	Kyazze’s	lab	at	the	University	of	
Westminster	(London,	UK).	Waste	frying	oil	was	obtained	from	Lion	King	Café	(London,	
UK).	 FITC	Mouse	Anti-Human	CD66b,	 PE	Mouse	Anti-Human	CD11b,	 PE	Mouse	Anti-
Human	CD86,	PerCP	Anti-Human	CD45	antibodies	were	purchased	from	BD	Biosciences	

























































































































by	12	mm	classic	pH	sensor	AppliSens	 (Sensor	 Innovation).	Dissolved	oxygen	 tension	
(DOT)	was	controlled	with	12	mm	classic	polarographic	DO2	sensor	(AppliSens	425mm)	













vessel	 was	 a	 420	 FerMac	 series	 and	 total	 volume	 was	 20	 L	 (Figure	 14).	 The	 vessel	




















minutes	using	 T25	basic	 homogeniser	 (IKA	 Labortechnik).	 The	obtained	biomass	was	













Production stage  







































































obtained	 culture	 was	 harvested,	 centrifuged,	 washed	 twice	 with	 10%	 ethanol,	











Polymer	 yield	 was	 estimated	 by	 extraction	 of	 the	 dried	 biomass	 by	 using	
















placed	 in	 the	 extraction	 thimble	 (Whatman	 28mmx100mm)	 obtained	 from	 GE	
Healthcare	 Life	 Sciences.	 The	 thimble	 with	 biomass	 was	 placed	 inside	 the	 Soxhlet	
extractor	attached	to	round	bottom	flask,	which	contained	methanol	and	boiling	stones	
(Figure	17).	The	system	was	attached	to	the	condenser	and	refluxing	was	carried	out	at	




215)	 and	 polymer	 was	 precipitated	 out	 in	 ice-cold	 methanol	 and	 dried	 at	 room	




















conducted	 on	 samples	 of	 polymers	 subjected	 to	 methanolysis,	 which	 results	 in	 the	
formation	 of	 volatile	 esters	 detectable	 by	 GC.	 20mg	 of	 the	 polymer	 sample	 were	
dissolved	in	2mL	of	chloroform.	2mL	of	the	15%	of	sulphuric	acid	solution	in	methanol	
was	added	and	mixed	well.	20μL	of	methyl	benzoate	was	used	as	an	internal	standard.	






and	 vigorously	mixed.	 Tubes	were	 left	 on	 the	 stand	 until	 two	 layers	 separated.	 The	
organic	 layer	 was	 collected	 and	 dried	 over	 10mg	 of	 sodium	 sulphate	 and	 sodium	
bicarbonate,	 filtered	using	Whatman	No	1	 filter	paper	and	transferred	to	the	vial	 for	
further	analysis	(modified	from	Lageveen	et	al.,	1988).	
GC-MS	analysis	was	carried	out	using	a	Varian	GS/MS	system	consisting	Chrompack	CP-
3800	 gas	 chromatograph	 and	 Saturn	 200	 MS/MS	 block.	 The	 chromatograph	 was	
equipped	with	a	capillary	column	(Elite-5MS,	Perkin	Elmer,	UK)	30	m	in	length	0.25mm	







The	 chemical	 structure	 of	 obtained	 polymers	 was	 determined	 by	 13C	 and	 1H	 NMR	
spectroscopy.	20mg	of	polymer	were	dissolved	in	1	mL	of	the	deuterated	chloroform	
(CDCl3)	and	transferred	into	an	NMR	tube.	The	chemical	shifts	were	referenced	against	
the	 residual	 solvent	 signals	 7.26ppm	and	 77.0ppm	 for	 1H	 and	 13C	 respectively.	NMR	




Thermal	 analysis	 of	 polymers	 was	 conducted	 using	 a	 DSC	 214	 Polyma	 (Netzsch,	




























Bacterial	 growth	 was	monitored	 by	measuring	 the	 optical	 density	 (OD).	 The	 optical	
density	 of	 the	 bacterial	 culture	 was	 measured	 at	 450nm	 (Pseudomonas	 mendocina	
CH50)	or	600nm	(Bacillus	subtilis	OK2)	in	the	spectrophotometer	using	media	as	a	blank	


























































used	 as	 a	 positive	 control.	 Distilled	 water	 was	 used	 as	 a	 negative	 control.	 Nitrogen	















in	 distilled	 water	 and	 boiled	 at	 100-105°C	 for	 20	 hours.	 After	 the	 reaction	 was	
completed,	50mL	of	distilled	water	was	added	to	the	solution	and	the	flask	was	washed	
twice	with	50mL	of	chloroform.	The	mixture	was	transferred	into	the	separating	funnel.	
The	 organic	 layer	 was	 collected,	 dried	 over	 sodium	 sulphate,	 filtered	 and	 partially	























P(3HB)	 and	 hydrolysed	 P(3HHx-3HO-3HD-3HDD)	 in	 ratio	 90/10	 was	 mixed	 barium	
sulphate	(BaSO4),	density	4.49g/cm3	was	milled	using	ZrO2	milling	media	and	dispersed	
in	 isopropanol	 (9	 wt%),	 particle	 size:	 0.3-3.0µm	 (Lucideon,	 UK)	 to	 obtain	 final	
concentrations	of	1,	 3	 and	5	wt%	BaSO4,	 in	 chloroform.	The	 composite	 solution	was	









evaporation	 rates	 of	 both	 solvents	 at	 room	 temperature.	 Hence	 presence	 of	 both	
solvents	 may	 affect	 uniform	 composite	 formation	 and	 has	 negative	 effect	 on	 the	
material	 morphology	 (e.g.	 increased	 porosity).	 Therefore,	 two-step	 composite	 films	
fabrication	was	performed	in	order	to	avoid	this	detrimental	effect.		
2.11.	Tubes	manufacturing	by	using	dip	moulding	technique	
The	 blend	 of	 P(3HB)/P(3HHx-3HO-3HD-3HDD)	 in	 ratio	 90/10	 was	 selected	 for	 tube	
manufacturing.	 Polymer	 concentration	 of	 4	 wt%	 in	 chloroform	 was	 used	 for	 the	
formation	 of	 tubes.	 Chloroform/1,1,2,2-tetrachloroethane	 solvent	 system	 with	
composition	70:30	wt/wt%	was	prepared	 (method	optimised	 in	 the	 lab).	Addition	of	
1,1,2,2-tetrachloroethane	 enabled	 to	 obtain	 stable	 solution	 of	 P(3HB),	 oligo-PHA	 in	
chloroform	 at	 room	 temperature.	 Higher	 boiling	 point	 of	 1,1,2,2-tetrachloroethane	
(146.7°C)	in	comparison	to	chloroform	(61.2°C)	allows	obtaining	an	optimal	evaporation	
rate	during	tube	formation	and	drying.		
















with	wall	 thickness	around	150	µm	 in	order	 to	compare	PHAs	with	currently	existing	
polymeric	stents.	Strut	thickness	of	currently	available	biodegradable	polymeric	stent	





The	 neat	 tubes	 prepared	 were	 coated	 with	 an	 additional	 layer	 of	 polymer	 with	

































cross-sectional	 area.	 The	 gauge	 length	 of	 the	 sample	 holder	 was	 23	 mm.	 The	
deformation	rate	was	5	mm	per	minute.	Young's	modulus,	ultimate	tensile	strength	and	
elongation	at	break	were	calculated	from	the	stress-strain	curve.	The	average	values	for	













































PHA	 and	 composites	 with	 BaSO4.	 Samples	 were	 analysed	 on	 a	 Brüker	 D8	 Advance	











were	rinsed	3	 times	with	phosphate	buffer	saline,	 (PBS)	and	 incubated	 in	1mL	of	2%	
sodium	dodecyl	sulphate	(SDS)	in	PBS	for	24	hrs	at	room	temperature	under	vigorous	
shaking.	 The	 total	 amount	 of	 proteins	 adsorbed	 on	 the	 surface	 of	 the	 samples	 was	
quantified	using	the	Bicinchoninic	Acid	Protein	Assay	Kit	(The	Thermoscientific,	Pierce,	
Hemel	 Hempstead,	 UK).	 The	 absorbance	 of	 the	 samples	 was	 measured	








in	 the	 sample	 was	 analysed	 using	 Lambda	 35	 UV-Vis	 spectrometer	 (PerkinElmer,	
Waltham,	USA)	at	278nm	wavelength.	Rapamycin	standards	in	methanol	were	prepared	
by	 serial	 dilutions	 and	 analysed	 using	 a	 UV-Vis	 spectrometer.	 The	 concentration	 of	
released	drug	was	calculated	from	the	standard	curve	(Ma	et	al.,	2011).			














The	 released	 tacrolimus	 concentration	 was	 calculated	 from	 the	 standard	 curve.	


















P(3HB)	 neat	 and	 blend	 film	 constructs	 were	 cut	 in	 to	 13mm	 diameter	 circles	 and	
sterilized	under	the	UV	light	for	30	minutes	each	side.	All	film	samples	were	soaked	in	
24well	plate	in	1mL	of	supplemented	DMEM	medium	for	16hrs	prior	to	cell	seeding.	Cell	
culture	 studies	were	performed	 in	 triplicates.	HMEC-1	cells	at	70	%	confluence	were	















was	 added	 and	 kept	 for	 15	 minutes	 at	 37°C.	 200μl	 of	 the	 resulting	 solution	 were	
transferred	to	96	well	plates	and	the	absorbance	at	540	nm	was	measured	on	a	FluoStar	






For	 the	 SEM	 imaging,	 HMEC-1	 cells	 seeded	 on	 the	 PHA	 films	 were	 fixed	 using		
4%	 paraformaldehyde.	 These	 samples	 were	 dehydrated	 by	 several	 treatments	 with	
different	 solutions	 of	 ethanol	 (20%,	 50%,	 70%,	 90%,	 100%)	 for	 10	minutes,	 dried	by	
immersion	in	hexamethylsilizalane	for	2-5	minutes	and	left	in	a	fume	cupboard	for	at	





non-fluorescent	 form	 of	 Calcein,	 present	 in	 live	 cells	 to	 green	 fluorescent	 form	 by	
intracellular	 esterase.	 Ethidium	 homodimer-1	 emits	 red	 fluorescence	while	 bounded	


















into	 each	 well,	 containing	 scaffolds.	 All	 samples	 were	 prepared	 in	 triplicate.	
Simultaneously,	HMEC-1	cells	were	seeded	at	20,000	cells	per	well	in	24-well	plates	in	










Haemolysis	 study	was	performed	according	 to	 the	protocol	provided	by	Wang	et	al.,	
2013	with	some	modifications.	Lithium	heparin	whole	blood	was	diluted	4:5	in	sterile	
0.9%	 (v/v)	 sodium	 chloride	 solution.	 For	 the	 films,	 discs	 of	 10	 mm	 diameter	 were	
prepared,	washed	with	 sterile	 0.9%	NaCl	 and	 placed	 into	 the	wells	 of	 24	well	 plate	
(Sigma-Aldrich,	Dorset,	UK).	For	the	tubes,	the	0.0045g	of	polymer	tubes	(an	equivalent	










was	 measured	 at	 540	 nm.	 The	 haemolysis	 ratio	 (HR,	 in	 %)	 was	 calculated	 by	 using	










of	polymer	present	 in	 the	10mm	discs)	were	placed	 inside	 the	24	well	plate.	50µl	of	
activated	 blood	was	 applied	 directly	 on	 the	material,	 placed	 into	 each	well.	 For	 the	
negative	control	100	µl	of	0.9%	sodium	chloride	in	1	ml	of	blood	was	used	as	negative	
control.	 TCP	was	used	as	 the	 control.	After	 30	 and	90	min	of	 incubation	 at	 ambient	
temperature	the	coagulation	was	stopped	by	the	addition	of	1.5mL	distilled	water.	The	
erythrocytes	 not	 trapped	 in	 the	 thrombus	were	 lysed	 by	 addition	 of	 distilled	water,	
releasing	free	haemoglobin.	After	5	minutes,	200	µl	were	transferred	to	a	96	well	plate	
and	the	absorbance	was	measured	at	540	nm.	All	samples	were	prepared	in	triplicate.	









innate	 immune	system.	They	 take	part	 in	acute	 inflammatory	 response.	They	can	be	
activated	 for	 example	 by	 lipopolysaccharide,	 present	 in	 cell	 wall	 of	 Gram	 negative	






For	 leukocyte	 activation	 analysis,	 samples	 which	 contained	 4.5mg	 of	 polymer	 were	
incubated	for	16	hours	with	1mL	of	blood	at	37°	C.	Whole	blood	and	blood	activated	
with	LPS	(100ng/mL)	were	used	as	negative	and	positive	control	respectively.	Two	types	
of	 antibodies	 were	 used:	 an	 activation	 antibody,	 which	 is	 CD11b-PE	 and	 selective	













For	 leukocyte	 activation	 analysis,	 100μL	 of	whole	 blood,	 blood	 activated	 by	 LPS	 and	
blood	 after	 incubation	 with	 PHAs	 was	 added	 to	 flow	 cytometry	 and	 fluorescence-




antibodies:	 CD66B	 conjugated	 with	 fluorescein	 isothiocynate	 (CD66b-FITC),	 CD86	











flow	 cytometer	 (Beckman	 Coulter,	 Inc.,	 Brea,	 USA),	 equipped	 with	 a	 488nm	 laser,	
530/40	and	575/25nm	band	pass	filters,	and	a	750-nm	long	pass	filter.	Determination	of	




























and	 weight	 loss	 behaviour.	 For	 measuring	 the	 %	WU,	 the	 immersed	 samples	 were	
removed	at	given	time	points,	the	surface	was	gently	wiped	with	a	tissue	paper	and	the	


















































high	 tensile	 strength	 and	 is	 highly	 elastomeric.	 Scl-PHAs	 are	 represented	 by	 3-
hydroxypropionate	(3HP),	which	contain	3	carbon	atoms	within	the	monomer	unit,	3-
hydroxybutyrate	 (3HB)	 or	 4-hydroxybutyrate	 (4HB)	 with	 4	 carbon	 atoms	 and	 3-
hydroxyvalerate	(3HV)	with	5	carbon	atoms.	In	addition,	there	are	scl-PHA	copolymers	
which	 include	 Poly(3-hydroxybutyrate-co-3-hydroxyvalerate),	 P(3HB-co-3HV),	 poly(3-
hydroxybutyrate-co-4-hydroxybutyrate),	P(3HB-co-4HB),	which	represent	intermediate	
properties	 between	 both	monomers	which	 are	 dictated	 by	 the	main	monomer	 unit	
within	the	copolymer	(Akaraonye	et	al.,	2010).	Scl-PHAs	can	be	produced	by	different	






et	al.,	2009;	Masaeli	et	al.,	2012).	The	main	application	 for	PHAs	 in	 this	work	was	to	
develop	biodegradable	coronary	artery	drug	eluting	stents.	Coronary	stents	are	known	
to	be	a	very	demanding	medical	device,	which	require	particular	material	properties,	
such	as	 strength	and	stiffness.	On	 the	other	hand,	 it	 also	needs	a	 certain	amount	of	






by	 clinicians,	 it	 presents	 several	 limitations	 as	 mentioned	 in	 the	 section	 1.4.1.	
Polyhydroxyalkanoates	can	be	an	alternative	solution	to	PLLA	as	a	platform	for	coronary	
artery	stents.	Hence,	the	main	objective	of	this	study	was	to	produce	scl-PHAs	using	a	















Bacillus	cereus	SPV	 Fructose	 7.5	 3HB	
























Depending	 on	 the	 carbon	 source,	 mainly	 the	 P(3HB)	 homopolymer	 was	 obtained.	
Bacillus	 species	 were	 grown	 on	 carbohydrates	 as	 the	 sole	 carbon	 source.	 Both	
conditions	resulted	 in	P(3HB)	production.	The	polymer	yield	obtained	from	B.	subtilis	
OK2	was	much	higher	(30.8%	dcw)	than	B.	cereus	SPV	(7.5%	dcw)	when	grown	using	
fructose	as	 the	only	 carbon	source.	 It	 is	well	 known	 that	Bacillus	 species	are	able	 to	
metabolise	 sugars	 and	produce	 scl-PHAs,	mainly	 homopolymer	P(3HB)	 (Faccin	et	 al.,	
2013).		Cupriavidus	necator	produced	P(3HB),	when	grown	on	several	different	carbon	
sources.	 The	 obtained	 polymer	 yield	 was	 from	 6.7%	 dcw	 when	 grown	 using	 γ-





























dcw),	 	 optical	 density	 at	 600nm,	 pH,	 biomass	 (g/L),	 	 glucose	
concentration	(g/L).	


















Obtained	 polymer	 was	 chemically	 characterised	 using	 Attenuated	 Total	 Reflectance	
Fourier	 Transform	 Infrared	 Spectroscopy	 (ATR-FTIR),	 Gas	 Chromatography–Mass	
Spectrometry	 (GC-MS)	 and	 Nuclear	Magnetic	 Resonance	 (NMR)	 as	 described	 in	 the	
sections	2.6.1.-2.6.3.	Molecular	weight	analysis	was	performed	according	to	the	method	
described	in	the	section	2.6.5.	
3.3.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	




Figure	20:	 ATR-FTIR	 spectrum	of	 the	polymer	produced	by	Bacillus	 subtilis	OK2	with	





























Figure	 22:	 Gas	 chromatogram	 of	 reference	 standards	 of	 methyl	 esters	 of	 3-
hydroxyalkanaotes:	 3-hydroxybutyrate	 (3HB),	 3-hydroxyhexanoate	 (3HHx),	 3-


















1H	 and	 13C	 NMR	 confirmed	 the	 chemical	 structure	 of	 the	 obtained	 scl-PHA	 polymer	





































Table	4:	 Summary	of	molecular	weight	analysis	of	 the	P(3HB)	obtained	 from	Bacillus	
subtilis	OK2	and	glucose	as	the	carbon	source;	where	Mw=	weight	average	molecular	
weight,	Mn=	number	average	molecular	weight,	PDI=	polydispersity	index.	
Polymer	sample	 Mw	(kDa)	 Mn	(kDa)	 PDI	
P(3HB)	 582.4	 306.7	 1.9	
	



























Polymer	sample	 Tm	(°C)	 Tg	(°C)	 Tc	(°C)	 ΔHf	(J/G)	














polymer	 using	 tensile	 test	 as	 described	 in	 the	 section	 2.11.3.2.	 Three	 different	
parameters	have	been	measured,	such	as:	tensile	strength,	which	is	a	measure	of	the	
strength,	Young’s	Modulus,	which	is	a	measure	of	the	stiffness	and	elongation	at	break,	


















Young’s	 Modulus	 were	 lower	 than	 generally	 reported	 in	 literature.	 However,	 the	
elongation	at	break	is	much	higher	(Pachekoski	et	al.,	2009).	In	this	experiment,	material	
properties	 were	 obtained	 using	 fresh	 films	 within	 3	 days	 after	 complete	 solvent	
evaporation.	To	 investigate	 the	 influence	of	 the	 time	of	 storage,	 known	as	 “material	
ageing”,	on	the	thermal	and	mechanical	properties	of	the	P(3HB)	neat	films,	DSC	and	





Thermal	 properties	 of	 the	 solvent	 cast	 films	 were	 studied	 for	 7	 weeks,	 in	 order	 to	
understand	the	impact	of	ageing	on	the	material.	The	results	obtained	are	summarised	
in	Table	7	and	Figure	26.	





Tg	(°C)	 Tc	(°C)	 Tm	(°C)	 ΔHf	(J/g)	
1	 -2.8	 35.9	 172.3	 83.22	
3	 -1.0	 40.1	 173.0	 82.16	
5	 -1.7	 41.6	 174.2	 84.35	













and	 increased	 from	 83.2	 to	 85.8	 J/g	 However,	 7	 weeks	 of	 storage	 did	 not	 result	 in	
changes	in	the	melting	temperature.		
3.3.8.	Mechanical	 characterisation	of	 the	neat	 P(3HB)	 films	 after	 7	weeks	of	
storage	at	room	temperature		




















1	 19.2±2.1	 0.8±0.01	 12.8±1.5	
3	 19.1±0.2	 0.9±0.08	 9.3±0.5	
5	 20.5±0.5	 1.1±0.06	 7.4±1.2	





































Ageing	 has	 influenced	 the	 mechanical	 properties	 of	 the	 P(3HB)	 films.	 The	 tensile	
strength	has	 slightly	 increased	 from	19.2±2.1MPa	at	week	1	 to	 21.5±2.7MPa	after	 7	
weeks	of	storage.	The	Young’s	Modulus	values	significantly	increased	from	0.8±0.01	GPa	
after	week	1	to	1.3±0.1	GPa	after	week	7.	Elongation	at	break	decreased	from	12.8±1.5%	






polyesters	 within	 the	 family	 of	 Polyhydroxyalkanoates	 (Karbasi	 et	 al.,	 2012).	 The	
polymer	yield,	varies	depending	on	the	bacterial	strain	used,	carbon	source,	conditions,	
fermentation	 mode	 and	 PHA	 production	 media	 (Shahid	 et	 al.,	 2013).	 For	 example:	
Alcaligenes	latus	was	able	to	accumulate	more	than	75%	dcw	of	P(3HB),	when	grown	on	
sucrose.	Bacillus	sp.,	cultured	on	sugarcane	produces	over	90%	dcw	of	P(3HB)	(Mozejko-








































In	 this	 study	 a	 novel	 strain,	 Bacillus	 subtilis	 OK2	 was	 used	 for	 P(3HB)	 production.	
Production	of	P(3HB)	by	Bacillus	subtilis	OK2	has	only	been	reported	by	Sukan	et	al.,	
2015.	The	main	advantage	of	using	Bacillus	subtilis	over	Bacillus	cereus	is	that	B.	subtilis	
is	 classified	 as	 GRAS	 bacteria	 (“Generally	 Recognised	 as	 Safe”).		
Moreover,	 B.	 subtilis	 OK2	 in	 contrast	 to	 Gram-negative	 bacteria	 does	 not	 contain	




weight,	 when	 glucose	was	 used	 as	 the	 only	 carbon	 source.	 Sukan	 et	 al.,	 2015	 have	






The	P(3HB)	homopolymer	produced	by	Bacillus	 subtilis	OK2	was	 selected	 for	 further	






drug	 delivery	 (Luef	 et	 al.,	 2015).	 For	 example,	 nanofibre	 mats	 of	 P(3HB)	 with	
incorporated	kanamycin	were	tested	against	S.	aureus	and	over	95%	of	the	drug	was	
successfully	 released	 within	 first	 8	 hours	 (Naveen	 et	 al.,	 2010).	 In	 another	 study	










when	 grown	 on	 soybean	 oil.	 Kusaka	 et	 al.,	 1999,	 reported	 synthesis	 of	 P(3HB)	with	
ultrahigh	 molecular	 weight	 from	 5.0	 MDa	 to	 20.0	 MDa	 from	 recombinant	 E.	 coli,	
harbouring	 genes	 from	 Ralstonia	 eutropha	 H16.	 Rai	 et	 al.,	 2011	 compared	 various	
techniques	of	P(3HO)	extraction	using	different	solvents.	Soxhlet	extraction	resulted	in	
the	 low	 polymer	 yield	 but	 the	 highest	 purity	 product,	which	 is	 crucial	 in	 biomedical	
applications.	The	molecular	weight	of	the	polymer	obtained	from	Soxhlet	extraction	was	
comparable	with	the	molecular	weight	of	the	polymer	obtained	from	solvent	extraction	






parameters,	 i.e.	 the	melting	event	as	well	 as	enthalpy	of	 fusion	 remain	 stable.	 From	







the	 literature.	 The	 largest	 changes	 were	 observed	 in	 the	 cold-crystallisation	
temperature,	which	 increased	 from	36	 °C	 to	51.5	 °C.	 	 In	 this	 study,	melting	peak	 for	
P(3HB)	obtained	was	a	double	peak.	This	is	with	an	agreement	with	literature.	Multiple	
melting	 peaks	 of	 P(3HB)	 have	 been	 reported	 previously	 as	 a	 consequence	 either	 of	
conditions	 used	 during	 DSC	 analysis,	 polymorphism,	 different	 size,	 maturation	 and	
stability	of	crystals	or	physical	ageing	of	the	material	(Gunaratne	and	Shanks,	2005).		
It	is	well	known	that	the	P(3HB)	polymer	becomes	increasingly	brittle	with	the	time	of	
storage	 due	 to	 secondary	 crystallization,	 which	 occurred	 during	 ageing.	 This	 has	 an	





age	 of	 the	 studied	material	 was	 not	 mentioned.	 All	 three	mechanical	 properties	 of	
P(3HB)	produced	from	B.	subtilis	OK2	in	this	study	were	within	the	ranges	mentioned	in	
the	literature.		
The	 mechanical	 properties	 of	 the	 P(3HB)	 produced	 in	 this	 work	 were	 found	 to	 be	
unsuitable	 for	 use	 as	 a	 platform	 for	 coronary	 stent	 development.	 The	 elongation	 at	




In	 conclusion,	 this	 study	 has	 demonstrated	 the	 ability	 of	 various	 bacterial	 strains	 to	
produce	 mainly	 P(3HB)	 using	 a	 range	 of	 the	 different	 carbon	 sources.	 This	 work	
confirmed	 the	 capability	 of	 a	 Gram-positive	 GRAS	 organism,	Bacillus	 subtilis	OK2	 to	
produce	P(3HB)	with	high	polymer	yield.	Characterisation	of	the	material	verified	the	
thermal	and	mechanical	properties	typical	to	P(3HB).	Due	to	its	high	brittleness,	P(3HB)	


































Polyhydroxyalkanoates	 are	 an	 emerging	 group	 of	 biomaterials,	 which	 can	 be	 an	
alternative	to	the	traditional,	petroleum	based	plastics.	PHAs	are	produced	by	a	wide	





PHAs	are	very	elastomeric,	have	 low	crystallinity,	 low	melting	 temperature	and	glass	
transition	temperature	(Rai	et	al.,	2011).	The	drawback	of	mcl-PHAs	is	their	low	Young’s	
modulus	and	 tensile	 strength	values,	 therefore,	 they	 cannot	be	used	 in	 load	bearing	
applications.	Also,	their	low	Tg	and	Tm	values	make	them	suitable	only	for	very	specific	
applications,	due	to	restricted	methods	of	processing.	Among	mcl-PHAs	are	commonly	




2017).	 Within	 mcl-PHA	 group,	 a	 lot	 of	 different	 types	 of	 copolymers	 have	 been	
produced,	 such	 as	 poly(3-hydroxyhexanoate-co-3-hydroxyoctanoate)	 P(3HHx-3HO),	
poly(3-hydroxyoctanoate-co-3-hydroxydecanoate)	 P(3HO-3HD)	 and	 poly(3-
hydroxyoctanoate-co-3-hydroxydecanoate-co-3	 hydroxydodecanoate)	 P(3HO-3HD-
3HDD)	(Anderson	and	Dawes,	1990).	Mcl-PHAs	can	be	produced	by	different	types	of	
Pseudomonas	 sp.,	 such	 as	 P.	 aeruginosa,	 P.	 putida,	 P.	 oleovorans,	 P.	mendocina,	 P.	
raguenesii,	P.	guezennei	and	P.	stutzeri	(Simon-Collin,	2009;	Simon-Collin,	2012).	Mcl-
PHA	production	was	also	achieved	by	using	Comamonas	testosteronii	or	recombinant	E.	











PHA	 production	 from	 mixed	 cultures	 (Choi	 and	 Lee,	 1997),	 genetically	 engineered	
microorganisms,	cheap	carbon	sources	(Luckachan	and	Pillai,	2012)	as	well	as	changes	
in	fermentation	strategies	towards	continuous	fermentation	with	high	cultures	density	






























































As	 seen	 in	 Table	 8,	 all	 studied	 carbon	 sources	 resulted	 in	 mcl-PHA	 accumulation.	











































2015	 have	 observed	 similar	 adsorption	 peaks,	 obtained	 from	 the	 analysis	 and	





Chemical	 composition	 of	 obtained	 PHAs	 polymer	 was	 identified	 by	 Gas	
Chromatography-Mass	 Spectrometry	 analysis.	 The	 GC	 chromatogram	 showed	 three	







The	 mass	 spectra	 analysis	 demonstrated	 that	 the	 peak	 with	 Rt=12.3	 minutes	 was	
comparable	with	the	MS	spectrum	of	the	methyl	ester	of	9-octadecenoic	acid,	known	
also	as	oleic	acid	(Figure	30A).	Peak	with	Rt=13.4	minutes	was	comparable	with	the	MS	
spectrum	 of	 the	 methyl	 ester	 of	 9,12-octadecadienoic	 acid,	 known	 as	 linoleic	 acid	



















































1H	and	 13C	NMR	 further	 confirmed	 the	 chemical	 structure	of	 the	 composition	of	 the	
waste	frying	oil.		The	1H	NMR	spectrum	(Figure	31A)	of	the	waste	frying	oil	showed	7	
peaks	corresponding	to	the	different	proton	environments	from	the	fatty	acids	(Figure	








































Figure	31:	 (A)	 1H	NMR	and	 (B)	 13C	NMR	spectra	of	waste	 frying	oil	used	 for	mcl-PHA	
production	 as	 the	 carbon	 source.	 Chemical	 structures	 of	 stearic	 acid	 C18H36O2	 (red),	


























a.	 5.3	 -	 e-CH=CH-	 e1,	e2	-	CH=CH-	
b.	 2.7	 -	 -	 f-CH2-CH=	
c.	 2.3	 a-CH2-	 a-CH2-	 a-CH2-	
d.	 2.0	 -	 d1,	d2-CH2-CH=	 d1,	d2-CH2-CH=	
e.	 1.6	 b-CH2-	 b-CH2-	 b-CH2-	
f.	 1.3	 c-(CH2)n-	 c1,	c2-(CH2)	n-	 c1,	c2-(CH2)	n-	
g.	 0.9	 d-CH3	 f-CH3	 g-CH3	














1.	 180.2	 C1	 C1	 C1	
2.	 130.2	 -	 C2	 C2-C3	
3.	 128.1	 -	 C3	 C4-C5	
4.	 34.1	 C2	 C4	 C6	
5.	 31.5	 C3	 C5	 C7	
6.	 29.3	 C4-C8	 C6-C13	 C8-C12	
7.	 27.2	 -	 -	 C13	
8.	 25.7	 C9	 C14-C15	 C14	
9.	 24.7	 -	 C16	 C15	
10.	 22.6	 C10	 C17	 C16	





Both	 NMR	 spectra:	 1H	 and	 13C,	 confirmed	 the	 composition	 of	 the	 waste	 frying	 oil	
obtained	by	GC-MS	analysis.	The	waste	frying	oil	has	3	main	compounds	listed	below:	
9,12-octadecadienoic	acid,	9-octadecenoic	acid	and	octadecanoic	acid.	









(%	dcw),	 Optical	Density	at	450nm,	 	pH,	 	biomass	 (g/L),	 	 	nitrogen	
concentration	(g/L).	
It	was	observed	that	the	Optical	Density	 (OD)	 increased	gradually	until	30	hours	 and	
reached	 a	maximum	 value	 8.5.	 After	 that	 the	OD	 decreased.	 Biomass	 concentration	








initial	 value	 of	 0.5	 g/L	 to	 0.01	 g/L	 within	 27	 hours	 of	 fermentation	 indicating	 that	 a	
nitrogen-limiting	 environment	was	maintained	 during	 the	 fermentation.	 The	 polymer	
yield	increased	from	3.1%	dcw	at	9	hours	to	38.0%	dcw	after	48	hours.	
4.4.	Mcl-PHA	characterisation	
Obtained	 polymer	 was	 chemically	 characterised	 using	 Attenauted	 Total	 Reflectance	
Fourier	 Transform	 Infrared	 Spectroscopy	 (ATR-FTIR),	 Gas	 Chromatography–Mass	
Spectrometry	 (GC-MS)	 as	 described	 in	 the	 sections	 2.6.1.-2.6.2.	 Molecular	 weight	
analysis	was	performed	according	to	the	method	described	in	the	section	2.6.5.	


























the	 calibration,	 the	 peaks	 observed	 corresponded	 to	 the	 methyl	 esters	 of	 the	 3-















Figure	 35:	 Mass	 spectra	 of	 peaks	 obtained	 from	 GC	 of	 polymer	 produced	 by	 P.	
mendocina	and	waste	frying	oil.	Retention	times	(A)	6.0	min,	(B)	7.7	min,	(C)	9.3	min	and	
(D)	10.7	min	identified	using	the	NIST	library	as	methyl	esters	of	3-hydroxyhexanoic	acid,	










similar	 with	 the	 MS	 spectra	 of	 the	 methyl	 ester	 of	 3-hydroxydecanoic	 acid	 and	 3-





The	 dominant	 monomer	 units	 in	 these	 copolymers	 were	 3-hydroxyoctanoate	 and		
3-hydroxydecanoate.	 Table	 13	 presents	 the	 molecular	 composition	 of	 the	 mcl-PHA	
synthesised	by	P.	mendocina	using	waste	frying	oil.	The	monomer	content	was	derived	





























Polymer	sample	 Tm	(°C)	 Tg	(°C)	 Tc	(°C)	




















neat	 P(3HHx-3HO-3HD-3HDD)	 obtained	 from	 Pseudomonas	 mendocina	 CH50	 using	
waste	frying	oil	as	the	carbon	source.	
Table	 15:	 Summary	 of	 molecular	 weight	 analysis	 of	 the	 P(3HHx-3HO-3HD-3HDD)	
obtained	 from	 Pseudomonas	 mendocina	 CH50	 using	 waste	 frying	 oil	 as	 the	 carbon	
source.	Mw=	weight	average	molecular	weight,	Mn=	number	average	molecular	weight,	
PDI=	polydispersity	index.		
Polymer	sample	 Mw	(kDa)	 Mn	(kDa)	 PDI	














cheap	 carbon	 sources	 and	 renewable	 materials.	 According	 to	 the	 literature	
Pseudomonas	 sp.	 readily	 use	 fatty	 acids	 for	 PHA	 production.	 Production	 of	mcl-PHA	
copolymers	 by	 Pseudomonas	 mendocina	 CH50	 using	 waste	 frying	 oil	 has	 not	 been	
reported	 so	 far.	 Waste	 frying	 oil	 was	 selected	 for	 the	 production	 of	 the	 mcl-PHA	







composition	of	saturated	and	unsaturated	 fatty	acids.	All	 fatty	acids,	detected	 in	 the	
waste	 frying	 oil	 were	 mainly	 originated	 from	 vegetable	 oils,	 obtained	 from	 corn,	
cottonseed,	soybean,	peanuts	and	sunflower	(Demirbas,	2003).	However,	the	ratios	of	




with	 the	 various	 bacterial	 strains,	 like	 Cupriavidus	 necator	 and	 Pseudomonas	 sp.	
According	to	literature,	P(3HB)	concentration	of	up	to	90%	dry	cell	weight	was	obtained	
from	 C.	 necator	using	 canola	 oil	 and	 fructose	 in	 a	 three-stage	 fermentation	 (Lopez-












when	 grape	 pomace	was	 used	 together	 with	waste	 frying	 oil	 as	 the	 carbon	 source.	
Similarly,	 Hwan	 et	 al.,	 2008	 observed	mcl-PHA	 copolymer	 production	 with	 yields	 of	
about	23.5%	dcw	from	waste	 frying	oil.	 	Hwan	et	al,	2008	observed	accumulation	of	
23.5%	dcw	of	mcl-PHAs	using	Pseudomonas	sp.	DR2	and	waste	frying	oil	as	the	carbon	




density	 culture	 with	 continuous	 feeding	 resulted	 in	 the	 highest	 polymer	 content	 of	
55.3%	 of	 dry	 cell	 weight	 after	 54	 hours.	 Waste	 materials,	 usually	 comprise	 many	
different	compounds	in	their	composition.	According	to	results	obtained,	Pseudomonas	








the	bacterial	 strains	 (Rai	et	al.,	2011).	 In	 this	 study	nitrogen	 limiting	conditions	were	
provided	from	27	hours	of	the	fermentation,	when	ammonium	sulphate	was	completely	
consumed	by	bacteria.	 In	 this	 study,	 only	batch	 fermentation	was	 carried	out	 in	 the	














Polymer	 obtained	 by	 using	Pseudomonas	mendocina	CH50	 and	waste	 frying	 oil	 was	
confirmed	 as	mcl-PHA	and	 the	 chemical	 structure	 and	monomer	 composition	of	 the	
polymer	 showed	presence	of	FTIR	peaks	 characteristic	 for	medium	chain	 length	PHA	
(Simon-Colin	et	 al.,	 2008).	 The	 chemical	 structure	 of	 the	 obtained	 polymer	was	 also	
confirmed	by	GC-MS.	 Four	different	monomer	units,	 including:	 3HHx,	 3HO,	3HD	and	
3HDD	were	 identified.	Ashby	et	al.,	2004	has	reported	production	pf	mcl-PHA,	which	
contains	 3-hydroxyoctanoic,	 3-hydroxydecanoic	 and	 3-hydroxytetradecadienoic	 acid	
when	P.	corrugata	grown	on	various	concentrations	of	biodiesel	waste.	In	the	literature,	
different	mcl-PHA	copolymers	were	obtained,	when	waste-frying	oil	was	used	as	 the	
carbon	 source.	 Follonier	et	 al,	 2014,	 reported	 copolymer,	which	 contains	 5	different	
monomer	 units:	 3-hydroxyhexanoate,	 3-hydroxyoctanoate,	 3-hydroxydecanoate,	 3-
hydroxydodecanoate,	 and	 3-hydroxytetradecenoate	within	 the	 polymer	 chain.	 Hwan	
and	 co-workers,	 2008	 produced	 mcl-PHA	 copolymer,	 which	 contain	 5	 different	





monomer	 units:	 3-hydroxyoctanoate,	 3-hydroxydecanoate	 and	 3-dodecanoate,	
whereas	strain	Pseudomonas	Gl06	was	able	to	produced	mcl-PHA	copolymer,	containing	
3-hydroxyxehanoate,	 3-hydroxyoctanoate,	 3-hydroxydecanoate	 and	 3-dodecanoate	
within	 the	 polymer	 chain.	 This	 composition	 is	 similar	 to	 the	 mcl-PHA	 copolymer	
obtained	in	this	study.			














or	 repeatedly	 treated	 at	 high	 temperature	 in	 the	presence	of	moisture	 and	 air.	 This	
causes	three	different	types	of	degradation	reactions,	such	as	hydrolysis,	oxidation	and	
polymerisation,	which	create	various	types	of	chemical	compounds,	such	as	free	fatty	







bacterial	 strains	 (Rai	 et	 al.,	 2011).	 In	 this	 study,	 nitrogen-limiting	 conditions	 were	
provided	from	27	hours	of	the	fermentation,	when	ammonium	sulphate	was	completely	






















glass	 transition	 temperature	 ranging	 from	 -14	oC	 to	 -55	oC	and	melting	 temperatures	
around	83-86	oC,	which	is	much	higher	than	usually	observed	in	mcl-PHAs.	The	mcl-PHA	
copolymer	 obtained	 in	 this	 study	 was	 amorphous	 in	 nature.	 Only	 glass	 transition	
temperature	was	detected	at	-32oC,	which	corresponded	with	the	values	presented	in	
the	 literature.	 Polymer	 thermal	 properties	 depend	 on	 the	 number	 of	 carbon	 atoms	









several	 factors	 which	 can	 influence	 the	 molecular	 weight	 of	 the	 PHAs,	 such	 as:		
concentration	 of	 the	 PHA	 synthase,	 PHA	 depolymerase	 activity,	 polymer	 recovery	
technique,	 bacterial	 strain	 as	well	 as	 culture	 conditions,	 such	 as	 temperature	 or	 pH	
might	affect	the	molecular	weight	of	the	final	polymer	(Tsuge,	2016;	Bugnicourt	et	al.,	
2014).	 Different	 researchers	 have	 reported	 production	 of	mcl-PHAs	 with	 a	 range	 of	
molecular	 weight	 values	 from	 60	 to	 330kDa.	 For	 example,	 Martelli	 and	 co-workers	
(2012)	produced	P(3HO-3HD-3HDD)	copolymer,	which	had	a	molecular	weight	140	kDa.	
Gumel	 et	 al.	 2012,	 reported	 the	 molecular	 weight	 of	 mcl-PHAs	 obtained	 from	
Pseudomonas	putida	Bet001	using	various	carbon	sources	to	be	between	55-77.7kDa.	












































Polyhydroxyalkanoates	 (PHAs)	 are	 the	 natural	 biopolyesters,	 intensively	 studied	 for	








Various	 approaches	 have	 been	 taken	 to	 improve	 the	 properties	 of	 the	 biomaterials.	
Physical	 blending	 is	 one	 of	 the	 approaches	 to	 obtain	 novel	 material	 with	 different	
properties,	superior	to	the	materials	already	existing	(Chen	and	Wu,	2005).	PHAs	have	





However,	 the	 results	 obtained	 are	 still	 not	 satisfactory.	 The	 problem	 with	 blending	
between	two	different	types	of	polymers	is	poor	miscibility	of	the	system,	which	leads	
to	 a	 phase	 separation	 (Chen	 and	 Luo,	 2009).	 Addition	 of	 low	 molecular	 weight	
compounds,	 such	 as	 hydrolysed	polymers,	might	 have	 an	 improvement	 in	 the	blend	
miscibility	by	acting	as	the	plasticisers.	Poor	compatibility	in	P(3HB)	blends	with	other	




Plasticizers	 are	 small	 molecules	 incorporated	 into	 polymeric	 materials	 in	 order	 to	
enhance	their	flexibility	and	processability	(Platzer,	1982).	Plasticizers	are	mainly	added	
to	 hard	 and	 brittle	 polymers	 in	 order	 to	 decrease	 glass	 transition	 temperature	 (Tg),	







properties.	 In	 order	 to	 be	 used	 as	 a	 plasticiser	 every	 substance	 has	 to	meet	 certain	
criteria.	This	include:	low	volatility,	temperature	stability,	odourless,	compatibility	with	






and	 safety	 concerns	 of	 the	 degradation	 products	 of	 various	 plasticisers	 (Horn	et	 al.,	
2004.).	 Therefore,	many	 research	 groups	 have	 been	working	 extensively	 in	 order	 to	
develop	safer	alternatives,	which	will	demonstrate	comparable	plasticising	effect,	faster	




Different	 types	of	esters	of	 citric	acid,	 known	as	biocompatible	 compatibilisers,	have	
been	an	attractive	additive	for	PHAs	(Ghiya	et	al.,	1995;	Hull,	1990).	
Biomedical	 applications	 require	 from	 any	 biomaterials	 including	 various	 additives,	
plasticisers	and	 fillers	high	biocompatibility,	non-toxicity,	degradability,	processability	





surrounding	 tissues	 may	 not	 only	 lead	 to	 toxicity	 effects	 but	 also	 drastically	 alter	
materials	properties	before	the	degradation	of	the	implanted	material	(Snejdrova	and	
Dittrich,	 2012).	 The	 smaller	 the	 plasticizer	 molecule,	 the	 greater	 its	 volatility	 and,	
therefore,	 the	 rate	 at	 which	 it	 is	 lost	 from	 the	 plasticised	 product	 (Li	 et	 al.,	 2008).	
Increase	 in	molecular	weight	of	plasticisers	 reduce	migration	 speed	or	 fully	prevents	















Garcia	 et	 al.,	 2017).	 Hence,	 plasticisers	 based	 on	 PHAs	 can	 be	 very	 attractive	
compounds,	due	to	natural	origin,	biodegradability	and	non-toxicity.	They	can	be	very	
attractive	 alternative	 for	 petroleum	 based	 plasticisers	 and	 allow	 obtaining	 fully	
compostable	 materials.	 	 Oligomeric	 derivatives	 of	 PHAs	 can	 be	 produced	 by	 using	




in	coronary	artery	stents.	 In	 this	study,	 three	different	blends	of	P(3HB)/oligo-PHA	 in	
ratios:	95/5,	90/10	and	80/20	have	been	developed.	Materials	were	fully	characterized	
in	 order	 to	 obtain	 their	 thermal	 and	 mechanical	 properties.	 	 Evolution	 of	 various	
properties	 have	 been	 studied	 during	 material	 storage	 for	 7	 weeks.	 In	 vitro	
biocompatibility	of	the	blends	was	tested	with	human	dermal	microvascular	endothelial	
cells	HMEC-1	to	evaluate	the	potential	of	new	biodegradable	material	 in	applications	
such	 as	 coronary	 artery	 stent.	 Additionally,	 haemocompatibility	 studies,	 including	
haemolysis	 and	 blood	 clotting	 studies,	 as	 well	 as	 white	 cell	 activation	 studies	 were	





































The	 hydrolysed	 P(3HHx-3HO-3HD-3HDD)	 was	 a	 waxy	 material.	 The	 material	 was	

















Four	 main	 adsorption	 peaks	 were	 observed	 at:	 2926cm-1,	 2856cm-1,	 1726cm-1	 and	





The	 thermal	 properties	 of	 the	 hydrolysed	 P(3HHx-3HO-3HD-3HDD)	 copolymer	 were	
analysed	by	DSC.	The	thermogram	of	the	hydrolysed	polymer	is	shown	in	the	Figure	39.	









of	 hydrolysis.	 Tm=	 melting	 temperature,	 Tg=	 glass	 transition	 temperature,	 Tc=	
crystallisation	temperature.		

























Polymer	 Mw,	kDa	 Mn,	kDa	 PDI	
oligo-PHA	 10	 4.6	 2.2	
	
The	GPC	results	obtained	 (Table	17)	clearly	confirmed	that	hydrolysis	of	 the	P(3HHx-
3HO-3HD-3HDD)	 copolymer	 has	 occurred.	 The	 molecular	 weight	 of	 the	 hydrolysed	
polymer	was	 reduced	 significantly	 and	measured	 as	 10kDa.	 The	 polydispersity	 index	









the	 storage	 is	 a	 well-known	 complex	 phenomenon	 which	 is	 mainly	 attributed	 to	 a	
secondary	 crystallisation	 and	 ageing	 of	 the	 amorphous	 phase	 (Barham	 et	 al.,	 1984).	


























Table	 19:	 Summary	 of	 the	 thermal	 analysis	 of	 P(3HB)/hydrolysed	 P(3HHx-3HO-3HD-
3HDD)	blends	during	7	weeks	of	storage.	Tm=	melting	temperature,	DHapp=	enthalpy	of	
fusion,	DHnorm=	entalphy	of	fusion	normalised	to	P(3HB),	Xc=	crystallinity	degree.	
Week	 Sample	 Tm,	oC	 DHapp,	Jg-1	
DHnorm,	𝐉𝐠𝐏(𝟑𝐇𝐁)C𝟏 	 XC,	%*	
2	 P(3HB)	neat	 174.8	 82.5	 82.5	 56.5	
	 95/5	blend	 174.2	 66.9	 70.4	 48.2	
	 90/10	blend	 167.0	 67.5	 71.0	 48.6	
	 80/20	blend	 171.4	 -	 -	 -	
5	 P(3HB)	neat	 175.2	 84.4	 84.4	 57.8	
	 95/5	blend	 170.4	 62.6	 69.6	 47.7	
	 90/10	blend	 173.9	 65.1	 72.3	 49.5	
	 80/20	blend	 167.2	 43.1	 53.9	 36.9	
7	 P(3HB)	neat	 176.6	 85.9	 85.9	 58.8	
	 95/5	blend	 171.7	 -	 -	 -	
	 90/10	blend	 174.8	 56.5	 70.6	 48.4	





storage	 for	 7	 weeks	 (Table	 18),	 confirming	 the	 previously	 reported	 secondary	
crystallisation	of	P(3HB).	 Total	 enthalpy	of	 fusion	 (DHapp)	was	 lower	 for	 all	 blends	 as	
compared	with	neat	P(3HB).	Also,	addition	of	the	oligo-PHA	resulted	in	a	small	decrease	
of	melting	temperature	(Tm),	between	2	to	5	oC.	No	further	changes	in	the	enthalpy	of	














DSC	 thermograms	 (Figure	 41)	 of	 blends	 did	 not	 show	 a	 thermal	 event	 in	 the	 range	
































95/5	 16.9±0.2	 600±100	 45.9±1.3	
90/10	 15.1±0.5	 600±100	 47.0±0.4	
80/20	 11.4±0.05	 300±40	 52.8±2.4	
2	
95/5	 11.6±0.1	 900±100	 36.1±3.5	
90/10	 12.4±0.5	 900±20	 24.2±4.7	
80/20	 11.3±0.2	 890±5	 39.0±4.1	
5	
95/5	 12.8±0.4	 1000±100	 4.9±3.0	
90/10	 8.3±0.6	 660±40	 11.2±3.4	
80/20	 5.3±0.2	 420±40	 18.6±3.5	
7	
95/5	 12.9±0.8	 1040±90	 3.8±0.4	
90/10	 14.8±0.7	 1240±80	 6.2±0.8	
80/20	 6.4±0.4	 480±30	 13.3±3.8	
	
Material	ageing	has	 influenced	 the	mechanical	properties	of	 the	P(3HB)/oligo-PHA	blend	
films.	 For	 P(3HB)/oligo-PHA	 blend	 in	 ratio	 95/5	 the	 tensile	 strength	 decreased	 from	





the	 Young’s	 Modulus	 values	 significantly	 increased	 from	 600±100MPa	 after	 week	 1	 to	
1240±80MPa	after	week	7	and	an	elongation	at	break	decreased	from	47.0±0.4%	after	week	
1	 to	6.2±0.8%	strain	after	week	7.	 For	P(3HB)/oligo-PHA	blend	 in	 ratio	80/20	 the	 tensile	
strength	decreased	from	11.4±0.05MPa	at	week	1	to	6.4±0.4MPa	after	7	weeks	of	storage;	













storage	at	room	temperature.	( )	P(3HB),	( )	95/5	blend,	( )	90/10	blend,	( )	80/20	
blend.	 
The	embrittlement	behaviour	is	a	characteristic	material	property	of	P(3HB).	Addition	of	













In	 summary,	 an	 addition	 of	 oligo-PHA	 resulted	 in	 obtaining	 materials	 with	 novel	





can	be	 seen	 from	SEM	 images	 shown	 in	Figure	43,	all	materials	had	 similar	 irregular	














characterised	 quantitatively	 as	 the	 root	 mean	 square	 roughness	 (Rq)	 using	 laser	
profilometry	 (Figure	 44).	 The	 mean	 square	 roughness	 of	 the	 P(3HB)	 neat	 film	 was	





















error	 bars=±SD).	 The	 data	 were	 compared	 with	 the	 neat	 P(3HB)	 using	 ANOVA.	 *	
indicates	p<	0.05	and	**	indicates	p<0.005.	
These	 results	 obtained	 from	 surface	 roughness	 measurements	 confirmed	 the	 SEM	


































Figure	45:	 Static	water	 contact	angle	measurements	 for	 the	neat	P(3HB)	 film	and	 its	
blends	with	oligo-PHA	(n=3;	error	bars=±SD).	The	data	were	compared	with	neat	P(3HB)	
using	ANOVA.		*	indicates	p-value	<	0.05.	
Materials,	 which	 have	 contact	 angle	 value	 higher	 than	 70°	 are	 considered	 as	












and	 95/5,	 90/10	 and	 80/20	 blends	 respectively.	 There	 was	 no	 significant	 difference	
between	P(3HB)	and	95/5	blend.	There	was	significant	difference	between	the	90/10	and	

























Figure	 47:	 Cell	 proliferation	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)	 film	 and	
P(3HB)/oligo-PHA	blend	film	samples	at	day	1,	3	and	7	(n=3;	error	bars=±SD).	The	data	
were	 compared	 with	 standard	 tissue	 culture	 plastic	 (positive	 control),	 which	 was	
normalised	to	100%	using	ANOVA.	*	indicates	p<	0.05	and	**	indicates	p<0.005.	( )	TCP,	











to	 TCP:	 152±0.5%,	 178.2±2.2%	 and	 192±1.6%	 at	 day	 1,	 3	 and	 7	 respectively.	 The	
differences	were	statistically	significant	in	comparison	to	TCP	at	day	1	(*p=0.019),	day	
3	 (*p=0.021)	 and	day	7	 (**p=0.0016).	 The	highest	 viability	 of	 the	HMEC-1	 cells	was	
achieved	on	the	surface	of	the	80/20	blend	which	supported	262.4±2.7%,	277.1±4.4%,	
291.7±2.1%	 of	 viable	 cells	 compared	 with	 TCP	 on	 day	 1,	 3	 and	 7	 respectively.	 The	
differences	were	statistically	significant	in	comparison	to	TCP	on	day	1	(**p=0.0048),	
day	3	(**p=0.0022)	and	day	7(**p=0.0031).	









Cell	 adhesion	 and	 proliferation	 was	 further	 characterised	 using	 SEM	 imaging.	
Micrographs	 presented	 in	 Figure	 46	 revealed	 that	 HMEC-1	 cells	 adhered	 and	
proliferated	evenly	 across	 the	 surface.	Cell	 density	evidently	 increased	with	a	higher	
concentration	of	oligo-PHA	within	the	blend,	which	is	in	agreement	with	the	results	of	
the	 MTT	 assay.	 This	 order	 of	 the	 materials	 ability	 to	 support	 cell	 proliferation	 also	
matched	 the	 order	 of	 increasing	 surface	 roughness,	 hydrophobicity	 and	 protein	







































HMEC-1	 cells	 (red)	 on	 different	 PHA	 materials	 at	 day	 7.	 (A)	 Neat	 P(3HB)	 film,	 (B)	
























Haemolysis	 study	 was	 performed	 on	 P(3HB)	 neat	 films	 as	 well	 as	 P(3HB)/oligo-PHA	
blends	to	check	if	the	materials	would	cause	haemolysis,	which	is	lysis	of	the	red	blood	



















than	 5%.	 The	 results	 obtained	 demonstrated	 that	 PHAs	 are	 non-haemolytic	 (%	
haemolysis	0-2%)	materials,	whereas	PL38	is	slightly	haemolytic	(%	haemolysis	2-5%).	
According	to	the	ISO	10993-4:2002	standard,	the	%	haemolysis	value	should	be	below	
5%.	 All	 tested	 materials	 demonstrated	 haemolysis	 at	 levels	 below	 5%.	 This	 result	
showed	that	all	tested	films	had	low	potential	to	destroy	red	blood	cells.	
5.5.2.	Whole	blood	clotting	
Whole	 blood	 clotting	 experiment	 was	 performed	 to	 investigate	 the	 potential	
procoagulant	 properties	 and	 thrombogenicity	 of	 the	 materials.	 Red	 blood	 cells	 not	












demonstrated	15.1±1.3%	blood	 clotting,	which	was	 significantly	 lower	blood	 clotting	
rate	 than	 the	positive	control,	 tissue	culture	plastic	 (TCP)	with	a	value	of	25.2±	0.2%	





































































































CD86-PE	 162.8	 41.7	 146.2	 -	





CD11b-PE	 715.2	 426.3	 1104.6	 683.9	
CD66B-FITC	 175.1	 -	 225.9	 38.7	
	
LPS	 is	 present	 in	 the	 cell	 walls	 of	 Gram	 negative	 bacteria.	 It	 is	 also	 known	 as	 an	
endotoxin.		
	From	 the	 results	 obtained	 it	 is	 evident	 that	 LPS	 triggered	 an	 increased	 activity	 of	
monocytes	and	neutrophils.	CD11b-PE	 is	a	marker	of	activation	 for	both:	neutrophils	
and	monocytes.	 It	 is	an	adhesion	molecule	and	its	expression	increases	several	hours	

















present	 within	 the	 polymer	 can	 lead	 to	 accelerated	 white	 blood	 activation	 and	
inflammatory	 response	 from	 the	 body	 against	 the	 polymeric	 material.	 Therefore,	

























CD86-PE	 176.5	 53.6	 117.3	 -	
CD45-PerCP	 51.3	 -	 79.1	 -	
CD11b-PE	 464.2	 241.5	 955.3	 578.0	




CD86-PE	 113.5	 -	 121.9	 -	
CD45-PerCP	 94.7	 -	 86.1	 -	
CD11b-PE	 665.1	 389.4	 742.32	 426.8	







CD86-PE	 217.4	 89.2	 162.6	 3.5	
CD45-PerCP	 135.9	 0.0	 117.8	 0.17	
CD11b-PE	 517.4	 280.7	 742.3	 426.8	
CD66B-FITC	 311.97	 53.9	 175.1	 7.5	
80/20	
blend	
CD86-PE	 126.4	 10.0	 136.9	 -	
CD45-PerCP	 121.9	 11.4	 94.7	 -	
CD11b-PE	 431.4	 217.4	 556.3	 294.8	
CD66B-FITC	 -	 -	 -	 -	
PL38	
CD86-PE	 106.6	 -	 101.6	 -	
CD45-PerCP	 113.5	 3.7	 101.8	 -	
CD11b-PE	 597.7	 339.8	 1584.1	 1024.3	
CD66B-FITC	 135.9	 -	 131.1	 -	
	
Results	 obtained	 after	 staining	 blood	 samples,	 exposed	 to	 various	 polymer	 samples	
demonstrated	different	levels	of	activity	of	monocytes	as	well	as	neutrophils.	The	neat	














analysis	 of	 P(3HB)/oligo-PHA	 blends	 (Figure	 41)	 confirmed	 good	 compatibility	 of	 the	







same	 material	 before	 hydrolysis.	 The	 glass	 transition	 temperature	 for	 oligo-PHA	
copolymer	was	at	-39oC.	Two	melting	events	were	detected:	at	28.6°C	and	38.6°C.	The	
observed	 low	 value	 of	 Tg	 as	 typical	 to	 mcl-PHAs.	 Melting	 events	 observed	 in	 the	
thermograms	were	 at	 lower	 temperatures	 than	mcl-PHAs.	 Although	 the	 addition	 of	
oligo-PHA	to	P(3HB)	caused	only	a	small	decrease	 in	melting	temperature,	 it	 led	to	a	
significant	drop	in	the	crystallinity	of	P(3HB).	Meszynska	and	co-workers	(2015)	reported	
application	 of	 oligomeric	 compounds	 of	 P(3HB)	 as	 plasticiser	 into	 P(3HB-co-4HB)	
copolymer.	 However,	 oligo-PHB	 worked	 more	 like	 nucleating	 agent,	 rather	 than	
plasticiser.	Oligo-PHB	did	not	have	any	influence	on	the	glass	transition	temperature	or	
crystallisation	 temperature.	Melting	 temperature	of	 the	new	system	and	crystallinity	
degree	increased	significantly	in	comparison	to	neat	P(3HB-co-4HB)	copolymer.	Type	of	
plasticiser	can	have	detrimental	effect	on	the	material	properties.	The	same	polymer	
(P(3HB-co-4HB),	 mixed	 with	 monoglyceride	 acetate	 demonstrated	 totally	 different	
thermal	 properties	 than	 P(3HB-co-4HB)	 mixed	 with	 oligo-PHB.	 Glass	 transition	
temperature	and	crystallisation	temperature	decreased,	while	other	parameters	did	not	







co-workers	 studied	 addition	 of	 butyryltrihexyl	 citrate	 to	 P(3HB).	 Obtained	 material	
presented	lower	value	of	Young’s	Modulus	and	higher	elongation	at	break	in	comparison	
to	neat	P(3HB)	 (Ghiya	et	al.,	1995).	 In	another	study	reported	by	Meszynska	and	co-
workers	 (2015),	 an	 addition	 of	 monoglyceride	 acetate	 to	 P(3HB-co-4HB)	 confirmed	
results	obtained	in	this	study.	However,	an	addition	of	oligomeric	form	of	P(3HB)	to	the	
same	 copolymer	 resulted	 in	 different	 mechanical	 properties	 of	 the	 final	 material.	
Material	 became	 more	 stiff	 and	 strong,	 without	 loss	 of	 any	 elastomeric	 properties	
(Meszynska	 et	 al.,	 2015).	 Experiments	 performed	 by	 Garcia-Garcia	 and	 co-workers	









glycols	 (PEG200,	 PEG1000	 and	 PEG4000),	 lauric	 and	 stearic	 acids	 on	 P(3HB-co-3HV)	
copolymer.	As	a	result,	among	all	tested	compounds,	only	addition	of	PEG1000	resulted	
in	 slight	 improvement	 of	 elastomeric	 properties	 in	 P(3HB-co-3HV)	 copolymers	 films	
(Requena	et	al.,	2016).	Another	very	important	aspect	was	related	to	the	concentration	
of	 the	 plasticiser.	 Panaitescu	 and	 co-workers	 (2016)	 reported	 that	 properties	 of	 the	
material	obtained	after	addition	of	plasticiser	depends	on	the	amount	of	the	compound	
added.	Higher	concentration	of	plasticisers	may	result	in	sudden	drop	in	the	properties	
of	 the	 material,	 which	 can	 be	 a	 consequence	 of	 phase	 separation	 and	 limited	
compatibility	 between	 polymer	 and	 an	 additive	 (Panaitescu	 et	 al.,	 2016).	 	 The	
mechanical	 properties	 of	 both	 neat	 P(3HB)	 and	 P(3HB)/oligo-PHA	 blends	 gradually	
changed	during	the	7-week	ageing.	Although	the	addition	of	oligo-PHA	did	not	eliminate	
the	 increase	 in	 stiffness	 of	 the	 P(3HB)-based	 materials	 attributed	 to	 the	 ageing	
processes,	oligo-PHAs	had	a	clear	plasticising	effect	on	the	P(3HB)	resulting	 in	softer,	







understood	 due	 to	 shortage	 of	 relevant	 literature.	 Different	 approaches	 have	 been	
taken,	 in	 order	 to	 increase	 surface	 roughness	of	 PHAs.	 These	 include	mainly	 surface	
modifications,	such	as	plasma	treatment,	laser	micropatterning,	chemical	modifications	
(Slepicka	 et	 al.,	 2017).	 Surface	 roughness	 can	 be	 also	 affected	 by	 using	 different	
processing	techniques.	For	example,	Yu	and	co-workers,	2009	reported	that	solvent	cast	


















on	 the	 hydrophobic	 surfaces	 in	 comparison	 to	 fibronectin,	 which	 prefers	 more	
hydrophilic	 materials	 (Iuliano	 et	 al.,	 1993).	 Both	 proteins:	 albumin	 and	 fibronectin	
supports	each	other.	For	example,	adsorbed	albumin	inhibits	conformational	changes	in	
fibronectin	 and	 allows	 fibronectin	 RGD	 active	 sites	 to	 be	 more	 accessible	 to	 cells	
(Anselme	et	al.,	2010).	 	 In	general,	mcl-PHAs	have	higher	contact	angle	values	due	to	
increased	 hydrophobicity	 of	 the	material	 induced	 by	 the	 longer	 length	 of	monomer	
chains.	 Surface	 roughness	 is	 one	 of	 the	 crucial	 factors	 which	 is	 measured	 while	
evaluating	 any	 biomaterial	 for	 biomedical	 applications	 (Das	 et	 al.,	 2007).	 Numerous	
studies	 have	 revealed	 that	most	 of	 the	 cells	 prefer	 to	 attach	 on	 a	 rough	 surface	 as	
compared	to	the	smooth	surface.	An	uneven	or	a	rough	surface	provides	the	cells	with	
several	adhesion	points	that	allow	them	to	migrate	and	proliferate	(Hao	and	Lawrence,	
2004).	 Restrained	 hydrophilic	 and	 positively	 charged	 materials	 encourage	 cell	
attachment	 due	 to	 the	 adhesion	 of	 specific	 molecules,	 such	 as	 vitronectin	 and	
fibronectin,	 which	 make	 specific	 sites	 accessible	 for	 the	 cell	 adhesion	 receptors	
(Bacakova	et	al.,	2011).	
The	 human	 dermal	 microvascular	 cell	 line	 was	 used	 for	 in	 vitro	 assessment	 of	
attachment	 and	 proliferation	 of	 cells	 relevant	 to	 coronary	 stent	 application.	
Biocompatibility	studies	confirmed	that	P(3HB)/oligo-PHA	materials	were	not	cytotoxic.	




morphology.	 All	 P(3HB)/oligo-PHA	 materials	 showed	 better	 ability	 to	 support	 cell	
growth	compared	with	control	standard	tissue	culture	plastic.	Cell	proliferation	on	the	




is	 covered	with	 proteins	 from	blood	 and	body	 fluids.	 Cells	 are	 able	 to	 sense	 foreign	
surfaces	by	this	adsorbed	protein	layer	and	respond	to	it	accordingly.	Process	of	cells	





to	 attach	 to	 rougher	 than	 smoother	 surfaces.	 However,	 the	 lever	 of	 roughness	 is	
individual	 for	 each	 cell	 type	 (Korovessis	 et	 al.,	 2002).	 For	 example,	 Kunzler	 and	 co-
workers	demonstrated	that	osteoblasts	more	favoured	rough	surfaces,	while	fibroblast	
definitely	 prefer	 smooth	 materials	 (Kunzler	 et	 al.,	 2007).	 Improved	 affinity	 of	
P(3HB)/oligo-PHA	blends	towards	proteins	could	contribute	to	the	materials	enhanced	
ability	to	support	cell	proliferation.	Also	by	variation	of	the	amount	of	plasticiser	varied	
the	 mechanical	 properties	 of	 the	 blend.	 There	 is	 growing	 research	 intrest	 in	
demonstrating	 the	 role	 of	 substrate	 mechanics	 in	 the	 behaviour	 and	 function	 of	
individual	 cells,	 in	 particular	material	 stiffness	 (Han	 et	 al.,	 2016).	 Pelham	 and	Wang	
(1997),	 demonstrated	 that	 rat	 kidney	 epithelial	 cells	 and	 3T3	 fibroblasts	 responded	
differently	 to	 varied	 flexibility	 of	 the	material	 (Pelham	 and	Wang,	 1997).	 In	 another	











environment	 for	 increased	 endothelial	 cell	 adhesion	 and	 proliferation	 by	 adjusting	
surface	chemistry	as	well	as	polymer	film	thickness	(Bhattacharyya	et	al.,	2010).	
The	compatibility	of	P(3HB)	and	P(3HB)/oligo-PHA	blends	after	direct	contact	with	blood	
were	 investigated.	 All	 materials	 demonstrated	 a	 non-haemolytic	 effect	 on	 the	




response	 is	 a	 very	 complex	 mechanism	 of	 several	 reactions,	 quite	 complicated	 to	
perform	in	one	study	(Ratner,	2007).	Many	different	experiments	need	to	be	carried	out	
to	evaluate	the	biomaterials	appropriately.	This	should	include	effect	on	haematology,	








and	 then	migrate	 into	 tissues	 and	 differentiate	 into	macrophages	 (Anderson,	 1993).	
Bacteria	and	their	metabolites	can	induce	activation	of	both:	neutrophils	and	monocytes	
(Gorbet	and	Sefton,	2004).	LPS	is	released	after	destruction	of	the	entire	cell	(Lynn	and	
Golenbock,	 1992).	 It	 can	 cause	 strong	 immunogenic	 response	 in	human	and	animals	
(Lemke,	1994).	FDA	approved	the	acceptable	level	of	endotoxin	in	medical	devices	to	be	
0.5EU/mL	 or	 20EU/device	 for	 products,	 which	 directly	 or	 indirectly	 contact	
cardiovascular	system	(FDA,	1987).	Leucocytes	can	be	activated	by	0.01	ng/ml	of	LPS,	an	
equivalent	of	0.05	EU/ml	(Weingarten	et	al.,	1993).	
P(3HB)	 was	 produced	 by	 Gram-positive	 bacteria,	 free	 from	 the	 presence	 of	 LPS.	
Therefore,	 it	was	worth	investigating	further,	the	reason	behind	obtaining	this	result.	
One	 of	 the	 hypothesis	might	 be	 an	 ability	 of	 some	 of	 the	Gram-positive	 bacteria	 to	









In	 conclusion,	 addition	 of	 oligo-PHA	 resulted	 in	 an	 improved	 material	 properties	 in	
comparison	to	neat	P(3HB).	This	include	mechanical	properties,	surface	topography	and	































value	 to	 the	 compatibility	 or	 radiopaque	 properties,	 by	 acting	 as	 a	 contrast	 agent.	
Composites	 can	 be	 produced	 by	 various	 techniques,	 such	 as	 a	 solvent	 casting,	melt	
extrusion,	hot	pressing,	cross-linking	and	melt-blending	(De	Arenaza	et	al.,	2015).	
Radiopacity	is	a	property	exhibited	by	some	of	the	materials,	which	allows	them	to	be	
visible	 under	 X-ray.	 These	 materials	 are	 able	 to	 absorb	 X-rays	 and	 occur	 white	 on	













the	 stent	 struts	 (Scott	 et	 al.,	 2004).	 Some	 of	 radiopaque	 markers,	 like	 for	 example	
tantalum	 have	 been	 studied	 as	 powder	 and	 be	 integrated	within	 stent	 (Nagy	 et	 al.,	
2014).	Several	studies	confirmed	significant	increase	of	visibility	of	the	stent	containing	
markers	 in	 comparison	 to	 neat	metallic	 stents	 (Nagy,	 2014;	Wiskirchen	 et	 al.,	 2004;	
Wiskirchen	 et	 al.,	 2003).	 Polymeric	 materials	 are	 not	 radiopaque	 in	 nature.	 Hence,	
addition	of	radiopaque	agents	is	required	in	order	to	be	able	to	be	implanted	within	the	
artery.	Commercially	 available,	polymeric	biodegradable	 stent,	named	Absorb	 (Abott	








materials	 such	 as	 polylactic	 acid,	 polyurethanes,	 polymethylmethacrylate	 and	
polypropylene	(Baleani	and	Viceconti,	2010;	Kurtz	et	al.,	2005).		
















6.1.	 Development	 of	 Poly(3-hydroxybutyrate)/oligo-PHAs	 radiopaque	
composites	
Three	types	of	P(3HB)/oligo-PHA	in	ratio	90/10	composites	with	1	wt%,	3	wt%	and	5	wt%	











Solvent	 cast	 composite	 films	 were	 characterised	 with	 respect	 to	 their	 thermal,	
mechanical	 and	 topographical	 properties.	 Additionally,	 biocompatibility	 and	
haemocompatibility	studies	were	perform	in	order	to	confirm	non-toxicity	and	safety	of	
the	biomaterials.		
6.2.1.	Attenuated	Total	Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
Preliminary	characterisation	of	the	P(3HB)/oligo-PHA	composites	with	barium	sulphate	






1	 and	 606cm-1,	 corresponded	 to	 the	 out	 of	 plane	 bending	 vibration	 of	 sulphate	
(Ramaswamy	et	al.,	2011;	Shen	et	al.,	2007).			
 
Figure	 55:	 ATR-FTIR	 spectrum	 of	 the	 P(3HB)/oligo-PHA	 composites	 with	 barium	
sulphate.	 ( )	 P(3HB)/oligo-mcl-PHA	 90/10	 blend	 without	 barium	 sulphate,	 ( )	
composite	 film	 containing	 1%	 barium	 sulphate,	 ( )	 composite	 film	 containing	 3%	
barium	 sulphate,	 ( )	 composite	 film	 containing	 5%	 barium	 sulphate	 indicating	
characteristic	peaks	for	PHAs	and	SO42-.		
FTIR-ATR	 analysis	 of	 the	 composites	 revealed	 absorption	 bonds	 at	 1720.5	 cm-1	 and	
1276.5	cm-1	corresponding	to	the	ester	carbonyl	group	and	the	-CH	group,	respectively.	
Obtained	 values	 are	 typical	 to	 scl-PHAs,	 as	 described	 in	 the	 section	 3.3.1.	 The	weak	























Tg	(°C)	 Tm	(°C)	 ΔHf	(J/g)	 Tc	(°C)	
1	
1	wt%	 -11.6	 171.3±1.1	 88.1±8.5	 53	
3	wt%	 -4.2	 168.2±0.3	 74.3±1.9	 53.8	
5	wt%	 -8.4	 167.5±1.9	 75.5±3.5	 45.9	
3	
1	wt%	 -2.9	 169.2±1.6	 87.3±1.1	 52.5	
3	wt%	 -4.3	 168.8±2.0	 81.0±4.2	 53.9	
5	wt%	 -2.5	 170.4±1.5	 77.2±4.3	 52.9	
5	
1	wt%	 -2.2	 169.7±1.9	 82.7±2.1	 55.3	
3	wt%	 -2.1	 169.8±1.6	 83.9±0.9	 58.3	
5	wt%	 -2.6	 170±1.9	 78.9±0.8	 56.8	
7	
1	wt%	 -3.2	 169.1±1.5	 84.2±3.02	 53.8	
3	wt%	 -3.3	 169.1±2.1	 85.5±3.5	 55.2	








Figure	 56:	 DSC	 thermograms	 of	 P(3HB)/oligo-PHA	 blend	 in	 the	 ratio	 90/10	 and	
composite	films	with	addition	if	1%,	3%	and	5	wt%	of	BaSO4	stored	for	7	weeks	at	room	







































1	wt%	 12.9±1.3	 520±60	 14.2±0.2	
3	wt%	 11.2±0.4	 430±120	 9.1±0.3	
5	wt%	 13.1±1.9	 680±140	 7.9±1.1	
3	
1	wt%	 18.2±0.9	 1310±50	 8.4±0.4	
3	wt%	 18.1±0.9	 1250±30	 7.9±1.7	
5	wt%	 18.5±3.2	 1230±70	 4.7±0.1	
5	
1	wt%	 17.1±1.5	 1160±140	 4.3±0.7	
3	wt%	 17.1±0.8	 1250±7	 4.5±0.1	
5	wt%	 16.0±0.6	 1070±280	 4.3±0.1	
7	
1	wt%	 16.2±2.1	 1020±100	 4.4±0.8	
3	wt%	 14.6±1.3	 920±80	 4.9±0.6	







Figure	 57:	 Changes	 in	 the	 ultimate	 tensile	 strength	 (A),	 Young’s	 modulus	 (B)	 and	
elongation	 at	 break	 (C),	 during	 storage	 of	 neat	 P(3HB)/oligo-PHA	 blend	 and	 its	
composites	with	BaSO4	for	7	weeks	at	room	temperature.	( )		0%	barium	sulphate	film,	






films	with	 barium	 sulphate	 had	 changed.	 For	 the	 composite	with	 addition	 of	 1	wt%	




90/10	 resulted	 in	decrease	of	 the	elongation	at	break	after	7	weeks	of	 storage	 from	
9.9±6.1%	to	4.9±1.6%.	Young’s	modulus	 increased	from	0.4±0.1	MPa	to	0.9±0.1	GPa.	
The	tensile	strength	increased	after	7	weeks	from	11.2±0.4	MPa	to	14.6±1.3	MPa.	For	
the	 composition	 with	 the	 addition	 of	 5	 wt%	 barium	 sulphate,	 elongation	 at	 break	
decreased	after	3	weeks	of	storage	from	7.9±6.1%	to	4.3±0.5%.	Young’s	modulus	value	
increased	from	0.7±0.1	MPa	to	1.1±0.1	GPa.	Tensile	strength	increased	after	7	weeks	





break,	 hence,	 the	 material	 became	 more	 brittle.	 The	 minimum	 amount	 of	 barium	

































BaSO4	 (n=3;	 error	 bars=±SD).	 The	 data	were	 compared	with	 P(3HB)/oligo-PHA	90/10	
blend	film	without	addition	of	barium	sulphate	using	ANOVA.	*	indicates	p<	0.05.		
Results	 obtained	 from	 surface	 roughness	measurements	 confirmed	 further	 the	 SEM	
findings.	The	surface	of	the	all	composite	samples	resulted	with	root	mean	square	(Rq)	
value	greater	than	1.	SEM	images	of	the	surface	topography	for	P(3HB)/oligo-PHAs	with	
an	 addition	 of	 BaSO4	 composites	 demonstrated	 rough	 surfaces.	With	 an	 increase	 in	
surface	 roughness	with	 the	concentration	of	BaSO4	 the	difference	was	significant	 for	
composition	with	the	5	wt%	BaSO4	in	comparison	to	the	neat	P(3HB)/oligo-PHA	blend	
film.	Higher	 surface	 roughness	of	 the	P(3HB)/oligo-PHA	 composites	with	 an	 increase	















in	 all	 tested	materials,	 therefore	materials	 were	 hydrophobic	 in	 nature.	 Addition	 of	
barium	 sulphate	 decreased	 the	 value	 of	 water	 contact	 angle,	 hence	 the	 related	
hydrophobicity.	Neat	blend	of	P(3HB)/oligo-PHAs	has	 contact	 angle	 value	112.5	±4.3	
degrees,	whereas	addition	of	5%	BaSO4	reduced	static	contact	angle	values	to	87.2±1.5	
degrees.	The	results	obtained	of	the	water	contact	angle	were	significantly	lower	for	the	
composites	 in	 comparison	 to	 the	 P(3HB)/oligo-PHAs	 blend	 in	 ratio	 90/10.	 Although,	


















Figure	 61:	 Protein	 adsorption	 to	 the	 composites	measured	by	BCA	assay	 (n=3;	 error	
bars=±SD).	The	data	were	compared	with	standard	tissue	culture	plastic	using	ANOVA.	
*	indicates	p<	0.05	and	**	indicates	p<0.005.	








The	 effect	 of	 addition	 of	 barium	 sulphate	 on	 crystallinity	 of	 the	materials	 as	well	 as	





and	 5	wt%	BaSO4.	 ( )	 P(3HB)/oligo-mcl-PHA	 90/10	 blend	without	 barium	 sulphate,										
( )	barium	sulphate	powder,	( )	composite	film	containing	1%	barium	sulphate,	( )	



















MTT	 assay	 was	 used	 to	 evaluate	 cell	 adhesion	 and	 proliferation.	 Attachment	 and	
proliferation	of	the	HMEC-1	cells	on	the	film	samples	were	studied	over	a	period	of	1,	




Figure	 63:	 Cell	 proliferation	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
composite	film	samples	on	day	1	( ),	day	3( )	and	day	7	( )		(n=3;	error	bars=±SD).	The	
results	were	compared	with	standard	tissue	culture	plastic,	which	was	normalised	to	







with	 1	 wt%	 barium	 sulphate	 was	 91.6±5.4%	 on	 day	 1,	 186.4±6.0%	 on	 day	 3	 and	









The	 results	 obtained	 demonstrated	 higher	 biocompatibility	 of	 all	 tested	 composite	
samples	 in	comparison	to	TCP.	However,	the	highest	cell	adhesion	was	observed	for	




Cell	 adhesion	 and	 proliferation	 was	 further	 characterised	 using	 SEM	 imaging.	 SEM	
images	presented	in	Figure	64	revealed	that	HMEC-1	cells	adhered	and	proliferated	
evenly	 across	 the	 surface.	 Cell	 density	 was	 comparable	 between	 the	 samples.	 The	
increase	 in	 cell	 adhesion	 and	 proliferation	 on	 the	 composites	 also	 matched	 the	
increasing	 surface	 roughness	 and	 protein	 absorption.	 All	 PHA-based	 materials	
supported	 HMEC-1	 cell	 attachment	 and	 proliferation,	 hence	 demonstrating	 good	





























Figure	 65:	 Indirect	 cytotoxicity	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
composites	film	samples	at	day	1	( )	and	day	3	( ))	(n=3;	error	bars=±SD).	The	data	were	
compared	with	 standard	 tissue	 culture	 plastic,	which	was	 normalised	 to	 100%	using	
ANOVA.	*	indicates	p<	0.05	and	**	indicates	p<0.005.		




BaSO4	 composite	 was	 higher	 than	 TCP	 on	 day	 3	 (163±8.9).	 The	 difference	 was	






































Haemolysis	 study	 was	 performed	 on	 P(3HB)/oligo-PHAs	 composites	 with	 barium	
sulphate	to	check	an	effect	of	the	materials	on	the	erythrocytes	after	direct	contact	with	






















coagulation	 cascade.	 After	 30	 minutes	 of	 incubation,	 composite	 with	 1%	 barium	
sulphate	 demonstrated	 29.2±2.6%	 blood	 clotting.	 Addition	 of	 BaSO4	 at	 level	 3	 wt%	
resulted	 in	 an	 increased	%	blood	 clotting	 after	 30	minutes	 to	 36.0±3.1%,	which	was	
significantly	 higher	 blood	 clotting	 rate	 than	 positive	 control	 25.2±	 0.2%	 (*p=0.014).	
P(3HB)/oligo-PHA	composite	with	5	wt%	barium	sulphate	showed	blood	clotting	rate	
35.5±2.3%	after	30	minutes.	With	the	increase	of	time,	the	%	blood	clot	increased	in	all	










than	neat	blend.	However,	 the	results	obtained	were	 lower	 than	positive	control.	To	
summarise,	composites	of	P(3HB)/oligo-PHA	with	barium	sulphate	did	not	demonstrate	









fresh	 whole	 blood	 incubated	 with	 P(3HB)/oligo-PHA	 blend	 90/10,	 P(3HB)/oligo-PHA	



















CD86-PE	 217.4	 89.2	 162.6	 3.5	
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135.9	 24.2	 117.8	 0.17	
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PE	
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physiological	 conditions.	 It	 is	 excreted	 from	 the	 body	 in	 unchanged	 form	 (Widmark,	
2007).	Barium	sulphate	has	been	used	as	a	contrast	agent	in	biomedical	applications,	







oral	 tablets.	 However,	 it	 has	 been	 reported	 that	 presence	 of	 BaSO4	 can	 facilitate	






composites	 with	 addition	 of	 barium	 sulphate	 was	 significantly	 lower	 than	 without.	
During	 storage	changes	 in	 the	 tensile	 strength	and	Young’s	Modulus	were	observed.	
Both	factors	increased	after	3	weeks	of	storage	and	then	decreased	after	that.	In	the	










which	 allows	 BaSO4	 application	 in	 pigments,	 printing	 inks,	 glasses,	 polymers	 and	
medicine	(Van	Leuween,	1998).	Additionally, BaSO4	particles	can	be	modified	in	order	
to	 improve	 reaction	 with	 polymer.	 Wang	 and	 co-workers	 demonstrated	 enhanced	
reinforcement	 effect	 of	 BaSO4	 particles	 on	 natural	 rubber	when	modified	 by	 5	wt%	
stearic	 acid.	 Achieved	 tensile	 strength	 was	 14.4MPa	 and	 elongation	 at	 break	 516%,	
which	was	240%	and	172%	higher	in	comparison	to	non-modified	BaSO4	(Wang	et	al.,	






barium	 sulphate	 particle	 can	 result	 with	 different	 material	 properties.	 Yan	 and	 co-
workers	 (2016)	 reported	 that	 composites	made	 from	 polytetrafluoroethylene	 (PTFE)	







like	 for	example	catheters,	an	 increased	roughness	of	 the	surfaces	can	be	a	negative	
factor	 (Baleani	and	Viceconti,	2011).	Addition	of	5	wt%	of	BaSO4	have	decreased	the	
contact	angle	values	around	33%	in	comparison	to	neat	blend.	This	can	be	explained	by	







wt%.	 	 However,	 Dios	 and	 co-workers	 observed	 that	 an	 addition	 of	 BaSO4	 at	
concentration	 5	wt%	 to	 the	 floating	 drug	 delivery	 system	was	 sufficient	 to	 obtain	 a	
radiopacity	 (Dios	et	al.,	 2016).	All	 tested	 composite	materials	with	 concentrations	of	
barium	sulphate	(1-5	wt%)	resulted	in	successful	absorbability	by	X-ray,	the	intensity	of	
the	signal	increased	with	higher	amount	of	barium	sulphate.		
Addition	 of	 barium	 sulphate	 also	 resulted	 in	 a	 significant	 increase	 of	 cell	 viability	 of	
HMEC-1	after	day	3	and	7.	In	the	indirect	cytotoxicity	analysis,	the	cell	viability	results	











In	 this	 study,	 presence	 of	 barium	 sulphate	 in	 the	 composites	 did	 not	 affect	 the	
haemocompatibility	of	the	tested	materials.	According	to	ISO	10993-4:2002	standard,	








concentrations	 of	 barium	 sulphate	 were	 minor.	 The	 main	 aim	 of	 this	 study	 was	 to	
develop	 radiopaque	 material,	 suitable	 for	 coronary	 stent	 application	 using	 barium	
sulphate	as	a	radiopacifier.	Hence,	 in	conclusion,	the	composite	with	5	wt%	of	BaSO4	
would	be	the	most	reasonable	choice	for	stent	application	because	of	its	strong	X-ray	




























Polymeric	materials	 can	be	processed	by	using	different	 techniques.	Selection	of	 the	
suitable	manufacturing	technique	depends	on	the	material	properties	as	well	as	final	
application.	Many	 techniques	 have	 been	 applied	 to	 the	 synthetic	 polymers,	 such	 as	
phase	 separation,	 gas	 foaming,	 freeze	 drying,	 solvent	 casting,	 particulate	 leaching,	
thermal	processing,	moulding,	 rapid	prototyping	or	electrospinning	 (Kim	et	al.,	2012;	
Chung	and	King,	2011;	Dhandayuthapani	et	al.,	2011).		
Polyhydroxyalkanoates	 represent	 a	 group	 of	 natural	 polymers	 with	 broad	 range	 of	
material	 properties.	 They	 can	 be	 processed	 by	 using	 different	 techniques,	 such	 as	
electrospinning,	solvent	casting,	spin	casting,	melt	extrusion,	to	form	films,	fibres,	3D	
structures,	tubes	and	foams	(Thellen	et	al.,	2012).	Solvent	casting	has	been	widely	used	
to	 study	 initial	 properties	 of	 the	 materials.	 Some	 of	 the	 applications	 required	 flat	
scaffolds,	 therefore	 this	 technique	 can	 be	 applied	 directly.	 The	main	 benefit	 of	 the	
solvent	 casting	 technology	 is	 obtaining	 materials	 by	 unique	 drying	 of	 the	 polymer	
solution	without	 additional	mechanical	 or	 thermal	 treatment	 (Siemann	et	 al.,	 2005).	
Fabrication	of	3D	structures	is	much	more	complicated.	There	are	few	factors,	which	can	
be	considered	during	material	processing,	such	as	solvents,	quantities	of	the	material,	
stability	 of	 the	 solution,	 processing	 conditions.	 Coronary	 stent	 applications,	 require	
tubular	 structures.	 Melt	 extrusion	 is	 a	 well-known	 technique,	 commonly	 used	 to	
produce	 tubes.	 However,	 this	method	 has	 some	 limitations,	 such	 as	 requirement	 of	
substantial	 quantities	 of	 the	 material,	 a	 large	 amount	 of	 waste	 material,	 not	 very	
suitable	for	sticky	polymers	(LaFountaine	et	al.,	2016).		
Dip	moulding	 is	a	 technique,	widely	used	 for	manufacturing	3D	structures	or	coating	
already	made	articles.	It	required	small	quantities	of	material	and	is	a	simple	piece	of	
equipment.	 The	 process	 is	 also	 cheaper	 than	melt	 extrusion.	 Important	 parameters	
which	require	an	optimisation,	include	the	right	choice	of	the	solvents,	stability	of	the	
solution,	correct	 temperature	and	time	of	drying.	Processing	of	 the	single	polymer	 is	
much	easier	than	mixture	of	two	different	types	of	the	materials,	therefore	preparation	
of	 blends	 or	 composites	 is	 much	 more	 challenging	 by	 using	 this	 method	
(Parameswaranpillai	et	al.,	2014).		





artery	 stents.	 Based	 on	 the	 results	 obtained	 for	 solvent	 cast	 films,	 one	 of	 the	
P(3HB)/oligo-PHA	 blends	 in	 ratio	 90/10	was	 selected	 for	 tube	manufacturing.	 Three	
different	types	of	tubes	were	prepared:	neat	P(3HB)/oligo-PHA	neat	tube,	P(3HB)/oligo-
PHA	 tube	 coated	 with	 PCL-PEG550	 and	 P(3HB)/oligo-PHA	 composite	 tube	 with	 an	
addition	of	5	wt%	barium	sulphate.		The	tubes	were	fully	characterized	with	respect	to	
their	 thermal	 and	mechanical	 properties.	 In	 vitro	 biocompatibility	 of	 the	 tubes	 was	
tested	 with	 human	 dermal	 microvascular	 endothelial	 cells	 HMEC-1	 to	 evaluate	 the	
potential	 of	 new	biodegradable	material	 in	 an	 application	 as	 coronary	 artery	 stents.	
Haemocompatibility	studies	were	carried	out	in	order	to	study	the	impact	of	the	tubular	













                  







Obtained	 tubes	 were	 characterised	 with	 respect	 to	 their	 thermal	 and	 mechanical	










Tubes	were	 stored	 for	 7	weeks	 at	 room	 temperature	 (Figure	 70A)	 in	 order	 to	 study	
ageing	of	the	material.		Some	of	the	tubes	were	incubated	in	the	DMEM	media	at	37°C	
(Figure	70B)	in	order	to	mimic	an	environment,	which	is	similar	to	the	human	body.	The	






















Tg	(°C)	 Tm	(°C)	 ΔHf	(J/G)	 Tc	(°C)	
1	 1.1	 166.00	 83.3	 58.6	
3	 2.7	 167.6	 69.1	 56.9	
5	 3.4	 171.4	 70.2	 54.1	
7	 2.5	 172.6	 79.3	 60.4	
	
The	thermal	properties	of	the	tubes	had	changed	during	7	weeks	of	storage.	The	glass	
transition	 temperature	 increased	 from	1.1°C	 to	2.5°C	after	 7	weeks.	 Temperature	of	
melting	 increased	 from	 166°C	 to	 172.6°C.	 Similarly,	 cold-crystallisation	 temperature	
increased	from	58.6°C	to	60.4°C.	The	value	of	enthalpy	of	fusion	decreased	from	83.3	






Figure	 71:	 DSC	 thermograms	of	 P(3HB)/oligo-PHA	 tubes	 stored	 for	 7	weeks	 at	 room	
temperature	illustrating	melting	peaks.	( )	week	1,	( )	week3,	( )	week	5	and	( )	week	
7.	
The	DSC	thermograms	represent	the	first	heating	cycle	during	DSC	analysis.	This	part	of	





























3	 18.5±1.8	 9.9±0.9	 1280±170	
5	 20.5±4	.6	 8.6±1.3	 1230±50	


































3	 17.1±1.9	 7.3±1.1	 690±90	
5	 17.8±0.1	 6.2±0.1	 690±10	



























temperature.	 Overall,	 tubes	 stored	 in	 the	 DMEM	 media	 and	 body	 temperature	





environment,	 presence	 of	 different	 organic	 compounds	 such	 as	 proteins	 or	 higher	
temperature	is	a	determinant	factor	to	cause	changes	to	the	material.		
7.2.3.	Scanning	Electron	Microscopy	of	the	P(3HB)/oligo-PHA	tubes			





the	 tube	 (Figure	73C).	SEM	 imaging	allowed	measuring	 the	wall	 thickness.	Presented	
tube	 on	 the	 Figure	 73D	 has	 wall	 thickness	 145.6	 ±	 0.5μm,	 which	 confirmed	 results	
obtained,	measured	by	caliper.	Wall	thickness	on	the	studied	tube	was	quite	uniform	





















Figure	 74:	 ATR-FTIR	 spectrum	 of	 the	 P(3HB)/oligo-PHA	 tubes	 during	 6	 months	 of	














material	 caused	 by	 tubes	 degradation.	 A	 summary	 of	 the	 results	 obtained	 has	 been	
listed	in	Table	30.	First	heating	cycle	thermograms	are	illustrated	in	the	Figure	75.	
Table	30:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	during	6	
months	 of	 degradation	 study.	 Tm=	 melting	 temperature,	 Tg=	 glass	 transition	
temperature,	Tc=	crystallisation	temperature,	DHf=enthalpy	of	fusion.	
	 Month	1	 Month	2	 Month	3	 Month	4	 Month	5	 Month	6	
Tg	(°C)	 -3.1	 -4.5	 -4.7	 1.1	 -0.4	 -2.7	
Tm	(°C)	 175.5	 173.4	 174.8	 175.6	 173.7	 172.7	
Tc	(°C)	 53.9	 51.5	 50.1	 59.1	 59.3	 51.3	
ΔHf	(J/g)	 72.2	 71.6	 78.7	 72.3	 78.6	 79.3	
	
During	6	months	of	degradation	study,	the	thermal	properties	of	the	materials	changed.	
Glass	 transition	 temperature	 slightly	 increased	 from	 -3.1°C	 at	 month	 1	 to	 -2.7°C	 at	
month	6.	Melting	temperature	decreased	from	175.5°C	to	172.7°C	after	month	1	and	6	
respectively.	Similarly,	the	cold-crystallisation	temperature	decreased.	The	enthalpy	of	





























































































Figure	 79:	 SEM	 micrographs	 of	 the	 P(3HB)/oligo-PHA	 tubes	 after	 6	 months	 of	
degradation	study.	(A)	tube	cross	section,	(B,	C,	D)	outer	surface	of	the	tube,	(E)	wall	
microstructure,	(F)	wall	thickness.	
SEM	 images	 confirmed	 the	 degradation	 process	 on	 the	 tubes	 after	 6	 months.	
Degradation	proceed	on	the	surface	of	the	tubes	along	with	decreasing	wall	thickness,	
which	decreased	30%	as	compared	to	that	before	the	incubation	(Figure	79F).	This	affect	
tube	 stability	 (Figure	 79A).	 Tubes	 became	 very	 fragile	 and	 brittle.	 Fractures	 were	








obtained	 in	 this	 study	 suggest	 that	 P(3HB)/oligo-PHA	 tubes	 undergo	 degradation	
process	by	surface	erosion.		



























7.4.3.	 Characterisation	 of	 P(3HB)/oligo-PHA	 tubes	 coated	with	monolayer	 of	
PCL-PEG550		










2947cm-1	 and	 2872cm-1,	 which	 corresponded	 to	 the	 asymmetric	 stretching	 -CH2	 and	
symmetric	-CH2	respectively.	These	bonds	were	more	intense	in	the	coated	tubes,	which	
confirmed	the	presence	of	another	polymer,	such	as	PCL-PEG550.	The	carbonyl	bond	at	















































































	1	 16.7±1.5	 9.3±1.3	 										0.7±0.1	
7	 29.2±1.0	 7.9±0.6	 1.4±0.1	
	
After	 7	 weeks	 of	 ageing	 at	 room	 temperature,	 the	 mechanical	 properties	 of	 the	
P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 had	 changed.	 The	 tensile	 strength	



















comparison	 to	 neat	 P(3HB)/oligo-PHA	 tubes.	 Initially,	 tensile	 strength	 values	 were	
similar.	However,	after	7	weeks	of	storage	the	PCL-PEG550	coated	tube	had	30%	higher	
tensile	 strength	 than	 neat	 P(3HB)/oligo-PHA	 tube.	 Coated	 tube	 had	 a	 slightly	 higher	
Young’s	Modulus.	At	first,	the	initial	elongation	at	break	of	the	coated	tube	is	30%	lower	




Microstructural	 studies	 of	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 were	







































































Tg	(°C)	 Tm	(°C)	 ΔHf	(J/G)	 Tc	(°C)	
1	 -1.7	 173.8	 79.1	 53.4	





well	 as	 the	 enthalpy	 of	 fusion	 presented	 similar	 trend.	 The	 largest	 changes	 were	















The	 analysis	 of	 the	mechanical	 properties	 of	 the	 P(3HB)/oligo-PHA	 composite	 tubes	
stored	at	room	temperature	were	carried	out	for	7	weeks,	in	order	to	check	the	material	
properties	during	material	ageing.	The	results	obtained	are	summarised	in	Table	34.	








	1	 18.9±0.6	 7.9±1.2	 									1.2±0.1	






After	 7	 weeks	 of	 ageing	 at	 room	 temperature,	 the	 mechanical	 properties	 of	 the	
P(3HB)/oligo-PHA	 tubes	had	 changed.	 The	 tensile	 strength	 increased	 from	18.9±0.56	










tube	 demonstrated	 that	 tubular	 structure	 of	 the	 stent	 was	 uniform	 (Figure	 86A).	
Porosity	of	the	material	was	not	visible	from	the	outer	surface	of	the	tube	as	well	as	
















































































Bicinchoninic	 acid	 assay	 was	 used	 to	 evaluate	 the	 affinity	 of	 the	 materials	 towards	
proteins	as	described	in	section	2.11.3.9.		It	was	found	that	total	protein	adsorption	was	
180.2±4.5,	225.6±5.6	and	170.7±7.1	µg/cm2	for	the	neat	P(3HB)/oligo-PHA	neat	tube,	





























tube	samples	on	day	1	 ( ),	day	3	 ( )	and	7	 ( )	 (n=3;	error	bars=±SD).	The	data	were	






and	 *p=0.017	 respectively).	 The	 growth	 of	 the	HMEC-1	 cells	 on	 the	 surface	 of	 PCL-
PEG550	coated	tube	was	80.0±5.2%	at	day	1	and	79.4±4.5%	and	77.5±2.0%	at	day	3	and	
7	respectively.	The	differences	were	statistically	significant	for	day	3	and	7	(*p=0.013,	
*p=0.011)	 in	 comparison	 to	 TCP.	 On	 the	 other	 hand,	 HMEC-1	 cell	 viability	 on	 the	
composite	tubes	with	5	wt%	BaSO4	was	slightly	lower	on	day	1	(87.7±3.5.0%)	and	higher	






The	 results	 obtained	 demonstrated	 higher	 biocompatibility	 of	 the	 P(3HB)/oligo-PHA	











media	 on	 the	 HMEC-1	 cell	 line.	 Cells	 without	 an	 extract	 were	 used	 as	 the	 negative	













and	91.4±4.4%	at	day	3	 compared	 to	 the	TCP.	The	differences	were	not	 statistically	
significant.	 The	 growth	 of	 HMEC-1	 cells	 treated	 with	 an	 extract	 from	 the	 neat	
P(3HB)/oligo-PHA	tube	was	similar	on	day	1	and	3	to	TCP.	The	growth	of	the	HMEC-1	


































































P(3HB)/oligo-PHA	 neat	 tubes,	 PCL-PEG550	 coated	 tubes	 and	 P(3HB)/oligo-PHA	






























5	 wt%	 barium	 sulphate.	 sulphate	 and	 PL38	 (n=3;	 error	 bars=±SD).	 The	 data	 were	
compared	with	standard	tissue	culture	plastic	using	ANOVA.	**indicates	p<	0.005	and	
***	indicates	p<0.0005.		
The	 results	 obtained	 indicate	 that	 P(3HB)/oligo-PHA	 neat	 tube	 and	 the	 PCL-PEG550	
















or	PCL-PEG550	coated	 tube.	To	 summarise,	all	 tested	materials	did	not	demonstrate	





































CD86-PE	 181.5	 57.9	 162.6	 3.5	
CD45-
PerCP	
225.4	 106.0	 121.9	 3.6	
CD11b-PE	 536.8	 294.9	 666.1	 372.7	
CD66B-
FITC	







CD86-PE	 209.7	 82.5	 175.3	 11.6	
CD45-
PerCP	
135.9	 0.0	 76.3	 -	











CD86-PE	 140.9	 22.6	 116.7	 -	
CD45-
PerCP	
94.7	 -	 86.8	 -	
CD11b-PE	 857.7	 531.1	 991.2	 603.5	
CD66B-
FITC	






5,	 Table	 21).	 Among	 three	 types	 of	 tubes,	 P(3HB)/oligo-PHA	 tube	 coated	 with	 PCL-
PEG550	demonstrated	the	lowest	values	of	CD11b	marker:	267.1%	for	monocytes	and	
316.5%	for	neutrophils	activity	higher	than	control.	The	percentage	change	of	MFI	for	








neutrophils	 and	monocytes,	which	was	 indicated	previously	 in	Chapter	6.	 It	 is	worth	















to	 material	 ageing.	 Changes	 in	 the	 properties	 of	 P(3HB)	 and	 its	 copolymers	 during	
storage	time	at	room	temperature	has	been	already	recognised.	Elongation	at	break	is	
the	main	parameter,	which	change	within	the	time	of	storage	and	is	a	measurement	of	




lower	 for	 the	 films	 in	 comparison	 to	 the	 tubes.	 This	might	 be	 explained	by	 applying	
completely	 different	 conditions	 during	 tube	 preparation,	 such	 as	 presence	 of	 an	






from	each	 layer	 after	 each	dipping	 cycle,	whereas	 in	 solvent	 cast	 technique,	 solvent	
evaporation	rate	is	lower	and	chloroform	gradually	evaporates	from	the	surface	of	the	
polymer	 solution	 until	 thin	 film	 remains.	 	 It	 has	 been	 reported	 previously,	 that	
processing	technique	has	great	impact	on	the	material	properties	(Renstadt	et	al.,	1998).	
Interestingly,	 the	changes	 in	the	mechanical	properties	of	the	tubes	 incubated	 in	the	
DMEM	media	at	37°C	for	the	period	of	7	weeks	resulted	in	much	lower	values	for	all	
measured	 parameters	 in	 comparison	 to	 the	 tubes	 stored	 dry	 at	 room	 temperature.	





properties	 obtained	 after	 incubation	 of	 tubes	 in	 DMEM	media	 at	 37°C	 can	 help	 to	
predict	the	material	behaviour	inside	the	human	body.		
Biodegradability	 of	 polyhydroxyalkanoates	 depends	 not	 only	 on	 their	 own	 material	
properties,	such	as	crystallinity,	presence	of	functional	groups,	but	also	on	the	surface	
area	 and	 the	 conditions	 in	 the	 surrounding	 environment,	 such	 as	 pH,	 temperature,	
moisture,	 presence	 of	 nutrients	 or	microbial	 activity	 (Sudesh	et	 al.,	 2000;	Doi	et	 al.,	
1989).	Highly	crystalline	materials	require	longer	time	to	degrade	in	comparison	to	semi-






important	 factor.	 It	 was	 found,	 that	 PHAs	 with	 low	 molecular	 weight	 are	 more	
susceptible	degradation.	The	thermal	properties	of	the	materials	have	an	influence	on	





reported	 that	 PHAs	 can	 degrade	 in	 aquatic	 environments	 within	 254	 days	 at	
temperature	below	60◦C	(Anjum	et	al.,	2016).	
In	general,	polymer	degradation	takes	place	mostly	through	scission	of	the	main	chains	
or	 the	 side-chains	of	 the	polymer	 structure.	 It	 can	be	 induced	by	 thermal	activation,	
photolysis,	 oxidation,	 radiolysis	 or	 hydrolysis	 (Doi	 and	 Fukuda,	 1994;	Benicewicz	 and	
Hopper,	1991).	The	degradation	process	via	hydrolysis	can	occur	with	or	without	the	
presence	 of	 enzymes;	 it	 can	 be	 catalysed	 by	 the	 presence	 of	 acid	 or	 base	 in	 the	
environment	(Rydz	et	al.,	2015;	Ikada	and	Tsuji,	2000).	Different	factors	can	trigger	the	
degradation	 process,	 like	 for	 example	 temperature.	 Therefore,	 one	 of	 the	 very	
important	 aspects	 to	 consider	 are	 processing	 conditions	 and	 chosen	 fabrication	
techniques.	 For	 example,	 melt	 extrusion	 and	 injection	 moulding	 require	 high	
temperature	and	 shear	 rate,	which	might	 lead	 to	 certain	 level	of	degradation	of	 the	






and	 accelerated	weight	 loss	 after	 3	months	 of	 incubation.	Minor	 changes	 in	 the	 pH	
during	the	degradation	suggested	absence	of	the	highly	acidic	products	released	during	
polymer	degradation.	 It	 is	a	well-known	that	the	degradation	products	released	from	
synthetic	 polymers,	 such	 as	 PLLA	 are	 highly	 acidic,	 which	 can	 trigger	 an	 elevated	
immunogenic	 response	 in	 the	 body	 (Mani	 et	 al.,	 2007;	 Liu	 et	 al.,	 2006).	 Hydrolytic	
degradation	of	PHAs	is	a	slow	process,	which	can	take	up	to	several	months	(Marois	et	
al.,	 2000;	 Doi	 et	 al.,	 1990).	 Addition	 of	 polymers	 or	 plasticizers	 can	 increase	 the	















can	 support	 the	 statement	mentioned	above.	Another	 reason	 for	enhanced	porosity	
might	 be	 possible	 migration	 of	 oligo-PHA	 form	 the	 polymeric	 matrix.	 Plasticiser	
















crystallisation	 temperature	 and	 enthalpy	 of	 fusion,	 related	 to	 PHAs	 decreased.	 This	
behaviour	was	 similar	 to	 the	 neat	 tube.	With	 respect	 to	 the	mechanical	 properties,	
tensile	strength	of	the	material	as	well	as	stiffness	have	improved	significantly.	Initially,	
the	elongation	at	break	of	the	coated	tube	was	lower	than	the	neat	tube	and	decreased	









The	 third	 type	 of	 tubes	 was	 prepared	 from	 P(3HB)/oligo-PHA	 90/10	 blend	 with	 an	
addition	 of	 5	 wt%	 barium	 sulphate.	 Within	 7	 weeks	 of	 storage	 the	 glass	 transition	
temperature,	enthalpy	of	fusion	and	cold-crystallisation	temperature	decreased.	There	
was	no	impact	on	melting	temperature	within	7	weeks	of	storage.	Addition	of	barium	
sulphate	 drastically	 influenced	 the	 elongation	 at	 break.	 The	 composite	 tube	became	
very	brittle	after	7	weeks	of	storage.	However,	the	material	became	much	stronger	and	
stiffer	after	week	7	in	comparison	to	week	1.	Addition	of	barium	sulphate	also	had	an	
impact	 on	 the	 topography	 and	 structure	 of	 the	 tubes.	 SEM	micrographs	 confirmed	
complete	absence	of	porosity	within	the	tube	wall	structure.	This	can	be	explained	by	
the	 fact,	 that	BaSO4	particles	could	act	as	 fillers	of	potential	 spaces	within	polymeric	
matrix.	The	surface	of	the	tube	was	rougher	due	to	the	presence	of	the	BaSO4	particles	















affect	 cell	 attachment.	 Presence	 of	 particles,	 allow	 obtaining	 rougher	 and	 enlarge	
surface	area,	which	creates	attachment	points	for	cells	 (Hao	and	Lawrence,	2004).	 It	
will	 be	 worth	 to	 investigate	 further	 an	 influence	 of	 barium	 ions	 on	 the	 functional	






PHA	 tube	coated	with	PCL-PEG550.	Obtained	 results	 suggest,	 that	 surface	 roughness	











from	 the	 materials	 incubated	 in	 the	 media.	 Moreover,	 PCL-PEG550	 coated	 tube	
demonstrated	higher	cell	viability	after	day	1	as	compared	to	TCP.		
All	type	of	tested	tubes	did	not	have	any	haemolytic	effect	towards	red	blood	cells.	Neat	
P(3HB)/oligo-PHA	 tube	 demonstrated	 blood	 clotting	 rate	 similar	 to	 the	 control.	 PCL-
PEG550	 coated	 tube	 and	 the	 composite	 tube	 resulted	 in	 decelerated	 blood	 clot	
formation.	This	can	be	explained	by	the	presence	of	poly	(ethylene	glycol)	unit,	which	is	
a	well-known	anti-coagulant	due	to	presence	of	an	ether	oxygen	within	the	monomer	
units,	 which	 hinder	 proteins	 adsorption	 (Meyers	 and	 Grinstaff,	 2012).	 	 Moreover,	







The	 results	 obtained	 confirmed	high	 biocompatibility	 of	 the	 P(3HB)/oligo-PHA	based	





presented	 an	 additional	 advantage	 over	 the	 neat	 P(3HB)/oligo-PHA	 and	 PCL-PEG550	






























trials	 were	 very	 promising.	 However,	 the	 long-term	 side	 effects	 appeared,	 such	 as	
thrombosis,	 which	 can	 lead	 to	 sudden	 death	 (Windecker	 and	 Meier,	 2007).	 As	 a	
polymeric	matrix,	non-biodegradable,	biodegradable	and	biological	polymers	have	been	
studied	 (Puskas	 et	 al.,	 2009).	 Four	 classes	 of	 drugs,	 such	 as:	 anti-inflammatory,	





the	 section	 1.5.	 Many	 research	 groups	 have	 been	 focusing	 on	 the	 development	 of	
appropriate	drug	delivery	 systems,	 to	allow	controlled	drug	delivery	of	 the	bioactive	
agent.	 Rapamycin,	 also	 referred	 as	 sirolimus	 is	 a	macrocyclic	 antibiotic	 produced	 by	
natural	fermentation	which	exhibits	potential	immunosuppressive	properties.	It	has	the	
ability	to	block	several	phases	 in	the	development	of	the	restenosis	cascade	(van	der	
Hoeven	 et	 al.,	 2005).	 Tacrolimus	 is	 an	 immunosuppressive	 agent,	 which	 has	 less	




the	 materials	 have	 met	 all	 specific	 requirements,	 such	 as	 high	 biocompatibility,	
appropriate	mechanical	properties,	degradation	kinetics	and	inflammation.	There	is	still	
high	demand	for	the	development	of	novel	materials	(Ramcharitar	and	Serruys,	2008).	
Polyhydroxyalkanoates	 are	 biopolyesters,	 which	 were	 not	 studied	 extensively	 in	
coronary	 stents,	 but	 have	 been	 studied	 as	 drug	 delivery	 vehicles.	 They	 are	 very	
promising	 materials	 for	 drug	 delivery	 systems	 due	 to	 proven	 biodegradability,	 non-





applications.	 Microspheres,	 nanoparticles,	 rods,	 discs,	 biodegradable	 implants,	 films	
with	 different	 drugs,	 such	 as:	 gentamycin,	 aspirin,	 cefoperazone,	 doxorubicin,	
tetracycline	 and	 ampicillin	 have	 been	 developed	 (Nigmatullin	 et	 al.,	 2015).	
P(3HB)/P(3HO)	blends	were	proposed	as	a	matrix	for	drug	carrier	in	DES	(Basnett	et	al.,	
2013).	
Both	 drugs,	 rapamycin	 and	 tacrolimus	 are	 considered	 as	 the	 bioactive	 agents	 for	
coronary	 stents.	 Therefore,	 the	main	 aim	 of	 this	 part	 of	 the	 project	was	 to	 develop	
P(3HB)/oligo-PHA	 based	 tubes	 using	 the	 dip	 moulding	 technique	 with	 incorporated	
drugs,	such	as	rapamycin	or	tacrolimus	for	the	development	of	medical	devices,	such	as	
coronary	 stents.	 Each	 drug	 was	 dissolved	 in	 the	 PCL-PEG550	 polymeric	 matrix	 and	
applied	 on	 the	 surface	 of	 the	 tube	 as	 a	 monolayer.	 The	 materials	 were	 fully	
characterized.	 In	 vitro	 biocompatibility	 of	 the	 tubes	 was	 tested	 with	 human	 dermal	
microvascular	 endothelial	 cells	 (HMEC-1)	 in	 order	 to	 evaluate	 the	 potential	 of	 new	




study	 was	 also	 performed	 on	 the	 PCL-PEG550	 coated	 P(3HB)/oligo-PHA	 tubes	 to	
investigate	the	degradation	rate	of	the	coated	PHA	tubes	with	incorporated	drugs.		
8.1.	Drugs	characterisation	
Analysis	of	 the	 chemical	nature	and	 thermal	properties	of	 rapamycin	and	 tacrolimus	
powders	 were	 carried	 out	 using	 Fourier	 Transform	 Infrared	 Spectroscopy	 and	
Differential	Scanning	Calorimetry	respectively.		
8.1.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
	






cm-1.	Additionally,	 two	bonds,	typical	 to	 imines	are	present	at	1644.6	cm-1	 (C=N)	and	
1633.6	cm-1	(C-N)	respectively.		
	
Figure	 94:	 ATR/FTIR	 spectrum	 of	 rapamycin	 powder	 indicating	 characteristic	 peaks	
corresponding	to	chemical	bonds	observed	in	rapamycin.	
The	tacrolimus	powder	exhibited	various	peaks	related	to	the	functional	groups	present	
in	 the	 structure	 of	 tacrolimus	 (Figure	 95).	 There	 was	 a	 peak	 at	 3438	 cm-1,	 which	
corresponded	 to	 O-H	 stretching	 vibration.	 Carbonyl	 group	 C	 =	 O	 (ester	 and	 ketone)	
stretching	vibrations	were	present	at	1739.8	cm-1.	An	absorption	peak	at	1692.3	cm-1	






















One	heating	cycle	was	performed	during	DSC	analysis	 in	order	 to	obtain	 the	thermal	
properties	 of	 the	 drugs.	 The	 thermogram	 for	 rapamycin,	 presented	 in	 the	 Figure	 96	
demonstrated	the	presence	of	melting	event	at	189.4°C.	There	was	also	thermal	event,	











8.2.	 P(3HB)/oligo-PHA	 tubes	 coated	with	 PCL-PEG550	 and	 incorporated	 drug	
manufacturing	



























The	 obtained	 tube	 had	 a	 wall	 thickness	 183.5±4.3	 µm	 and	 coating	 thickness	 with	







8.3.	 P(3HB)/oligo-PHA	 tubes	 coated	with	 PCL-PEG550	 and	 incorporated	 drug	
characterisation	
P(3HB)/oligo-PHA	tubes	with	incorporated	dugs	were	characterised	with	respect	to	their	
thermal,	mechanical	 and	 topographical	 properties.	 Additionally,	 biocompatibility	 and	
haemocompatibility	studies	were	perform	in	order	to	confirm	non-toxicity	and	safety	of	
the	biomaterials.		
















PEG550	 ( )	 in	 comparison	 to	 P(3HB)/oligo-PHA	 tube	 with	 incorporated	 rapamycin	
within	 PCL-PEG550	 coating	 ( )	 indicating	 major	 peaks	 characteristic	 for	 PHA,	 PCL-
PEG550	 and	 rapamycin.	 (B)	 ATR/FTIR	 spectra	 of	 neat	 P(3HB)/oligo-PHA	 tube	 with	
monolayer	 of	 PCL-PEG550	 ( )	 in	 comparison	 to	 P(3HB)/oligo-PHA	 tube	 with	














































































The	 release	 of	 rapamycin	 from	 the	 P(3HB)/oligo-PHA	 90/10	 blend	 tube	 containing	

















After	 72	 days,	 no	 further	 release	was	 recorded.	 In	 this	 study,	 cumulative	 release	 of	
rapamycin	of	98.2%	occurred	within	a	period	of	90	days.		
	
The	 release	 of	 tacrolimus	 from	 the	 P(3HB)/oligo-PHA	 90/10	 blend	 tube	 containing	
monolayer	of	PCL-PEG550	with	tacrolimus	was	carried	out	as	described	in	section	2.13	








Tacrolimus	 was	 released	 slowly	 throughout	 the	 period	 of	 study.	 Burst	 release	 was	




60.0%	 of	 tacrolimus	was	 released.	 In	 this	 study,	 cumulative	 release	 of	 tacrolimus	 of	
69.2%	occurred	within	a	period	of	90	days.		
8.4.	In	vitro	biocompatibility	studies	



































MTT	 assay	 was	 used	 to	 evaluate	 cell	 adhesion	 and	 proliferation.	 Attachment	 and	
proliferation	of	HMEC-1	cells	on	the	tube	samples	were	studied	over	a	period	of	1,	3	










Cell	 proliferation	 on	 the	 surface	 of	 P(3HB)/oligo-PHA	 90/10	 blend	 tubes	 with	
incorporated	tacrolimus	within	PCL-PEG550	matrix	was	slightly	lower	in	comparison	to	
TCP	on	day	1,	3	and	7.	The	cell	viability	obtained	on	the	tube	samples	was	89.6±5.4%	on	









rapamycin	within	 the	polymeric	matrix	had	a	negative	 impact	on	the	viability	of	 the	
HMEC-1	cells.		






















Figure	 105:	 SEM	 micrographs	 of	 the	 HMEC-1	 cells	 attached	 to	 the	 surfaces	 of	







With	 respect	 to	 the	 results	obtained,	not	all	 tested	materials	based	on	P(3HB)/oligo-












Figure	 106:	 Indirect	 cytotoxicity	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
tubes	coated	with	monolayer	of	PCL-PEG550	with	incorporated	rapamycin	or	tacrolimus	
samples	on	day	1,	3	(n=3;	error	bars=±SD).	The	data	were	compared	with	standard	tissue	
culture	 plastic	 containing	 DMEM	 medium,	 which	 were	 normalised	 to	 100%	 using	










3	 (45.1±0.5).	 The	 difference	 was	 statistically	 significant	 (**p=0.0033)	 for	 the	 result	





interfered	 with	 endothelial	 cells	 and	 inhibited	 their	 attachment	 and	 proliferation.	

















Figure	107:	Haemolysis	 rates	of	 the	P(3HB)/oligo-PHA	 tubes	 coated	with	PCl-PEG550	









Whole	 blood	 clotting	 experiment	 was	 performed	 to	 investigate	 the	 potential	









Figure	 108:	 Summary	 of	 whole	 blood	 clotting	 results	 after	 30	 minutes	 ( )	 	 and	 90	
minutes	 ( )	 of	 incubation	 on	 the	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	
containing	rapamycin	or	tacrolimus.	Tissue	culture	plastic	was	used	as	the	control	(n=3;	


























fresh	 whole	 blood	 with	 P(3HB)/oligo-PHA	 90/10	 tube	 coated	 with	 PCL-PEG550,	



















CD86-PE	 209.7	 82.5	 175.3	 11.6	
CD45-
PerCP	
135.9	 24.2	 76.3	 -	
CD11b-PE	 498.9	 267.1	 586.8	 316.4	
CD66B-
FITC	







CD86-PE	 188.9	 64.4	 109.3	 -	
CD45-
PerCP	
66.9	 -	 98.4	 -	
CD11b-PE	 642.3	 372.6	 1104.2	 683.6	
CD66B-
FITC	







CD86-PE	 140.9	 22.6	 116.7	 -	
CD45-
PerCP	
131.5	 20.2	 109.4	 0	
CD11b-PE	 436.7	 321.4	 546.2	 287.6	
CD66B-
FITC	







monocytes	 and	 neutrophils.	 All	 tested	 samples	 presented	 higher	 activity	 in	 the	
activation	 marker	 CD11b-PE.	 The	 percentage	 change	 of	 MFI	 for	 tube	 containing	
tacrolimus	was	 321.4%	 for	monocytes	 and	 287.6%	 for	 neutrophils	 in	 comparison	 to	
control.	 The	 tube	 with	 rapamycin	 demonstrated	 1.5-2.0-fold	 higher	 white	 cells	
activation	 than	 the	 neat	 tube	 PCL-PEG550	 coated	 tube	 without	 any	 drug.	 The	







A	degradation	 study	was	 carried	out	 for	 a	 period	of	 3	months	 at	 37°C	 in	 phosphate	
buffered	 saline	 solution	 (PBS)	 to	 investigate	 the	 degradation	 behaviour	 of	 the	
P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 with	 incorporated	 rapamycin	 or	
tacrolimus.		
	












tacrolimus	 (B)	 after	 3	 months	 incubation	 in	 PBS	 indicating	 characteristic	 peaks.	 ( )	
month	1	of	degradation	study,	( )	month	3	of	degradation	study.	
There	 were	 no	 differences	 between	 all	 spectra	 obtained	 after	 month	 1	 and	 3	 for	
P(3HB)/oligo-PHA	tubes	with	 rapamycin	or	 tacrolimus.	All	 the	chemical	bonds,	which	














Tg=	 glass	 transition	 temperature,	 Tc=	 crystallisation	 temperature,	 DHf=enthalpy	 of	
fusion.	
Type	of	drug	 Tube	with	incorporated	Rapamycin	 Tube	with	incorporated	Tacrolimus	
Time	 Month	1	 Month	2	 Month	3	 Month	1	 Month	2	 Month	3	



























During	3	months	of	degradation	 study,	 the	 thermal	properties	of	 the	materials	have	
changed.	In	the	tube	with	rapamycin,	the	glass	transition	temperature	slightly	decreased	
from	 0.4°C	 at	 month	 1	 to	 -0.1°C	 at	 month	 3.	 There	 were	 2	 melting	 temperatures	
detected:	one	related	to	PCL-PEG550,	present	in	the	coating	and	one	related	to	PHAs.	
Tm	 for	PCL-PEG550	 increased	 significantly	 from	64.4°C	 to	79.2°C	after	3	months.	The	
melting	temperature	for	the	PHAs	also	increased	from	173.1°C	to	176.6°C	after	month	



























for	 PCL-PEG550	 after	 month	 3,	 whereas	 this	 peak	 was	 still	 present	 in	 tube	 with	
rapamycin.	No	other	thermal	events	were	observed.	Both	types	of	tubes	demonstrated	





















Rapamycin	 20.8±1.6	 7.8±1.5	 0.8±0.1	
Tacrolimus	 19.7±1.8	 7.4±1.2	 0.9±0.06	
2	
Rapamycin	 21.7±0.9	 4.4±0.7	 1.4±0.15	
Tacrolimus	 22.3±0.8	 4.1±0.4	 1.6±0.04	
3	
Rapamycin	 16.1±2.1	 1.7±0.3	 1.1±0.05	










material,	 which	 might	 be	 caused	 by	 degradation	 and	 weight	 loss	 of	 the	 tubes.	
Mechanical	properties	of	the	tubes	incubated	with	PBS	were	different	than	tubes	stored	




environment	 had	 a	 negative	 effect	 on	 the	 mechanical	 properties,	 i.e.	 decrease	 in	
stiffness	of	the	P(3HB)/oligo-PHA	tubes	coated	with	PCL-PEG550.	
8.6.4.	 pH	measurements	 of	 the	 PBS	 during	 degradation	 studies	 of	 neat	 PHA	
tubes	
	




Figure	 111:	 pH	 changes	 of	 PBS	 after	 incubation	 of	 P(3HB)/oligo-PHA	 tubes	 with	














described	 previously	 in	 the	 section	 2.16.3.	 The	 summary	 of	 the	 results	 has	 been	
illustrated	in	the	Figure	112.	
	













Percentage	 of	 water	 uptake	 (%WU),	 which	 is	 an	 amount	 of	 water	 absorbed	 by	 the	
material	during	incubation	was	measured	at	month	1,	2	and	3	of	degradation	study	as	




















































SEM	 images	 of	 the	 P(3HB)/oligo-PHA	 tube	with	 incorpotayed	 rapamycin	within	 PCL-
PEG550	polymeric	coating	have	confirmed	that	the	degradation	process	occurred	after	
3	months.	 The	 degradation	mechanism	 seemed	 to	 involve	 the	 surface	 erosion	 from	
external	 layer.	Therefore,	within	3	months	only	the	coating	layer	was	affected	by	the	
degradation	process.	The	 loss	of	 the	coating	thickness	was	16%	(Figure	114C).	 In	 the	
Figure	114B	it	 is	clearly	visible,	how	hydrolytic	degradation	eroded	the	surface	of	the	
tube.	 The	 internal	 layer	 of	 the	 tube	 (Figure	 114D)	was	 however	 not	 affected	 by	 the	






























SEM	 images	 of	 the	 tubes	 with	 incorporated	 tacrolimus	 confirmed	 the	 degradation	
process	has	started	within	3	months	(Figure	115A-D).	The	degradation	had	happened	by	





to	 the	 PCL-PEG550	 coating.	 Hydrolytic	 degradation	 obtained	 after	 3	 months	 of	
incubation	of	tubes	in	PBS	at	37°C	damaged	the	coating	layer	on	the	surface	of	the	tube.	
PCL-PEG550	polymeric	matrix	 layer	 is	hardly	 visible;	 a	 lot	of	polymeric	debris	on	 the	
surface	 of	 the	 tube	 (Figure	 115B).	 Internal	 layer	 of	 the	 tube	 presented	 increased	
porosity,	 caused	 by	 hydrolytic	 environment	 within	 3	 months	 time	 (Figure	 115D).	
Monolayer	 of	 PCL-PEG550	 protected	 core	 of	 the	 tube	 before	 degradation.	 After	 3	
months	the	tubes	were	still	stable	in	the	structure	and	easy	to	handle,	whereas	the	neat	
tubes	were	quite	fragile	and	brittle.		
The	 results	 obtained	 in	 this	 study	 suggest	 that	 P(3HB)/oligo-PHA	 tubes	 with	 a	 PCL-
PEG550	coating	undergo	a	degradation	process	by	surface	erosion.	P(3HB)/oligo-PHA	






site	 of	 injury	 to	 allow	 ordinary	 healing	 of	 the	 artery	wall	 and	 to	 prevent	 neointimal	
proliferation,	which	lead	to	restenosis	(Ako	et	al.,	2007).	In	this	study,	P(3HB)/oligo-PHA	









drug	release	studies	were	carried	out.	 	Drug	powders	were	characterised	 in	order	 to	
check	 the	 thermal	 properties	 and	 the	 presence	 of	 typical	 chemical	 bonds.	 In	 vitro	
degradation	study	was	performed	for	3	months	to	test	the	influence	of	the	hydrolytic	
environment	along	with	higher	temperature	on	the	tubes.	
The	 presence	 of	 both	 drugs	 was	 confirmed	 by	 FTIR	 analysis.	 Coated	 tubes	 with	
incorporated	 drugs	 showed	 weak	 chemical	 bonds	 characteristic	 of	 rapamycin	 and	
tacrolimus	in	comparison	to	tubes	without	loaded	drugs	(Patel	et	al.,	2013).		
SEM	was	carried	out	to	investigate	the	effect	of	drug	loading	on	the	surface	topography	












coated	 tubes	 without	 drugs	 (neat	 PHA	 tube<PCL-PEG550	 coated	 PHA	 tube	 with	
incorporated	drugs<PCL-PEG550	coated	PHA	tube).	This	was	exactly	in	agreement	with	
the	results	obtained	in	this	study.	Hence,	the	higher	protein	adsorption	observed	on	the	




















defined	 as	 the	 scission	 of	 chemical	 bonds	 in	 the	 polymer	 backbone	 by	molecules	 of	
water	to	form	oligomers	and	finally	monomers.	After	immersing	the	material	in	the	PBS	
or	other	media,	the	biomaterial	absorbs	water	and	swells,	and	degradation	will	progress	
from	 the	 external	 part	 of	 the	material	 toward	 its	 internal	 site	 (Williams	 and	 Zhong,	
1994).	It	is	well-known	fact,	that	the	nature	of	the	materials	influences	their	degradation	




presence	 of	 strong	 covalent	 bonds	 in	 the	 backbone	 (like	 C-C)	 and	 non-hydrolysable	
groups	 require	 longer	 time	 for	 degradation.	 This	 is	 in	 agreement	 with	 the	 results	
obtained	in	this	study.	In	vitro	degradation	studies	demonstrated	lower	percentage	of	
water	 adsorption	 and	 lower	 rates	 of	 weight	 loss	 after	 3	 months	 of	 incubation	 in	
comparison	 to	neat	 tubes.	Minor	changes	 in	 the	pH	suggested	absence	of	 the	highly	
acidic	products	released	during	polymer	degradation.	Homopolymer	PCL	required	over	
110	weeks	to	degrade	in	phosphate	buffer	(Dai	et	al.,	2009).		PCL	is	well	known	synthetic	















neat	 tube	 resulted	 in	 the	 initiation	of	 the	degradation	process	on	 the	 surface	of	 the	
tubes.	After	3	months,	the	coating	was	mainly	present	as	debris	on	the	surface	of	the	
tube.	In	this	study,	the	addition	of	PCL-PEG550	layer	slowed	down	the	degradation	rate	
of	 the	 PHA	 tubes.	 DSC	 data	 of	 the	 tube	 coated	 with	 PCL-PEG	 with	 incorporated	
tacrolimus	 confirmed	 the	 absence	 of	 the	 melting	 peak,	 characteristic	 for	 the	 PCL-
PEG550	from	the	coating.	An	 increased	porosity	was	observed	across	 the	wall	of	 the	
tube.	The	mechanical	characterisation	of	the	blend	tubes	coated	with	PCL-PEG550	with	




Another	test	 that	was	done	on	these	tubes	with	 incorporated	drugs	was	the	 indirect	
cytotoxicity	 study.	 This	 experiment	 was	 performed	 to	 determine	 the	 effect	 of	 the	
rapamycin	 or	 tacrolimus	 on	 the	 growth	 of	 HMEC-1	 cells.	 Considering	 the	 potential	




cells	 incubated	 with	 the	 extract	 from	 the	 tubes,	 containing	 rapamycin.	 This	 was	
confirmed	with	the	results	from	the	literature	(Liu	et	al.,	2010).	On	one	side,	rapamycin	
inhibits	 smooth	muscle	cells	migration,	which	has	a	positive	effect	 inhibiting	 in-stent	
restenosis.	 On	 the	 other	 hand,	 presence	 of	 rapamycin	 leads	 to	 undermined	
endothelialisation,	 which	 can	 cause	 late	 stent	 thrombosis	 and	 therefore	 requires	
prolonged	 antiplatelet	 therapy	 (Moss	 et	 al.,	 2010).	 	 This	 has	weakened	 the	 positive	











1	cell	 line.	Obtained	results	were	 in	an	agreement	with	results	reported	 in	 literature.	




inhibits	 endothelial	 cell	 migration	 and	 proliferation	 as	 well	 as	 smooth	 muscle	 cells,	





attachment	 and	 proliferation	was	much	 less	 on	 the	 surface	 of	 the	 tubes	 containing	
rapamycin.	All	of	the	tested	tubes	did	not	have	any	haemolytic	effect	towards	red	blood	
cells.	Both	types	of	tubes	demonstrated	blood	clotting	rate	lower	than	the	control.	The	




activation,	 although	 it	 is	 a	 well-known	 inhibitor	 of	 inflammatory	 response.		
Haemocompatibility	 study	was	performed	after	24hrs,	hence	only	acute	mechanisms	
could	 be	 observed.	 Extended	 time	 of	 this	 experiment	 could	 possibly	 bring	 more	

























































PHA	 production	 and	 characterisation,	 development	 of	 P(3HB)/oligo-PHA	 blends,	
development	of	radiopaque	composites,	fabrication	of	tubes	and	incorporation	of	drugs	
into	the	polymeric	matrix.		
The	 first	 part	 of	 the	 project	 focused	 on	 scl-PHA	 production,	 using	 various	 types	 of	






obtained	 from	B.	 subtilis	OK2,	when	grown	on	glucose	as	 the	 sole	 carbon	 source.	B.	
subtilis	is	a	Gram-positive	bacterium,	which	does	not	contain	lipopolysaccharides	within	
the	cell	wall,	hence	do	not	trigger	enhanced	immunogenic	response.	B.	subtilis	has	been	
classified	 by	 FDA	 as	 GRAS	 bacteria,	 which	 means:	 “Generally	 Recognised	 as	 Safe”	
























frying	 oil	 resulted	 in	 the	 highest	 polymer	 accumulation,	 which	 was	 38%	 dcw.	 The	
chemical	 structure	 of	 the	 material	 was	 confirmed	 by	 FTIR	 and	 GC-MS.	 The	 results	
demonstrated	 that	 waste	 frying	 oil	 was	 a	 promising	 carbon	 source	 for	 mcl-PHAs	
production.	 P(3HHx-3HO-3HD-3HDD)	 copolymer	 obtained	 was	 very	 sticky	 and	
amorphous	in	nature.	Moreover,	a	lack	of	solubility	in	organic	solvents	was	observed.	
These	 results	 demonstrated	 that	 P.	 mendocina	 was	 capable	 of	 utilising	 sugarcane	
molasses,	biodiesel	waste,	various	types	of	vegetable	oils,	waste	frying	oil	and	mixed	
carbon	 sources	 as	 the	 feedstock	 for	 the	 production	 of	 PHAs.	 The	 use	 of	 these	






The	main	objective	of	 this	 research	project	was	 to	develop	 a	 novel	 PHA	 for	medical	
devices,	such	as	coronary	stents.	To	meet	this	objective,	novel	blends	of	P(3HB)	with	an	
addition	 of	 low	 molecular	 weight	 mcl-PHA	 copolymer	 (oligo-PHA)	 were	 developed	
focusing	on	the	potential	use	of	these	2D	blend	films	as	a	platform	material	for	coronary	





technique.	 The	 blend	 films	were	 characterised	 in	 order	 to	 evaluate	 the	 effect	 of	 an	
addition	of	oligomers,	acting	as	plasticising	agents	on	the	properties	of	the	polymer.	The	
results	obtained	emphasized	the	role	of	 these	additives	 in	enhancing	the	mechanical	
properties	 of	 these	 blend	 films.	 Especially	 elongation	 at	 break	 was	 improved	 in	
comparison	 to	 neat	 P(3HB).	 Thermal	 analysis	 confirmed	 miscibility	 of	 the	 obtained	
system.	According	to	the	wettability	studies,	there	was	an	increase	in	the	water	contact	
angle	of	the	blend	films	compared	to	the	neat	P(3HB)	films,	due	to	the	addition	of	the	










the	weakest	mechanical	 properties,	 such	 as	 stiffness	 and	 strength.	 Therefore	 blend,	
which	contains	10%	addition	of	oligo-PHA	was	selected	for	further	study.	In	these	blend,	
the	mechanical	 properties	were	 similar	 to	neat	P(3HB),	 but	 the	biocompatibility	 and	
surface	 characteristic	were	 improved	 significantly.	 These	 results	 indicated	 that	 these	



















mechanical,	 thermal	 and	 surface	 properties.	 They	 were	 also	 characterised	 for	 their	




topography	of	 the	 composite	materials.	 Composites	with	barium	sulphate	presented	
higher	surface	roughness	and	protein	adsorption	in	comparison	to	neat	blend.	With	an	
increased	concentration	of	barium	sulphate	the	contact	angle	values	decreased,	hence	






Additionally,	 radiopacity	 of	 the	 materials	 was	 achieved	 and	 the	 x-ray	 adsorption	
increased	 with	 greater	 amount	 of	 BaSO4.	 Composites	 did	 not	 demonstrate	 any	
haemolytic	effect	towards	red	blood	cells.	The	materials	had	decelerating	effect	on	the	











were	 fully	 characterised	 in	 order	 to	 investigate	 mechanical,	 thermal	 properties,	
conditions	of	storage,	surface	topography	and	biocompatibility.	Neat	P(3HB)/oligo-PHA	
90/10	 blend	 tubes	 demonstrated	 promising	 thermal	 and	 mechanical	 properties.	
However,	 the	 material	 underwent	 embrittlement	 phenomenon	 within	 7	 weeks	 of	
storage.	 Incubation	 of	 tubes	 in	 DMEM	 media	 at	 37°C	 influenced	 the	 mechanical	
properties	of	the	tubes	in	comparison	to	tubes	stored	at	room	temperature	without	any	













investigate	 the	 potential	 of	 PHAs	 as	 drug	 delivery	 vehicles	 for	 drug	 eluting	 coronary	
stents.	 The	 FTIR	 and	DSC	 analysis	 clearly	 confirmed	 presence	 of	 additional	 polymer,	
which	 demonstrated	 different	 propertied	 than	 PHAs.	 Presence	 of	 an	 additional	
polymeric	 layer	had	a	positive	effect	on	 the	mechanical	properties	of	 the	 tubes.	The	
strength	as	well	as	stiffness	of	the	material	had	improved.	The	PCL-PEG550	layer	had	a	








inside	 the	 body.	 Addition	 of	 barium	 sulphate	 to	 the	 blend	 resulted	 in	 enhanced	
brittleness	of	the	tubes.	Also,	it	did	affect	the	microstructure	of	the	tubes.	Composite	
tubes	did	not	have	any	porosity.	A	MicroCT	scan	confirmed	the	potential	radiopaque	
effect,	 caused	 by	 the	 presence	 of	 BaSO4.	 PCL-PEG550	 coated	 tube	 demonstrated	
significantly	 higher	 protein	 adsorption,	 which	 can	 be	 explained	 by	 increased	
hydrophobicity	of	the	material	by	addition	of	PCL-PEG550.	Biocompatibility	study	was	
carried	out	for	7	days.	Composite	tubes	demonstrated	the	highest	cell	attachment	and	
proliferation,	 which	 might	 be	 the	 enhanced	 roughness	 of	 the	 material,	 due	 to	 the	
addition	 of	 BaSO4	 particles	 resulted	 in	 a	 rougher	 surface	with	 anchor	 points	 for	 the	
endothelial	cells.	Indirect	cytotoxicity	studies	confirmed	the	non-toxic	effect	of	extracts	
from	all	kinds	of	tested	tubes	on	the	HMEC-1	cell	line.	The	tubes	did	not	demonstrate	
any	 haemolytic	 effect	 on	 the	 erythrocytes.	 PCL-PEG550	 coated	 tube	 significantly	
decelerated	blood	clot	formation	rate.	The	coagulation	cascade	was	not	activated	in	the	
presence	of	composite	tube.	Presence	of	barium	sulphate	led	to	higher	neutrophils	and	





	Finally,	 an	 investigation	 of	 the	 P(3HB)/oligo-PHA	 blend	 tube	with	 PCL-PEG550	 layer	
containing,	as	the	base	material	for	the	development	of	a	drug	eluting	biodegradable	
stent	was	carried	out	by	incorporation	of	immunosuppressive	drugs,	such	as	rapamycin	
or	 tacrolimus.	 Influence	 of	 the	 tubes	 on	 surface	 topography,	 biocompatibility,	
haemocompatibility	and	the	degradation	rate	were	investigated.	A	drug	release	study	
was	 carried	 out	 by	 using	 UV-VIS	 Spectrophotometry	 and	 High	 Performance	 Liquid	
Chromatography	 (HPLC)	 for	 rapamycin	 and	 tacrolimus	 respectively.	 Microstructural	
study	demonstrated	no	 influence	on	 the	 surface	 topography	of	 the	 tubes.	However,	






tacrolimus.	 Rapamycin	 had	 an	 inhibiting	 effect	 on	 cell	 viability,	 attachment	 and	
proliferation.	Presence	of	drugs	lead	to	the	reduction	of	side	effects,	such	as	restenosis,	
which	was	the	main	limitation	of	bare	metallic	stent	(Alfonso	et	al.,	2014).	One	of	the	













with	 rapamycin	 and	 tacrolimus	 respectively.	 The	 tube	 containing	 tacrolimus	 had	 a	
higher	water	absorption	in	comparison	to	the	tubes	with	rapamycin.	Tubes	with	drugs	
were	identified	to	be	non-haemolytic	with	very	low	risk	of	thrombogenicity.	Addition	of	
drugs	 resulted	 in	 higher	 activation	 of	 neutrophils	 and	 monocytes,	 especially	 in	 the	
presence	of	rapamycin.		
In	 summary,	 a	 drug	 delivery	 system	 for	 the	 controlled	 delivery	 of	 rapamycin	 and	
tacrolimus	 was	 successfully	 developed.	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-
PEG550	 with	 and	 without	 drugs	 were	 prepared	 using	 the	 dip	 coating	 technique	 to	
investigate	 their	 potential	 as	 a	 drug	 delivery	 system	 for	 the	 controlled	 release	 of	


























	Various	 types	 of	 surface	 modifications	 of	 these	 blend	 tubes	 can	 be	 explored.	 For	
example:	 laser	 micropatterning	 (physical	 method),	 plasma	 treatment	 (biochemical	
method),	chemical	modifications	of	the	PHAs.	This	will	create	a	more	attractive	surface	




















In	 this	 study,	only	 two	antiproliferative	drugs	were	 tested.	 It	will	be	worth	exploring	
another	possible	bioactive	agent,	in	order	to	reduce	risk	of	restenosis,	but	with	minimal	
reduction	 of	 biocompatibility	 of	 the	 construct.	 Additionally,	 different	 types	 of	 drug	






contact	 of	 developed	 biomaterial	 with	 blood.	 Special	 attention	 needs	 to	 be	 paid	 to	










as	 antibodies	 within	 the	 stent	 prototype	 and	monitoring	 their	 drug	 release	 kinetics	
would	be	 the	next	 step	 forward.	 Cell	 culture	 and	degradation	 studies	of	 these	 stent	








In	 this	 study,	 P(3HB)/oligo-PHA	 blend	 tubes	 were	 fabricated	 for	 their	 use	 in	 the	
development	 of	 biodegradable	 stents.	 In	 the	 future,	 in	 vivo	 evaluation	 of	 stent	
prototypes	in	small	and	large	animals	would	be	a	great	addition.	In	vivo	study	can	also	
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